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Lymphatic vessels (LVs) are thin walled structures that transport lymph from tissues to 
lymph nodes. By this function they are complementary to the cardiovascular system in the 
maintenance of body fluid homeostasis. They play a pivotal role in many (patho)-
physiological processes, such as inflammation, immune surveillance and tolerance, fat 
abortion and metabolism, and general tissue homeostasis, and are involved in disease 
conditions as diverse as hypertension, atherosclerosis, transplant rejection and survival, 
and tumor metastasis. Although our understanding has been improved substantially, the 
biology of LVs is still in its infancy. During recent years many details have emerged as to 
how LVs function in diseased states, mostly in cancer related conditions. However, the 
functional significance of the lymphatic network in individual organ health and disease is 
still poorly understood. Data obtained in kidney transplantation, albeit few, support the 
important role of LV in intra-organ pathophysiology. Lymphangiogenesis, the outgrowth of 
preexisting and genesis of new LVs, is an important component of the tissue response to 
microenvironmental changes, and can have huge impact on disease progression and tissue 
homeostasis. In this thesis therefore, we aim to explore the relevance of intrarenal 
lymphangiogenesis in the pathophysiology of kidney damage, and its possible role as a 
target for renoprotective intervention.  
Outline of the thesis 
In chapter 2, we comprehensively reviewed the current state of knowledge regarding the 
anatomy, physiology and pathophysiology of LVs, with special focus on the role of LVs and 
lymphangiogenesis in renal diseases, as a potential target of therapy.  
Experimental studies showed that under conditions of high dietary salt intake, vascular 
endothelial growth factor C (VEGF-C) induces lymphangiogenesis in the skin and contributes 
to water-free storage of salt, thereby preventing a salt-sensitive blood pressure response. 
This fascinating discovery prompted us to study whether this mechanism plays a role in salt 
homeostasis and blood pressure regulation in humans as well. Hence, in chapter 3, we 
measured circulating VEGF-C levels and blood pressure during different well-controlled salt 
intakes in healthy subjects and in chronic kidney disease (CKD) patients.  
In order to better explore the association of lymphangiogenesis with renal damage, 
tubulointerstitial lymph vessel density has been evaluated in a number of different renal 
conditions which are presented in Chapters 4-6. Several original publications have revealed 
that lymphangiogenesis occurs after renal transplantation, especially in kidney transplant 
rejection. The cause and consequence of this renal lymphangiogenesis on kidney transplant 
graft survival and function is not clear yet. Kidneys from deceased brain dead (DBD) donors 
always present worse post transplantation function than those from living donors (LD), 
possibly due to the inflammatory response in DBD donors. In this regard, kidneys from DBD 
have more interstitial changes such as tubulointerstitial fibrosis and inflammation 
compared to kidneys from LD, which are strong potent inducers of lymphangiogenesis. 
Therefore, in chapter 4 we aimed to evaluate whether renal lymphangiogenesis also occur 
as one of the tubulointerstitial remodeling phenomena in pretransplant DBD’s kidneys, and 




Although we have gathered extensive knowledge on lymphangiogenesis up to now, we do 
not have that much information about the mechanism and functional relevance of LVs 
regression. To explore this more, in chapter 5, we investigated LVs regression in an 
experimental kidney disease model using Angiotensin II infusion, and thereafter checked 
the renal lymphangiogenesis, and LVs regression in the recovery period after stopping 
Angiotensin II treatment.  
As proteinuria is an important cause of progressive tubulointerstitial damage we evaluated 
the time course of LV formation in relation to proteinuria and interstitial damage up to 30 
weeks after induction of proteinuria in a rat model of chronic unilateral adriamycin 
nephrosis in chapter 6.  
In the chapters mentioned above, we performed observational studies to see when, and 
where renal lymphangiogenesis occurs in different renal diseases. In order to clarify the 
significance of this renal lymphangiogenesis more we executed interventional studies, 
described in Chapters 7 and 8. As we discussed in chapter 2, inflammatory cells can directly 
promote lymphangiogenesis, as has been shown previously in renal allograft rejection. Rho 
kinase pathway plays an important role in epithelial dedifferentiation and inflammatory cell 
infiltration. For that reason, in the next study presented in chapter 7, we investigated 
whether targeted inhibition of the Rho kinase pathway in proximal tubular cells reduces 
inflammation and lymphangiogenesis in an experimental rat acute renal allograft rejection 
model. 
We previously showed (in chapter 6) that proteinuria can trigger renal lymphangiogenesis 
before the onset of interstitial inflammation and fibrosis. Then, in chapter 8 we targeted 
lymphangiogenesis (VEGFR3 blocking antibodies), inflammation (deplete 
monocytes/macrophages) and profibrotic changes/fibrosis (S1P receptor agonist), and 
evaluated interstitial pathology and renal function. In the final chapter (9), we summarised 
the most striking findings of our experiments, and discuss the possible potential of renal 
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Lymphatic vessels are involved in a number of physiological and pathophysiological 
processes such as fluid homeostasis, immune surveillance, and resolution of inflammation 
and wound healing. Lymphangiogenesis, the outgrowth of existing lymphatic vessels and 
the formation of new ones, has received increasing attention over the past decade on 
account of its prominence in organ physiology and pathology, which has been enabled by 
the development of specific tools to study lymph vessel functions. Several studies have 
been devoted to renal lymphatic vasculature and lymphangiogenesis in kidney diseases, 
such as chronic renal transplant dysfunction, primary renal fibrotic disorders, proteinuria, 
diabetic nephropathy and renal inflammation. This review describes the most recent 
findings on lymphangiogenesis, with a specific focus on renal lymphangiogenesis and its 
impact on renal diseases. We suggest renal lymphatics as a possible target for therapeutic 
interventions in renal medicine to dampen tubulointerstitial tissue remodelling and 
improve renal functioning. 




The discovery of a second vascular system in the body goes back to the ancient Greeks, most 
importantly Herophilos (335-280 BCE) and Erasistratus (310-250 BCE), who described a 
vascular system resembling what we now call the lymphatic system. The lymphatic network 
was updated in more detail almost four centuries ago (in the mid-17th century) by Gasparo 
Aselli as ‘lacteal vessels’ and was grounded on his observations of a dog’s abdomen (Ref. 1). 
Since then, and until two or three decades ago, the lymphatic vasculature had received much 
less attention than blood vessels, mostly because of the difficulty of distinguishing between 
blood and lymph vessels. With the discovery of several cellular markers that are exclusively, 
or at least predominantly, expressed by lymphatic endothelial cells (LECs), our knowledge of 
lymphology has increased remarkably. These tools have enabled the study of the molecular 
mechanisms of lymphangiogenesis, the growth and formation of new lymphatic vessels (LVs), 
which have appeared to be an important phenomenon in many pathological conditions in 
various organs. In this paper we review the current state of knowledge of the lymphatic 
system, with a focus on the role of lymphangiogenesis in renal diseases. Further, we explore 
the possible mechanistic link between renal lymphangiogenesis and other pathological 
processes such as inflammation and fibrosis. Finally, we discuss the potential value of renal 
lymphangiogenesis as a new target for therapeutic intervention in renal diseases. 
Lymphatic vessels 
Anatomy and physiology 
Unlike blood capillaries, lymphatic capillaries consist of overlapping oak leaf-shaped 
endothelial cells, with incomplete or no basement membrane. Lymph capillaries lack smooth 
muscle cells or pericyte coverage, but are equipped with thin fibrillar structures called 
anchoring filaments, which permit expansion and prevent collapse. By connecting the 
abluminal surface of LECs to the surrounding interstitial matrix, anchoring filaments enable 
these cells to respond to changes in interstitial fluid pressure, as in oedema, when high 
interstitial pressure tends to collapse LVs (Ref. 2). The precollecting segment does exhibit 
some coverage (Ref. 3); however, collecting vessels are fully equipped with perivascular SMCs 
(Ref. 4). To ensure their unidirectional fluid movement, LVs possess two kinds of valves to 
prevent lymph backflow: overlapping endothelial junctions in the initial lymphatics serve as a 
primary valve (also called a microvalve) which allows fluid to flow from the interstitial space 
into the lumen of the LVs while considerably reducing the leakage back into the interstitium, 
and the traditional intraluminal valve serves as a secondary valve (Ref. 5). 
With their special structural and functional properties, LVs are central to a wide variety of 
actions in the body. They play a central role in the maintenance of tissue fluid homeostasis, 
immune surveillance and trafficking, and fatty acid absorption. LVs drain excess fluid 
entering the interstitial space from the blood capillaries, and take up extravasated cells and 
macromolecules and transport them unidirectionally to the draining lymph node, thoracic 
duct and into the inferior vena cava. LVs thus complete one of the most important 
physiological functions, by returning interstitial tissue fluid back to the blood circulation. 
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LVs are not simple ducts, since LECs actively participate in a variety of vital biological 
processes such as reorganisation and remodelling of the extracellular matrix (ECM), 
modulation of capillary morphogenesis, cellular migration and more importantly, immune 
response and peripheral tolerance (Ref. 2). 
Visualization and phenotyping of LECs 
Until recently, our understanding of the lymphatic vascular system was much more limited 
than of its counterpart blood vasculature. The main reason was a lack of reliable tools to 
differentiate between LECs and blood endothelial cells. With the discovery of several markers 
predominantly expressed on LECs, knowledge in this field has substantially improved in 
recent years. In this respect, although several markers have been identified to date, the 
extent of their expression and reliability in all pathological conditions has long been a matter 
of debate. The consensus, however, is that there still is no perfect and ideal marker available 
that works reliably in all disease conditions in different organs. Several markers have been 
proposed in the literature (Table 1); however, the most extensively tested and studied 
markers yielding satisfactory results are lymphatic vessel endothelial hyaluronan receptor 1 
(LYVE-1), vascular endothelial growth factor receptor 3 (VEGFR-3), prosperorelated 
homeobox transcription factor 1 (Prox1) and mucin-type transmembrane glycoprotein 
podoplanin. Care should be taken when using these markers, as many other cells and 
structures can show positivity. Therefore, multiple markers need to be used for confirmation. 
LECs at developmental stages 
The heterogeneity of LECs at different developmental life stages is a complicated matter and 
the origins of LVs have been controversial. To date, two major hypotheses have been put 
forward to explain the origins of LVs: one proposes the budding of primary lymph sacs 
‘centrifugally’ by endothelial budding and lymphangiogenesis; the other involves a role for 
mesenchymal cells. The first centrifugal sprouting hypothesis was proposed by Florence Sabin, 
based on her observation of LVs sprouting from the jugular veins of pig foetus (Ref. 6). This 
hypothesis is widely supported, principally by mouse molecular genetics (Ref. 7). Several years 
later, a second alternative model was proposed by Huntington and McClure. This hypothesis 
proposes that the initial lymph sacs develop in the mesenchyme while, in contrast to the 
previous model, their origins are independent of the veins (Ref. 8). However, it has been shown 
that LVs start growing from distinct endothelial cells (ECs) which express Prox-1 in the anterior 
cardinal vein (Ref. 9), and that the establishment of blood circulation, which happens in humans 
at around the sixth to seventh week of embryonic development, is a prerequisite for LV 
development. Later, this Prox-1-expressing EC population migrates and establishes the primary 
lymph sac and then, by remodelling, forms the LV system (Ref.10). The reader is referred to 
recent excellent reviews (Refs 11, 12, 13) for further details on lymphatic development. 
Lymphatic vessels in kidney 
Before the discovery of specific markers, observations by light or electron microscopy and 
dye injection studies had revealed no major differences in the distribution of the renal 
lymphatic system in mammals (Refs 14-18). Later studies taking advantage of more specific 
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markers such as podoplanin, LYVE-1, Prox-1 and VEGFR-3 confirmed the previous findings 
on the distribution of renal lymphatics (Refs 19-22). D2-40, a monoclonal antibody which 
recognizes human podoplanin, validated the pattern of human renal LVs that had been 
uncovered by previous investigations (Refs 23-25). This antibody is a promising marker for 
the study of human LVs and is in use in daily clinical practice. 
Using these novel markers, recent studies have provided in-depth information on the 
development of renal LVs in the embryonic and adult rodent kidney. Although the extra-
renal lymphatic network in mice is well-developed at embryonic day (E) 12, the first 
intrarenal LV is observed at E13 (Ref. 19). In contrast, no LVs can be found in developing rat 
kidney until E20, at which point the first LVs are observed in the renal hilus and interstitium 
around the pelvis (Ref. 20). There are no LVs at that point around the arcuate arteries and 
in the cortical area. However, one day after birth, several small LVs can be observed around 
the branches of arcuate veins and arteries in the corticomedullary region; since no LVs can 
be found at this time on the cortex, these LVs appear to be unconnected to the cortical 
area. The first small LVs in the cortex of rat kidneys are observed around the interlobular 
arteries at days ten to twenty after birth (Ref. 20). 
 
Table 1. Summary of markers for lymphatic vessels. 
Marker Full/alternative name Molecular function 
VEGFR3 vascular endothelial growth factor receptor 3 tyrosine kinase receptor (for 
VEGF-C and VEGF-D) 
Podoplanin D2–40, Gp38, T1α, AGGRUS transmembrane glycoprotein 
LYVE-1 lymphatic vessel endothelial hyaluronan receptor 1 hyaluronan receptor 
Prox-1 prospero-related homeobox 1 transcription factor 
CCL21 chemokine (C-C motif) ligand 21 CC-chemokine for CCR7+ cells 
FOXC2 forkhead box C2 Transcription factor 
5'NT 5'-nucleotidase (CD73, 5'-Nase) membrane glycoprotein (enzyme) 
D6 chemokine decoy receptor chemokine receptor 
LA102 monoclonal antibody marker for mouse LEC 
Dsp Desmoplakin junctional protein 
Nrp2 neuropilin 2 growth factor receptor 
MRC1 macrophage mannose receptor type 1 C-type lectin, CD206 
Integrin alpha9 ITGA9 adhesion molecule 
Plakoglobin gamma-catenin, JUP junctional protein 
AQP1 aquaporin-1, CHIP28 membrane water channel molecule 
B27 mouse monoclonal antibody marker for rat LEC 
 
LVs accompany intrarenal arteries and veins up to the interlobular branch in the cortex in 
adult rat kidneys, and occasionally some LVs can be observed near glomeruli. Although 
there can be several LVs in the renal pelvis, virtually no LVs have been reported in the 
parenchymal tissue in the cortex and medulla (Refs 20, 21). 
Two lymphatic systems have been observed in human kidneys. One is the intrarenal LVs, which 
show the same pattern of distribution as in rat kidneys. They follow the intrarenal distribution 
of blood vessels up to the level of interlobular arteries and veins in the cortex. LVs in the cortical 
area are occasionally observed in the tubulointerstitial space and around glomeruli, while LVs 
are absent or very rarely found in the outer or inner medulla. LVs are also found in the adipose 
tissue of the hilum, around the blood vessels beneath the interstitium of the pelvic transitional 
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epithelium, and also in the vicinity of the hilar and sinus arteries and veins (Refs 24, 25). The 
second capsular lymphatic system is found in addition to these blood vasculature-accompanied 
intrarenal LVs (Refs 26, 27, 28). As the number of LVs decrease in the outer cortex, these 
capsular LVs mostly drain superficial cortical lymph and run parallel to the renal capsule, 
eventually connecting to LVs in the renal sinus in the hilum. In healthy kidneys these capsular 
LVs drain little fluid, but if there is a urinary tract obstruction (UUO), these LVs become the main 
route of lymph drainage (Ref. 26). The specific roles of this dual lymphatic network in renal 
health and disease remain unclear and warrant future investigation. A schematic representation 
of the anatomy of renal lymphatics is presented in Figure 1. 
Renal Lymphangiogenesis 
Lymphangiogenesis in adults occurs in physiological processes and in a number of 
pathological conditions. Although there are several similarities between these processes, 
pathological lymphangiogenesis requires some additional factors (Ref. 29). Physiological 
lymphangiogenesis occurs in embryogenesis, during the development of the corpus luteum 
and in wound healing in adults (Refs 30, 31). To date, various growth factors and mediators 
have been shown to promote lymphangiogenesis in different organs, and their number 
continues to increase (Table 2, Refs 32-34). The best-known factors are vascular endothelial 
growth factor-C (VEGF-C) and VEGF-D. VEGF-C signals primarily through its receptor VEGFR-
3, and plays a crucial role in the proliferation, migration and survival of LECs. VEGF-C has a 
vital role in LV development and VEGF-C deficiency results in embryonic death in mice (Ref. 
35). VEGF-D is another major inducer of lymphangiogenesis, also signalling via VEGFR3, but 
its ability to promote lymphangiogenesis is less important than that of VEGF-C. Both VEGF-C 
and D are also able to induce angiogenesis (Refs 36, 37). In the next sections we will discuss 
recent findings surrounding lymphangiogenesis and its implications in kidney diseases. 
Inflammation and inflammatory cells 
Lymphangiogenesis has been reported to occur at sites of tissue inflammation, following 
immunization and bacterial infection. It is also involved in many inflammatory conditions 
such as psoriasis, chronic airway inflammation, Crohn’s disease, inflammatory bowel 
disease, rheumatoid arthritis, transplant rejection and tumour metastasis (Ref. 38). An 
increasing body of data supports those hypotheses proposing the existence of mutual 
interaction between inflammation and lymphangiogenesis. LVs form the exit route for 
inflammatory cells, cytokines, chemokines, inflammatory exudate fluid and 
macromolecules from tissues to lymph nodes, where the immune response arises. LECs 
efficiently react to microenvironmental alterations. In this sense, the inflammatory process 
can affect LVs, while LVs also play a crucial role in promoting inflammatory responses. A 
wealth of evidence from many investigations has shown that LVs are not just passive 
conduits but active players in many biological responses such as immunoregulation, which 
is necessary for immune surveillance and inflammation (Ref. 39). 
Chemokines – Secondary lymphoid tissue chemokine (SLC/CCL21), which is constitutively 
expressed by LECs in small LVs under a steady state, is induced and secreted in large 
amounts in an inflammatory microenvironment. CCL21 has been shown to be a key 
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regulator of the translymphatic migration of dendritic cells (DC) and other leukocytes in 
both homeostasis and in inflammation (Ref. 40). CCL19 is also secreted by LECs, but in very 
small amounts compared to CCL21 (Ref. 41). Like blood ECs (BECs), LECs express 
macrophage inflammatory protein (MIP-3ß/CCL20) and monocyte chemotactic protein 
(MCP-1/CCL2) upon stimulation with several inflammatory cytokines such as TNF-α. LECs 
also express several other chemokines and a large number of chemoattractants like CCL5 
(RANTES), CXCL12 (SDF-1) and CX3CL1 (Fractalkine), which together with CCL21 promote 
leukocyte transmigration through LVs (Refs 42, 43). In the precollector segment, LECs 
express low podoplanin and significantly upregulated CCL27, whereas in the initial 
capillaries, LECs – which also express high level of podoplanin – secrete CCL21. It has been 
suggested that precollector segments with low podoplanin most probably act in trafficking 
pathogenicCCR10+ T lymphocytes in inflammation, highlighting the potentially distinct 
functions of LV segments in normal tissue homeostasis and inflammation (Ref. 44). Seminal 
work by Kerjaschki D. et al. (Ref. 45) has shown that LECs express CCL21 in renal biopsies 


























Figure 1. Anatomy of renal lymphatics. 
Renal lymph vessel after entering the kidney follows the same hierarchical distribution as of renal veins and arteries, up to the 
level of interlobular arteries. In normal kidney, there is almost no lymphatic vessel in cortical interstitium and few may 
observe in close proximity to glomeruli. In the medullary part, lymphatic vessels are absent or very rarely observe. Kidney 
capsule has also some lymphatic vessels. (Modified with permission from ref. 75) 
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glycoprotein podoplanin is bound to CCL21 on the basolateral membrane of LECs in nodular 
infiltrates, unlike in the luminal expression of podoplanin in normal tissue. This result 
confirms the active role of podoplanin in CCL21 binding, and the recruitment of CCR7+ 
inflammatory cells, assigning a unique role in the organization of nodular infiltrates in the 
renal transplants. 
Receptors – LECs upregulate intercellular adhesion molecule 1 (ICAM-1), junctional 
adhesion molecule 1 (JAM1), vascular cell adhesion molecule (VCAM-1) and E-selectin in 
response to inflammatory stimuli. These adhesion molecules help leukocyte transmigration 
by promoting leukocyte-endothelial adhesion (Ref. 46). Another receptor which has been 
shown to be expressed by LECs in renal allografts is CXCR7 (Ref. 47). CXCR7, a receptor for 
ligands CXCL11 or CXCL12, is involved in leukocyte trafficking by LVs in allografts. CXCR7 is 
expressed by LECs in allograft tissues, whereas its expression is restricted to smooth 
muscles and some peritubular endothelial cells in the healthy control kidney. CXCR7 
expression is increased in renal allograft rejection both in LVs and blood vessels, and can 
play a role in the recruitment and activation of inflammatory cells in renal allografts. It is 
deemed that CXCR7 might be involved in adhesion of cells to LVs and peritubular capillaries 
in the 
 
Table 2. Summary of lymphangiogenic growth factors and mediators. 
Name Full/alternative name Receptor / function 
VEGF-C vascular endothelial growth factor C VEGFR3  (Neuropilin-1 & 2, VEGFR2a) 
VEGF-D vascular endothelial growth factor D VEGFR3  (Neuropilin-1 & 2, VEGFR2a) 
VEGF-A vascular endothelial growth factor A VEGFR2 
PDGF-BB platelet-derived growth factor-B PDGFreceptor-ß  (PDGFR-ß) 
HGF hepatocyte growth factor HGF receptor (HGFR; C-Met) 
IGF1 & 2 insulin-like growth factor-1 and -2 IGF receptor-1 and 2 (IGFR1-2) 
OPN osteopontin α-9 integrin 
EGF epidermal growth factor epidermal growth factor receptor (EGFR) 
AM adrenomedullin calcitonin-receptor-like receptor (CRLR) 
FGF-2 fibroblast growth factor-2 fibroblast growth factor receptor-1 
ET-1 endothelin-1 endothelin B receptor (ETBR) 
EPO Erythropoietin erythropoietin receptor (EPOR) 
Ang 1,2,3,4b Angiopoietins Tie1 and Tie2 
LT-α lymphotoxin-α unclearc 
COX-2 cyclooxygenase-2 upregulation of VEGF-C and/or VEGF-A 
 
aVEGF-C and VEGF-D can also bind to neuropilin-1 and -2 coreceptors, and their fully processed forms bind to VEGFR-2. 
bAll four forms of angiopoietins have been shown to stimulate lymphangiogenesis (Ang1 is the most potent inducer). 
cIt not clear yet whether the effect of lymphotoxin-α has a direct or indirect effect on lymphangiogenesis  
 
Kidney. However, the exact role of this upregulation in renal vasculature is not yet 
understood clearly (Ref. 48). Future targeting interventions are warranted to further clarify 
the biological function and importance of this CXCR7 upregulation in renal allograft injury. 
Duffy antigen/receptors for chemokines (DARC) and protein D6 are also expressed by LECs 
and are able to bind with high affinity to different inflammatory chemokines (Ref. 49). D6 is 
thought to act as a chemokine scavenger; while in contrast, DARC presents chemokines 
(Ref. 50). Although both are integral to inflammatory reactions, their importance and exact 
interplay with LECs in kidney inflammation and the resolution of inflammation is not 
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investigated yet. Sphingosine-1-phosphate receptor 1 (S1P1), a receptor for sphingosine-1-
phosphate (S1P), is expressed on LECs (Refs 51, 52). S1P promotes LEC migration and tube 
formation in vitro as well as lymphangiogenesis in vivo. S1P1 is also involved in 
lymphangiogenesis (Refs 53, 54). FTY720, a microbe-derived immunosuppressive that acts 
as an agonist for the S1P receptors, inhibited lymphangiogenesis in experimental islets 
allografts and significantly prolonged graft survival (Ref. 55). The role of S1P has been 
investigated in various renal diseases (Refs 56, 57, 58). Modulation of S1P1 receptor on 
renal lymphatics might serve as a new strategy to prevent renal lymphangiogenesis. 
Leukocytes – The important role of leukocytes in lymphangiogenesis has been extensively 
investigated (Ref. 59). Several subsets of leukocytes are able to produce mediators and growth 
factors at the site of inflammation that can promote lymphangiogenesis, such as mast cells, 
macrophages, neutrophils, dendritic cells, B cells, T cells and inflammatory fibroblasts (Refs 60-
63). Macrophages play a prominent role in these subsets. Macrophages participate in 
lymphangiogenesis in two distinct ways: by producing paracrine lymphangiogenic stimuli and 
mediators, or by directly trans-differentiating into LECs (Ref. 64). However, the exact role and 
the significance of the contribution attributed to macrophages in postnatal lymphangiogenesis 
are still under investigation (Ref. 65). We and other groups have shown that macrophages can 
be actively involved in renal lymphangiogenesis in several diseases (Refs 21, 23, 66-69). 
However, studies of several kidney injury models have shown that CD68+ macrophages are not 
the main source of lymphangiogenic mediators, at least in producing VEGF-C. In a mouse UUO 
model, macrophage depletion by clodronate liposomes markedly abolished renal 
lymphangiogenesis (Ref. 67). In the same disease model in rats, Suzuki Y. et al. (Ref. 69) showed 
that unlike macrophages, tubular epithelial cells are the major contributor to renal 
lymphangiogenesis, by secreting large amounts of VEGF-C. In a time-course study of 
adriamycin-induced nephropathy, we found that renal lymphangiogenesis significantly 
increases at week 12, while there is no macrophage influx up to that time. Even after prominent 
influx of ED1-positive cells at later time points, less than five percent of these cells showed 
VEGF-C expression by double immunofluorescent staining (Ref. 70). This implies that the 
participation of macrophages in lymphangiogenesis is highly context-dependent, at least in the 
kidney. Besides, the precise role of different subtype of macrophages such as M1 (classically 
activated, pro-inflammatory) and M2 (alternatively activated, anti-inflammatory) in inducing 
lymphangiogenesis is not well characterized. Specifically targeting macrophages, and its 
subtypes, in the various renal disease models with high lymphangiogenesis will help understand 
the role of macrophages in renal lymphangiogenesis and is currently a focus of our study.  
Nodular infiltrates are shaped by the accumulation of T cells, B cells, dendritic cells and 
probably macrophages. These structures resemble tertiary lymphoid organs (TLO), are 
commonly formed during chronic inflammatory conditions and have been shown to be 
constantly associated with LVs in the kidney (Refs 45, 71). Recently, we observed strain-
dependent lymphocytic infiltration and TLO formation in the kidneys of aged mice (Ref. 72). 
Candidate genes that can be linked to aging-associated TLO formation have been identified. 
To date, it remains unclear what the functional importance of these structures could be in 
renal diseases. They seem to be a part of a local immune system (Ref. 73), although 
whether TLOs and secondary lymphoid organs possess the same functional properties has 
not yet been clarified (Ref. 74). 
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In summary, inflammatory cells and their mediators can induce renal lymphangiogenesis in 
kidney diseases accompanied by tubulointerstitial inflammation. This expansion of 
lymphatic vessel network in cortical region of the kidney seems to be a positive response of 
microenvironmental milieu in order to increase the washout of overloaded interstitial fluid 
in both inflammatory and oedematous injuries in renal diseases (Ref. 75). However, it is not 
known yet to what extent these newly formed lymphatic vessels are truly functional in 
fluid, inflammatory cells and macromolecular transport from the kidney. Using in vivo 
imaging techniques or injecting dyes into renal capsule will help to understand the 
significance of this lymphatic expansion in removing interstitial fluids in different kinds of 
kidney injury models. Moreover, using knock-out animal models for different inflammatory 
cells, or drugs specifically targeting/depleting leukocytes will be informative to unravel the 
role of leukocyte subsets in renal lymphangiogenesis. 
Fibrosis 
Fibrosis has a close connection to inflammatory cells and mediators, as clearly stated in a 
recent comprehensive review ‘no inflammation, no fibrosis’ (Ref. 76). Therefore, it is highly 
likely that lymphangiogenesis in the kidney or other organs are associated with fibrosis. 
Several studies of distinct organs and disease conditions, and renal diseases, have reported 
that new lymph vessel formation occurs in diseases accompanied by fibrotic conditions 
(Refs 21, 23, 67, 69, 77). However, the causal relationship between lymphangiogenesis and 
fibrosis, evidenced by collagen deposition and scar formation, has not been completely 
elucidated. Lymphangiogenesis is proposed to be involved in the pathogenesis of idiopathic 
pulmonary fibrosis (Ref. 78). Recently, ectopic secretion of PDGF-B by LECs, which signals 
through its PDGFR-ß receptor on mural cells, was shown to recruit aberrant mural cells on 
LVs. This attachment of mural cells to LVs hampers their drainage capacity, and this defect 
in the lung’s LVs has been reported to be a critical step in progressing to pulmonary fibrosis. 
This process occurs in the early stage of pulmonary fibrosis development, and by blocking 
the PDGF-B/PDGFR-ß signalling, the authors were able to prevent recruitment of mural cells 
to LVs, to restore lymphatic drainage and to ameliorate pulmonary fibrosis (Ref. 79). This 
elegant study revealed a crucial role for LVs in the pathogenesis of fibrotic diseases, 
although it is not yet clear whether the same process holds true for other fibrotic 
conditions, such as renal fibrosis. Sakamoto I. et al. (Ref. 23) evaluated biopsies from 
several different chronic renal diseases for LVs by immunohistochemistry. They observed 
significant increases in LV density (LVD) in tubulointerstitial lesions, which correlate with 
the degree of tissue interstitial fibrosis. CCR7-positive fibrocytes migrate to the kidney in 
response to CCL21 chemokine and contribute to the pathogenesis of renal fibrosis. Blocking 
this CCL21/CCR7 pathway has shown to reduce kidney fibrosis (Ref. 80). As LECs have been 
shown to actively express and secrete CCL21 chemokine in the kidney (Ref. 45), it is likely 
that blocking LEC expression of CCL21 could prevent renal fibrosis. We found that 
prominent lymphangiogenesis in proteinuric kidneys occurs before the influx of 
macrophages, deposition of collagens and interstitial fibrosis (Ref. 72). It appears that 
lymphangiogenesis would occurs before clear signs of fibrosis, at least in our rat proteinuric 
model, and this is more in line with a profibrotic response.  
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TGF-β showed both inhibitory and stimulatory effect on lymphangiogenesis (Refs. 81, 82, 
83), and LECs are also able to secrete TGF-β (Refs. 84, 85). Whether LECs in renal disease 
conditions can secrete TGF-β and play a direct role in fibrogenesis needs further 
investigations. Zhao, T. et al. (Ref. 86) recently proposed that VEGF-C directly induces 
fibrogenesis. It is therefore very intriguing to examine VEGFR-3 decoy receptor strategies to 
catch away and block VEGF-C in some renal diseases with, for example, VEGF-C secretion by 
activated tubular epithelial cells. By this intervention both fibrosis and lymphangiogenesis 
should be prevented at the same time. Figure 2 shows how activated renal lymphatic 
endothelium contributes to inflammation and fibrosis, and therefore could substantially 
contribute to tubulointerstitial remodelling in kidney diseases. 
Transplantation 
The exact role of LVs and lymphangiogenesis in organ transplantation remains under debate. 
Lymphangiogenesis is suggested to be beneficial, for example, by draining inflammatory cells 
and cytokines, but could also be detrimental, by transporting antigen-presenting cells to 
lymph nodes and initiating immune responses. Inhibiting lymphangiogenesis in rodent 
corneal transplantation models was reported to be beneficial by promoting allotransplant 
survival and appears to be a promising therapeutic tool in enhancing corneal transplant 
outcomes (Refs 87-91). Corneal lymphangiogenesis appears to have negative effects on 
human cornea graft survival, and has been suggested as a sign of poor prognosis in corneal 
transplant rejection (Ref. 91). Lymphangiogenesis has also been shown to be a common 
phenomenon in solid organ transplantation, at least in the lungs, kidneys and heart (Refs 92, 
93, 94). Specific blocking of lymphangiogenesis in experimental heart and islet transplantation 
models enhances graft survival (Refs 55, 95). Nykänen AI. et al. (Ref. 95) convincingly 
demonstrated in experimental mouse cardiac allografts that targeting LVs with anti-VEGFR-3 
antibody decreases the number of LECs that express CCL21, infiltrating CD4+T cells and 
arteriosclerosis, suggesting a novel intervention to regulate alloimmune activation in solid 
organ transplantation. Adair A. et al. (Ref. 66) showed that almost all rejected kidney 
transplantation samples had increased LV numbers as a common phenomenon. Biopsies from 
human renal allografts showed active lymphangiogenesis, with an approximately fifty-fold 
increase in LV numbers being associated with nodular mononuclear infiltrates (Ref. 45). LECs 
have been reported to express CCL21 chemokine and attract CCR7+ cells, such as lymphocyte 
and dendritic cells, providing evidence of an active role for these LECs in organizing nodular 
infiltrates around LVs in the kidney (Ref. 45). This pioneer study highlighted the newly formed 
LVs and perilymphovascular infiltrates as important origins for alloimmune responses, which 
have a central role in renal transplant rejection. We, among others, also observed renal 
lymphangiogenesis in experimental renal transplantation rat models (Refs 96, 97, 98). 
Inhibition of the mammalian target of rapamycin (mTOR) blocked lymphangiogenesis, and 
this anti-lymphangiogenic effect can most probably explain prolonged lymphoedema in renal 
transplanted patients treated with rapamycin (Ref. 99). In line with these findings, the 
beneficial effect of sirolimus, another mTOR inhibitor, in ameliorating experimental chronic 
kidney allograft injury has been related largely to its anti-lymphangiogenic properties (Ref. 
98).In addition to sirolimus-related lymphedema, Ersoy A. et al. (Ref. 100) recently reported 
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everolimus-related lymphedema in renal transplantation, which indicates the anti-
lymphangiogenic activity of everolimus. The therapeutic value of these mTOR inhibitors in 
blocking lymphangiogenesis remains to be elucidated in some conditions where new lymph 
vessel formation is detrimental. Blocking lymphangiogenesis seems to be a double-edged 
sword intervention after organ transplantation. It might be beneficial by interrupting the 
route of antigen presenting cells (APCs) to reach lymph node and preventing raising of 
alloimmune response or detrimental by hampering the clearance of inflammatory cells, 
interstitial fluids and macromolecules. This area needs further experimental and clinical 
studies in order to prove the pros and cons of therapeutic values of targeting renal lymphatic 


























Figure 2. The connection between renal lymphangiogenesis, inflammation and fibrosis in the 
progression of tubulointerstitial remodelling in kidney diseases. 
In many renal diseases, the initial insults via different mechanisms are able to activate tubular epithelial cells. Upon activation, 
injured tubular cells start making and secreting a variety of chemokines and mediators which have huge impacts on several 
key processes in kidney diseases, like renal inflammation and fibrosis. The reciprocal connection between inflammation and 
fibrosis are very well studied and known. Both infiltrated inflammatory cells, (myo)fibroblasts and their mediators are shown 
to promote indirectly renal lymphangiogenesis and remodelling. However, these effects are mutual. In addition to indirect 
effects, activated tubular epithelial cells (mostly of proximal tubules) secrete specific lymphangiogenic growth factors like 
VEGF-C and VEGF-D; therefore directly stimulate the formation of new lymphatic vessel in tubulointerstitial area. Lymphatic 
endothelial cells under this inflammatory microenvironment also secrete several chemokines as among which CCL21, which 
can attract CCR7-expressing inflammatory cells and fibrocytes into the perilymphovascular space, and in this way exacerbate 
further inflammatory and fibrotic reactions. 
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Renal microenvironmental homeostasis and oedema 
LVs have a central role in maintaining fluid transport in the body, and disruption of this 
pivotal function leads to accumulation of tissue fluid and oedema formation. Interstitial 
fluid pressure increases in conditions where lymphatic drainage is insufficient, such as in 
lymphoedema, causing tissue swelling, increased hydraulic conductivity and remodelling of 
interstitial matrix (Ref. 101). Renal interstitial oedema and swelling are common as a 
consequence of the tubulointerstitial injuries in chronic kidney diseases associated with 
proteinuria (Ref. 102). The establishment of renal lymphatic circulation appears to be 
crucial to renal homeostasis and function. 
Experimental disruption of lymphatic circulation in rat kidneys causes protein-rich fluid 
retention in renal interstitium, fibrosis, renal cell apoptosis and severe proteinuria, and 
collectively leads to marked chronic kidney failure (Refs 103, 104). On the other hand, 
lymphangiogenic therapies have shown promising results in restoring lymphatic function 
and drainage, thereby ameliorating tissue oedema (Ref. 105). Provoking lymphangiogenesis 
by viral vector over-expression of VEGF-C or exogenous administration of recombinant 
VEGF-C profoundly decreased interstitial fluid accumulation in experimental 
lymphoedemamodels (Refs 106, 107). Of remarkable interest is a recent study by Planas-
Paz L. et al. (Ref. 108), which convincingly showed that increased interstitial fluid pressure 
can mechanically prompt lymphangiogenesis in embryos. They demonstrated that 
mechanical stretching of LECs induces their proliferation in embryonic life, leading to 
increased LV’s size to improve their ability to drain fluid. This mechanism could be 
important for oedematous disorders in adult life. 
Fascinating discoveries from Titze’s lab (Refs 109, 110, 111) on the subject of non-osmotical 
storage of sodium in the subcutaneous interstitium involving immune cells and lymphatic 
vessels usher in a new era in the sodium homeostasis and hypertension field. This unique 
sodium storage subsequently induces lymphangiogenesis in the skin via the 
macrophage/VEGF-C signalling pathway, thereby creating buffering phenomena to halt 
hypertension in the salt-overload state. This lymphangiogenic response to high-salt diet 
appears to be specific to the skin and is not observed in the kidney. Interestingly, we found 
that plasma VEGF-C is modulated by salt intake, at least in proteinuric patients with chronic 
kidney disease, with higher VEGF-C levels being observed during high salt intake. We also 
reported increased VEGF-C level in proteinuric patients compared to healthy control 
individuals for both sodium intakes (Ref. 112). Circulating VEGF-C is also higher in 
preeclamptic women compared to normal pregnant women (Ref. 113). Although the 
response of VEGF-C to altered sodium intake in preeclamptic women remains unclear, this 
does suggest that increase in the lymphangiogenic state also occurs in preeclampsia, as a 
parallel to our observation of CKD proteinuric patients (Ref. 114). These data emphasize 
that blood pressure regulation is not only a kidney affair and actually is more complex, 
highlighting the role of LVs and immune cells in hypertensive disorders. How these 
advances can be transferred to daily clinical practice for preventive or curative therapy is 




Many renal diseases are associated with proteinuria. Since proteinuria is independently 
associated with the decline in renal function, anti-proteinuric treatment comprises a major 
cornerstone in clinical nephrology. Nevertheless, annihilation of proteinuria is very difficult, 
and most patients slowly progress towards renal failure. This indicates the need for 
additional treatment modalities: not only in trying to reduce proteinuria even further, but 
also to reduce the harmful effects of proteinuria downstream. Overexposure to filtered 
plasma proteins injure and activate tubular epithelia cells, and upon activation they start 
secreting several kinds of chemokines and mediators (Ref. 115). We recently showed in a 
time-course study of experimental rat proteinuric nephropathy that proteinuria can trigger 
renal lymph vessel formation (Ref. 70). Secretion of VEGF-C by activated proximal tubular 
epithelial cells secondary to proteinuria was suggested to be the main source for promoting 
proteinuria-driven renal lymphangiogenesis. We observed in this model that early 
proteinuria can not evoke renal lymphangiogenesis up to six weeks. However, prolonged 
and chronic proteinuria by activation of the tubular epithelial cells can trigger massive renal 
lymphangiogenesis at week twelve. In addition, anti-proteinuric intervention prevented this 
renal lymphangiogenesis. We found that renal lymphangiogenesis occurs in line with 
tubular activation (evidenced by osteopontin expression), profibrotic reactions (interstitial 
α-SMA); however, before the influx of ED1-positive macrophages, and before deposition of 
collagen I and III. This suggests that renal lymphangiogenesis is an early response, at least in 
our model, and starts prior to the development of fibrosis and inflammation. As already 
mentioned, LECs also express CCL21, which can attract CCR7+ fibrocytes and immune cells 
and are therefore able to promote renal fibrosis. Although we did not investigate whether 
LECs express this chemokine at the early phase (6 weeks), blocking lymphangiogenesis 
appears to be a promising intervention to prevent proteinuria-mediated tubulointerstitial 
inflammation and fibrosis, and is currently under investigation. Another observation was 
concomitant tubular expression of osteopontin which, after VEGF-C, is a potent 
lymphangiogenic factor, at least in the melanoma cell line (Ref. 116). To date, the role of 
osteopontin in renal lymphangiogenesis remains unknown.  
Diabetic nephropathy 
Hyperglycaemia has been linked to LV remodelling and lymphangiogenesis in various 
organs (Refs 117-120). Sakamoto I. et al. (Ref. 23) reported that lymphangiogenesis and 
VEGF-C expression was significantly higher in human biopsies with type 2 diabetic 
nephropathy than in non-diabetic renal diseases. Notably, there was no correlation 
between renal lymphangiogenesis, the extent of fibrosis and inflammation in these 
biopsies, which could suggest that diabetic conditions have a direct impact on the growth of 
renal lymphatics. Similarly, oedematous renal tissues with nephropathy and renal 
lymphangiogenesis have been observed in diabetic mouse kidneys (Ref. 121). However, the 
effect of glucose and advanced glycation end-products on VEGF-C production and other 
lymphangiogenic mediators which orchestrate renal lymphangiogenesis in diabetic 
nephropathy and its impact on renal pathophysiology has not yet been fully explored. 




The potent impact of lymphatic invasion and lymphangiogenesis in cancer development 
and metastasis has been extensively investigated, and is suggested to be associated with 
poor prognosis in several human malignant tumours (Ref. 122). However, the significance 
of lymphangiogenesis, compared to angiogenesis, is unclear in renal cancers, even in the 
most common kidney tumour, renal cell carcinoma. Despite the fact that the VEGF-
C/D/VEGFR-3-axis has been reported to be important in lymphatic tumour spread (Ref. 
123), others (Ref. 124) found no correlation for this axis with clinicopathologicalparameters. 
Using the D2-40 antibody and applying an immunohistochemistry approach, one study (Ref. 
125) reported that intratumoural LVs and lymphatic invasion are associated with renal cell 
carcinoma tumour aggressiveness, and that patients with intratumoural LVs have poor 
prognosis. Two other studies reported that intratumoural LVs rather than peritumoural 
lymphatic vessels correlate with prognostic values such as distant metastasis, and can be 
used as indicators of high risk of renal cell carcinoma metastasis (Refs 126, 127).However, 
other studies aiming to evaluate lymphangiogenesis in renal cell carcinoma were largely 
unable to find intratumoural LVs and no correlation between these findings (intratumoural 
and peritumoural LVs)and prognostic clinical parameters was found (Refs 25, 128, 129). LV 
involvement within the sinus and renal pelvis have also been proposed to be sources for 
tumour cell spread via LVs and lymph node metastasis in clear cell renal cell carcinoma (Ref. 
130). Recently, in a large single institution analysis of renal cell carcinoma patients, 
capillary-lymphatic invasion was suggested to be independently associated with renal cell 
carcinoma death and metastasis (Ref. 131). Although this needs to be validated by further 
studies, Kroeger N. et al. (Ref. 132) reported for a small cohort that clear cell renal cell 
carcinoma with lymphatic spread can be characterized by unique molecular, 
clinicopathological and genetic changes, such as high epithelial VEGFR-2 protein expression 
and low chromosome 3p loss at the genetic level. Other studies have revealed no induction 
of VEGF-C in renal cell carcinoma (Ref. 22) and a very limited ongoing lymphangiogenesis 
(Ref. 129). Collectively, the conflicting data on lymphangiogenesis in renal cell carcinoma 
does not yet allow any clear conclusion on its potential roles in tumour growth and 
metastasis and warrant future investigations. 
Summary 
Lymphatic vessels (LV) and lymphangiogenesis are actively involved in many pathological 
conditions. In various diseases, LEC activation and lymphangiogenesis is the response of LVs 
to disturbances in microenvironmental homeostasis in order to maintain the physiological 
conditions. One of the main functions of LVs is to enforce the balance between interstitial 
fluid transport and maintaining tissue homeostasis. Therefore, it is conceivable that any injury 
that has a negative effect on LV function, leads to tissue fluid accumulation and interstitial 
oedema. In almost all chronic kidney diseases, especially those associated with proteinuria, 
interstitial swelling and oedema is a common finding. This swelling of the renal interstitial 
space is known to induceremodelling of the interstitial matrix and, as a consequence, renal 
fibrosis. As CKD is a multifactorial disease with complex pathophysiology, renal oedema can 
be considered as a one of the active factors in promoting CKD. The potential significance of 
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LVs can be evaluated by modulating its development in experimental models of CKD. 
Potential strategies, including increasing LV number and/or function, have been proposed as 
a therapeutic option in patients suffering from lymphedema. These interventions may have 
the same promising effects in kidney diseases associated with renal oedema. In many cases, 
an increase in LV number might be detrimental by exacerbating the inflammatory milieu and 
thereby actually promoting the disease condition. There is a well-established reciprocal 
interaction between inflammation and lymphangiogenesis. Inflammatory cells and mediators 
are the most potent lymphangiogenic inducers, and the activated LECs in this inflammatory 
milieu secrete several chemokines that attract inflammatory cells around those LVs that are 
further upholding that inflammatory microenvironment. Recent evidence showed that 
modulating lymphangiogenesis could serve as a therapeutic strategy in inflammatory 
diseases. Many renal diseases are associated with inflammatory reactions; therefore 
targeting LVs might be useful in reducing the progression of renal inflammation. Several 
fibrotic renal diseases are closely associated with renal lymphangiogenesis. Although not 
investigated specifically in renal diseases yet, a direct causal link between lymphangiogenesis 
and fibrosis in other organs has also been proposed. LECs are able to secrete various 
mediators and chemokines which not only promote the inflammatory process, but are also 
directly involved in the initiation and progression of fibrosis. Inhibiting renal 
lymphangiogenesis, and as a result, blocking the expression of several mediators by LECs 
might be considered as a therapeutic rationale in preventing the progression of renal fibrosis. 
Proteinuria triggers renal lymphangiogenesis. Currently, the significance of this proteinuria-
induced renal lymphangiogenesis is not known. Since proteinuria is associated with renal 
oedema, LV formation may be a positive response in order to promote removal of 
accumulated excess interstitial fluids from the kidney. In addition, renal lymphangiogenesis is 
one of the interstitial remodelling processes downstream of proteinuria. The direct blocking 
of lymphangiogenesis may not be an effective approach, as continuous activation of tubular 
epithelial cells by ultrafiltrated plasma proteins plays the major role in the expression of 
lymphangiogenic growth factors such as VEGF-C. Stimulation of renal lymphangiogenesis 
might be useful as an add-on to other drugs that directly target activated tubular cells or 
downstream secreted mediators. Lymphangiogenesis in the context of transplantation may 
be a double-edged sword. Lymphangiogenesis can be beneficial in order to remove the 
inflammatory cells and mediators as well as excess fluid from the transplanted organ and in 
this way preventing oedema and further tissue injury. On the other hand, lymphangiogenesis 
can be detrimental as they facilitate transport of antigen presenting cells as well as 
chemokines, cytokines, and inflammatory mediators to the draining lymph nodes and 
initiating alloimmune reactions thereby promoting graft rejection. The usefulness of blocking 
pre- and post-transplant lymphangiogenesis has been shown in experimental models of organ 
transplantation. However, this has not been described renal transplantation yet and needs 
further investigation before it can be considered as a clinical approach in renal transplant 
medicine.  
Lymphangiogenesis is mostly investigated in the cancer field of research as one of the main 
routes for tumour metastasis. Several kinds of renal cancers are also shown to be 
associated with pre and/or intratumoural lymphangiogenesis. Inhibiting lymphangiogenesis 
might also be a therapeutic option to target malignancies of the kidney. Extensive 
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investigations that are currently being performed in both the experimental and clinical 
cancer field will definitely provide us with more knowledge about the role and therapeutic 
values of anti-lymphangiogenic therapy in preventing tumour growth and metastasis, and 
may have the same implication in kidney tumours. 
Perspective 
The active role of lymphatic vessels and lymphangiogenesis in many pathological conditions 
is well-established today. Recently, the anti-VEGFR3 antibody for blocking tumour 
lymphangiogenesis entered phase 1 clinical trials. However, the beneficial or detrimental 
effects of lymphangiogenesis would appear to be very context-dependent and organ-
specific. As such, both promoting lymphangiogenesis – for example, by using VEGF-C – and 
inhibiting it could be served as therapeutic modalities. The available knowledge brings the 
renal lymphatic network forward as an intriguing and promising structure in modulating 
interstitial homeostasis, inflammation and fibrosis in kidney diseases. Specific targeting of 
lymphangiogenesis in renal disease models would appear to be crucial to unravelling the 
causal relation between lymphangiogenesis and fibrosis, and could be a novel therapeutic 
strategy to prevent renal fibrosis, progression to End Stage Renal Disease (ESRD) and renal 
function loss. Improved understanding of the detailed mechanisms involved in renal 
lymphatic functions and remodelling are needed and require future research to provide 
possible therapeutic interventions for curative or preventive approaches in renal diseases.  
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Background. Recent experimental findings demonstrate vascular endothelial growth factor 
C (VEGF-C)-mediated water-free storage of salt in the interstitium, which prevents a salt-
sensitive blood pressure state. It is unknown whether this mechanism plays a role in salt 
homeostasis and regulation of blood pressure in humans as well. Therefore, we 
investigated circulating VEGF-C levels and blood pressure during different well-controlled 
salt intake in chronic kidney disease (CKD) patients and in healthy subjects. 
Methods. In two crossover studies, non-diabetic proteinuric CKD patients (n = 32) and 
healthy subjects (n = 31) were treated with consecutively a low-sodium diet (LS, aim 50 
mmol Na+/day) and a high-sodium diet (HS, aim 200 mmol Na+/day) in random order, 
during two 6-week (CKD patients) and two 1-week periods (healthy subjects). 
Results. We found that VEGF-C levels are higher during HS than during LS in CKD patients (P 
= 0.034) with a trend towards higher VEGF-C in healthy subjects as well (P = 0.070). In CKD 
patients, HS was associated with higher NT-proBNP levels (P = 0.005) and body weight (P = 
0.013), consistent with extracellular volume (ECV) expansion and with higher blood 
pressure (P < 0.001), indicating salt sensitivity. In healthy subjects, blood pressure was not 
affected by dietary salt (P = 0.14), despite a rise in ECV (P = 0.023). 
Discussion. Our findings support a role for VEGF-C-mediated salt homeostasis in humans. 
Considering the salt sensitivity of blood pressure, this buffering mechanism appears to be 
insufficient in proteinuric CKD patients. Future studies are needed to provide causality and 
to substantiate the clinical and therapeutic relevance of this VEGF-C regulatory mechanism 
in humans. 




Classically, total body salt and extracellular volume (ECV) are thought to be closely linked 
and controlled by renal salt excretion and dietary salt intake only. Based on the assumption 
that extracellular body fluids are in equilibrium, excess interstitial salt is considered to be 
readily mobilized into the bloodstream for renal salt clearance. Blunted renal salt excretion 
in this concept results in ECV expansion, which can induce a rise in blood pressure, denoted 
as the salt sensitivity of blood pressure [1, 2]. In support of this concept, we found that salt-
sensitive healthy men have a higher ECV than salt-resistant men during high salt intake but 
not during low salt intake [3]. However, recent experimental findings demonstrating water-
free storage of salt question our current understanding on internal environment 
composition and warrant novel insights into regulatory mechanisms for salt homeostasis 
[4–9]. Salt can be stored in a newly discovered subcutaneous interstitial compartment by 
binding to polyanionic proteoglycans and glycosaminoglycans without commensurate 
water retention [10, 11]. In response to salt-mediated interstitial osmotic stress, 
mononuclear phagocyte system (MPS) cells secrete vascular endothelial growth factor C 
(VEGF-C), which stimulates lymphatic growth and endothelial nitric oxide synthase (eNOS) 
expression [12, 13]. When this system is inhibited, high salt intake induces excess interstitial 
salt retention and hypertension [4, 5]. 
In patients with refractory hypertension, a condition which is eminently salt sensitive [14, 
15], circulating VEGF-C levels were elevated compared to normotensive subjects [4], 
suggesting that this extrarenal regulatory mechanism might play a role in salt homeostasis 
and regulation of blood pressure in humans as well. If so, it can be hypothesized that 
circulating levels of VEGF-C respond to changes in salt intake, with higher VEGF-C levels 
during high salt intake. To test this hypothesis, we investigated circulating VEGF-C levels 
and blood pressure during steady state on different well-controlled salt intake in two 
independent studies, in proteinuric chronic kidney disease (CKD) patients and in healthy 
subjects, respectively. 
Materials and Methods 
This is a post hoc analysis of two previous studies described in detail elsewhere [3, 16]. 
 
CKD patients 
For the current study, we used data and samples collected during placebo treatment on a 
high-sodium diet (HS, target intake 200 mmol Na+/day) and low-sodium diet (LS, target 
intake 50 mmol Na+/day) from 32 non-diabetic proteinuric CKD patients [age 50 ± 2 years, 
73% men, all Caucasian, body mass index (BMI) 27 ± 1 kg/m2]. Mean achieved sodium 
intake was above target (90 ± 10 mmol/day) and according to protocol (200 ±10 mmol/day) 
during LS and HS diet, respectively. Duration of the dietary interventions was two times 6 
weeks, and the order was random. For two subjects from the original study, good quality 





From the original 34 study subjects, samples of sufficient quality were available for 31 
subjects (age 23 ±1 years, 100% men, all Caucasian, BMI 24 ±1 kg/m2). Data and samples 
were obtained after 1 week on a LS diet (target intake 50 mmol Na+/day) and after one 
week on a HS diet (target intake 200 mmol Na+/day), respectively, in random order. Mean 
achieved dietary sodium intake was below and above target values (34 ± 11 mmol/ day and 
257 ± 16 mmol/day, respectively) during LS and HS diet, respectively. 
 
Measurements and calculations 
At the end of each study period, all participants collected 24 h urine and, after an overnight 
fast, blood pressure was measured and blood was sampled. Proteinuria was measured by 
the pyrogallol red-molybdate method. Dietary sodium intake was assessed from 24 h 
urinary sodium excretion. Blood pressure was measured at 1-min intervals by an automatic 
device (Dinamap®; GE Medical Systems, Milwaukee, WI), with the patient in semisupine 
position. After 15 min of measurements, the mean of the last four readings was used for 
further analysis. Plasma VEGF-C levels were measured by ELISA (R&D Systems, Wiesbaden-
Nordernstadt, Germany). Intra- and interassay variation of the ELISA is 6.6 and 8.5%, 
respectively. The minimal detection level is 48.4 pg/mL. In the healthy subjects, ECV was 
measured by the distribution volume of 125-I-iothalamate as described previously [17]. 
 
Data analysis 
Data are given as mean with SEM or geometric mean with interquartile range (IQR) when 
skewed. Before statistical testing, skewed variables were subjected to natural log 
transformed to obtain normality. Comparisons between HS and LS were performed using 
paired T-tests.  
P<0.05was considered statistically significant. SPSS 18.0 for Windows (SPSSInc., Chicago, IL) 
was used for analyses. 
Results 
VEGF-C and general parameters in CKD patients 
CKD patients had overt proteinuria, a slightly elevated blood pressure and a rather 
preserved renal function (Table 1). Urinary sodium excretion, a measure of dietary sodium 
intake, was lower during LS than during HS. VEGF-C levels were significantly higher during 
HS than during LS [median (IQR) 1228 (1024–1471) versus 1004 (857–1177) pg/mL, 
respectively, P = 0.034; Figure 1]. NT-proBNP levels and body weight were also higher 
during HS than during LS, consistent with ECV expansion during HS. Blood pressure and 
proteinuria were higher during HS as well, indicating salt sensitivity of blood pressure and 
proteinuria in CKD patients. 
 
VEGF-C and general parameters in healthy subjects 
As expected, the healthy subjects had normal blood pressure, normal renal function and no 
proteinuria (Table 2). Urinary sodium excretion was considerably lower during LS than 
during HS, indicating excellent dietary compliance. VEGF-C levels tended to be higher 
VEGF-C levels in proteinuric CKD patients and in healthy subjects 
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0.001105±15101±11Mean arterial pressure – mmHg
0.0341228 (1024-1471)1004 (857-1177)Plasma VEGF-C – pg/mL
Table 1. General parameters in CKD patients
LS HS P-value
Proteinuria – g/day 3.0±0.4 3.8±0.4 <0.001
Systolic blood pressure – mmHg 137±3 143±3 <0.001
Diastolic blood pressure – mmHg 83±1 86±2 0.004
Creatinine clearance – mL/min 82±6 89±5 0.21
NT-proBNP – pg/mL 62 (41-93) 91 (60-137) 0.005
Body weight – kg 89±3 91±3 0.013
Plasma Na+ – mmol/L 139.0±0.4 139.1±0.4 0.67
Urinary Na+ excretion – mmol/day 90±10 200±10 <0.001
during HS than during LS, but the difference was not statistically significant [median (IQR) 
881 (758–1023) versus 773 (748–921) pg/mL, respectively, P =0.070; Figure 1]. Assuming 
that VEGF-C distributes over the ECV, we calculated the total amount of VEGF-C as product 
of plasma VEGF-C levels X ECV. Total VEGF-C was higher during HS than during LS [median 
(IQR) 18176 (14320–26405) versus 14539 (1002–22751) pg, respectively, P = 0.016). In line 
with the higher ECV during HS, NT-proBNP levels, body weight and creatinine clearance 
were also significantly higher during HS than during LS. Blood pressure in the healthy young 
men was not affected by dietary salt intake. Individual values for blood pressure and VEGF-
C during LS and HS in the CKD patients and the healthy subjects are given in Figure 2. No 
significant correlation could be detected in the healthy subjects nor in the CKD patients. For 
the pooled data on either sodium intake, a borderline significant correlation was present 
(R2= 0.217, P = 0.095 and R2= 216, P = 0.096 on LS and HS, respectively). However, the 
correlation disappeared after adjustment for population. The individual change in VEGF-C 
elicited by HS intake was not correlated with the change in mean arterial pressure in either 
study population, separately or pooled (Figure 3). Furthermore, no significant associations 
were found between change in VEGF-C levels/total amount of VEGF-C and change in ECV, 
NT-proBNP or body weight. VEGF-C levels, however, were significantly higher in CKD 






































































Figure 1. VEGF-C levels in CKD patients and healthy subjects. 
Abbreviations: VEGF-C, vascular endothelial growth factor C; LS, low sodium; HS, high sodium. 
Discussion 
We found that VEGF-C levels are modulated by salt intake in two different independent 
studies, with higher VEGF-C levels during high salt intake. Firstly, in proteinuric CKD patients 
after two 6-week periods of dietary intervention and secondly, in healthy subjects, after 
two 1-week periods of dietary intervention, albeit the latter of borderline statistical 
significance. In the CKD patients, higher salt intake was associated with higher blood 
pressure, whereas in the healthy subjects, the measured blood pressure was not affected 
by dietary salt, despite a rise in ECV. Animal studies have found that during high salt diet, 
the content and polyanionic character of glycosaminoglycans increase, accompanied 
byhypertonic salt storage in the ensuing reservoir tissue [7, 18]. VEGF-C, which is secreted 
by MPS cells in response to interstitial hypertonicity, induces eNOS expression by binding to 
VEGFR-2 [12] and stimulates lymphangiogenesis by binding to VEGFR-3 [13]. The resulting 
vasodilatory response and electrolyte removal from the interstitium prevents a salt-
sensitive blood pressure state [4, 5, 19–21]. This non-osmotic VEGF-C–macrophage–
lymphangiogenesis pathway may act alongside the osmotic storage of salt that translates 
into ECV excess. As currently no methods are established for investigation of salt storage in 
patient-oriented research, we can only speculate that dietary salt induces salt storage in 
specific reservoirs as well. However, the close association between changes in dietary salt 
intake followed by parallel changes in plasma VEGF-C levels supports the notion that 
changes in MPS-derived VEGF-C levels might serve as a clinical indicator for salt overload 
and salt storage in humans. 
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0.070881 (758-1023)773 (648-921)Plasma VEGF-C – pg/mL
0.01618176 (14320-26405)14539 (1002-22751)Total amount of VEGF-C – pg
0.02320.8±0.519.8±0.5Extracellular volume – L
0.2587±786±8Mean arterial pressure – mmHg
Table 2. General parameters in healthy subjects
LS HS P-value
Proteinuria – g/day <0.2 <0.2 -
Systolic blood pressure – mmHg 123±2 124±1 0.14
Diastolic blood pressure – mmHg 68±1 69±1 0.45
Creatinine clearance – mL/min 103±5 123±5 0.003
NT-proBNP – pg/mL 14 (11-19) 26 (20-35) 0.002
Body weight – kg 80±2 82±2 <0.001
Plasma Na+ – mmol/L 138.5±0.4 139.8±0.4 0.001













Abbreviations: LS, low sodium diet; HS, high sodium diet; VEGF-C, vascular endothelial growth factor C.   
 
We believe that this new research area warrants further investigation in patient-oriented 
research. In our proteinuric CKD patients, blood pressure increased during the high-salt 
diet, in line with the well-established salt sensitivity of blood pressure in CKD [22, 23] and 
along with a rise in body weight and NT-proBNP, suggesting ECV expansion. Concomitantly, 
VEGF-C levels were increased, suggesting that high salt intake induces an extrarenal 
homeostatic pathway in these patients as well. This increase in VEGF-C was present despite 
the fact that during LS dietary sodium intake was substantially higher than the target of 50 
mmol/day, thus limiting the difference with the HS period. Animal data support a role for 
the VEGF-C–macrophage–lymphangiogenesis pathway in the protection against developing 
hypertension in response to a HS intake [5]. Furthermore, subjects with refractory 
hypertension show higher plasma VEGF-C levels than controls, suggesting that this pathway 
is relevant in the pathogenesis of human hypertension as well [4]. In our study populations 
we did not find a between-individual correlation between levels of VEGF-C and blood 
pressure or between the responses of VEGF-C and blood pressure to HS when analyzing for 
individual responses, neither in the separate populations, nor for pooled data. This could 
implicate either absence of an association, or complete protection against a sodium 
induced rise in blood pressure by the adaptive response of the VEGF-C–macrophage–
lymphangiogenesis pathway. Whereas we want to emphasize that a head-to-head 
comparison between the two populations should be interpreted with caution, due to 
differences in the experimental design and patient characteristics, nevertheless, it is 
noteworthy that VEGF-C levels were higher in the CKD patients, i.e. in the population where 
blood pressure was sodium sensitive. The mechanism for the higher VEGF-C levels in CKD 
patients is of interest, but cannot be derived with certainty from our data. The data are 
consistent with the assumption that in CKD patients VEGF-C is stimulated more than in 
healthy controls on a similar sodium intake, which can be hypothesized to reflect a less 
effective response to sodium intake and hence a persisting stimulus. Whether this is due to 
differences in osmotic storage, non-osmotic storage, or to blunted sodium excretion in CKD 
leading to difference in overall sodium balance cannot be ascertained from our data. 
However, the higher NT-proBNP levels in CKD on each sodium intake are consistent with a 




The rise in blood pressure during HS in CKD patients suggests that the presumed extrarenal, 
MPS-driven regulatory mechanism is not sufficient to preclude a rise in blood pressure in 
response to HS. Of note, as VEGF-C reduces the permeability of the glomerular filtration 
barrier and promotes podocyte survival [24, 25], an increase in VEGF-C is theoretically 
expected to reduce proteinuria, independently of blood pressure. At variance with this 
consideration, in our patients proteinuria increased during high salt intake, probably 
secondary to the rise in blood pressure. In an independent study in healthy subjects, VEGF-
C levels were also increased by a 1-week period on high-salt diet, with a concomitant rise in 
the ECV and creatinine clearance, whereas blood pressure was salt resistant. These data 































































 Figure 2. Association between VEGF-C levels and MAP during low and high sodium diet.  
Abbreviations: LS, low sodium diet; HS, high sodium diet; VEGF-C, vascular endothelial growth factor C. 
 
specific for local tissue salt storage, is stimulated by high salt intake, alongside the 
conventional renal osmotic pathways of salt homeostasis. The rise in creatinine clearance 
can be considered part of the integrative homeostatic response to HS and is considered 
instrumental in facilitating excretion of the excess sodium and sodium resistance of blood 
pressure. This is consistent with our current observation of a rise in creatinine clearance in 
our sodium resistant healthy subjects and a smaller, non-significant rise in creatinine 
clearance in our sodium-sensitive CKD patients. Of note, we previously demonstrated that 
the rise in GFR on HS closely corresponds to the rise in ECV, i.e. the osmotic storage 
































Figure 3. Association between change in VEGF-C levels and change in MAP elicited by HS diet. 
Abbreviations: MAP, mean arterial pressure; VEGF-C, vascular endothelial growth factor C; HS, high sodium. 
 
Our data are the first to document an effect of a salt intake on VEGF-C, a crucial step in the 
newly identified VEGF-C–macrophage–lymphangiogenesis pathway as an extrarenal 
homeostatic mechanism in the response to an increase in salt intake in humans, in a salt-
sensitive as well as a salt-resistant condition. Unfortunately, we have no data on total body 
composition and salt content. Furthermore, it would be of great interest to directly monitor 
local interstitial changes in humans during dietary salt intervention in future research.  
To conclude, VEGF-C levels are increased by a high-salt diet in proteinuric CKD patients and 
in healthy subjects, supporting a role for VEGF-C-mediated interstitial regulatory 
mechanisms in salt homeostasis in humans. Considering the rise in blood pressure during a 
high-salt diet, this buffering mechanism for salt-sensitive hypertension appears to be 
insufficient in proteinuric CKD patients. Future studies should investigate the clinical 
relevance, the reasons for failure in CKD and potential targets for intervention, of VEGF-C 
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Organs derived from deceased brain dead (DBD) donors show worse function than those 
from living donors (LD), possibly due to the inflammatory burst in DBD donors. Recently, 
renal lymphangiogenesis has been documented as an important player in inflammation, 
fibrosis and tubulointerstitial remodeling. We studied lymphatic vessels (LVs) in pre-
existent renal damage in kidney biopsies from DBD and LD and investigated their 
associations with other histological parameters.  
In biopsies of 73 DBD and 131 LD, the degree of focal glomerulosclerosis (FGS), interstitial 
fibrosis (IF), intima thickness and vascular hyalinosis were analyzed. Sections were 
evaluated for number of macrophages, granulocytes, lymphatic vessel density (LVD), α-SMA 
and interstitial fibrosis (IF).  
Arteriopathy, tubulointerstitial inflammation and fibrosis were increased in DBD compared 
to LD (p<0.05). LVs were mainly localized in the adventitial area around arteries and 
arterioles. LVD was ~1.7-fold higher in DBD kidneys compared to LD kidneys (p<0.001). 
Within the DBD group, LVD and other histological parameters were significantly higher in 
donors that died as a result of a CVA compared to traumatic BD.  
The increased signs of arteriopathy, IF and inflammation in DBD donor biopsies correlated 
to renal LVD which stresses the importance of investigating LVD in prospective studies on 
kidney transplant biopsies. 




The majority of organs for transplantation are derived from deceased brain dead (DBD) 
donors. Unfortunately, the process of brain death is associated with a cascade of 
hemodynamic, inflammatory, hormonal and immunologic events that negatively affect 
function and outcome of transplanted kidneys (1-3). In kidney transplantation, Living 
Donation (LD) is a well-established way to increase the number of transplants and in many 
countries this is common practice. Transplantation outcome of LD kidneys is superior 
compared to DBD kidneys (4). 
The critical importance of donor organ quality, ability to withstand transplant-related 
injury, and capacity for repair in determining short- and long-term outcome is well 
recognized. In the kidney, minor interstitial, vascular and glomerular damage can already be 
present without clinical signs of deterioration such as proteinuria or decreased kidney 
function due to the large reserve capacity. Besides clinical parameters, donor baseline 
biopsies have been used to assess the quality of a donor organ mainly in centers in the USA 
(5-8). One of the components of the inflammatory events that take place in the DBD donor 
is the influx of macrophages and granulocytes (9-11). This infiltration is initially meant to 
modulate the inflammatory process and subsequently take part in repairing process once 
the initial trigger has vanished. Ultimately the continuing presence of inflammation 
becomes pathological, resulting in renal fibrosis with damaging consequences for the donor 
organ (12). Several studies have evaluated histological lesions in assessing organ quality as 
well as predicting early- and long-term transplantation outcomes (13-20). Interstitial 
fibrosis (IF), fibrous intimal thickening, focal glomerulosclerosis (FGS) and arteriolar 
hyalinosis have variably been identified as parameters in predicting delayed graft function 
(DGF) and/or poorer graft function and survival (7, 14, 21-23).  
 
Lymphatic vessels (LVs) and its outgrowths (lymphangiogenesis) seem to play an important 
role in kidney pathophysiology, especially in renal transplantation (24, 25). However, 
conflicting results on the role of LVs and lymphangiogenesis in organ transplantation have 
been reported. Lymph vessel density (LVD) has been reported to increase early after renal 
transplantation independently of signs of rejection, and associates with different kinds of 
inflammatory reactions (25, 26). Pre-existing lymphatic vessels in corneal transplant 
recipients significantly reduced corneal graft survival; while recipient’s pre-transplant 
blocking of lymphangiogenesis prolonged this graft survival (27, 28). The exact role of LVs 
within pre-existing renal damage at time of kidney donation and transplantation has not 
been established yet. 
 
Baseline histologic lesions at time of transplantation and their effect on kidney function and 
graft survival have been evaluated using different scoring systems. Although 
lymphangiogenesis has been proposed to be an interesting novel therapeutic target in 
kidney transplantation (25), none of these studies (5, 15, 18, 19, 29-32) have evaluated LVD 
and its association with other histological changes in biopsies from (pre)transplant DBD and 
living donors. In the light of the current knowledge about kidney transplant biopsies, we 
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aimed to study our single center kidney transplant population. Therefore we quantified LVD 
and other pre-existent damage parameters in kidney biopsies of DBD and living donors, and 
investigated the association between these structural changes. We hypothesize that LVD, 
pre-fibrotic, fibrotic and inflammatory glomerular, vascular and interstitial changes are 
increased in biopsies of DBD donors compared to biopsies of LD. Next, we expect the origin 
of brain death to be reflected by these pre-existent renal damage parameters. To provide 
more insight in the development of pre-existent renal damage in the DBD donor, we 
performed secondary analyses comparing all parameters between DBD donors who died 
due to a cardiovascular accident (CVA) with DBD donors who died because of a traumatic 
accident. 
Methods and Materials 
Biopsies from 238 donor kidneys were consecutively collected during organ procurement 
and transplantation procedures from 2005 through 2008 at the University Medical Center 
Groningen. Renal biopsies were obtained from DBD (n=73) and living donors (n=131) at 
three different time points: just prior to donation (before kidney recovery and start of 
preservation), at the end of cold ischemia and 45 min after reperfusion. All DBD donors 
were declared brain dead on the intensive care and samples were collected after 
declaration of brain death with consent from the legally authorized relative according to 
the Dutch Transplantation Law. According to this law, general consent for organ donation 
and transplantation includes consent for research projects. Nevertheless, the Institutional 
Review Board approved the study protocol, which was in adherence to the Declaration of 
Helsinki and all methods were carried out in accordance with the approved guidelines. 
All clinical data were anonymized prior to analysis. Biopsies were taken using a 16-gauge 
needle (Acecut®, TSK Laboratory, Japan), and subsequently stored in formalin and paraffin 
fixed until analysis. Renal donor biopsies from 21 donors showed merely non-cortical tissue 
and were excluded from analysis. Since three biopsies were taken from each kidney the 
exclusion was not considered to have any effect on the outcome. Screening or follow-up 
data from 13 donors were missing. This results in a total of 204 donors eligible for analysis.  
 
Immunohistochemistry 
Deparaffinized sections were subjected to heat-induced antigen retrieval either by 
overnight incubation in a 0.1 M Tris-HCl buffer (PH 9.0) at 80°C, or 10 mM Tris-1 mM EDTA 
buffer (PH 9.0) for 15 minutes in the microwave. Endogenous peroxidase was blocked with 
0.3% H2O2 in PBS for 30 min. Sections were incubated with D2-40 antibody (clone D2-40, 
diluted 1:40, DAKO, Glosstrup, Denmark) for lymphatic vessels, α-SMA antibody (clone1A4, 
diluted 1:10000, Sigma, Zwijndrecht, The Netherlands), CD68 antibody (clone PGM-1, 
diluted 1:250, DAKO, Glosstrup, Denmark) for macrophages, or with monoclonal antibody 
12.8 (33) (clone 12.8, diluted 1:10) for 60 min at room temperature for neutrophils. This 
monoclonal antibody was a gift from Prof. Dr. C.A. Stegeman (University Medical Center 
Groningen, The Netherlands). Binding of the antibody was detected using sequential 
incubations (30 min each) with PO-labeled rabbit-anti-mouse (RAMPO, diluted 1:100, 
DAKO) and PO-labeled goat-anti-rabbit antibodies (GARPO, diluted 1:100, DAKO). PO 
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activity was developed using 3, 3’-diaminobenzidine tetrachloride (DAB) for 10 min. 
Sections stained for lymphatic vessels and macrophages were counterstained with PAS. 
Sections for neutrophilic granulocytes were counterstained with hematoxylin. Interstitial 
cortical lymphatic vessels were counted manually (Image J version 1.46r) and expressed as 
the number of LVs per mm2 of cortical area, lymph vessel density (LVD). As we do not 
expect any new lymph vessel formation during cold ischemia or after reperfusion, the mean 
score of all counted lymphatic vessels in three biopsy time points were calculated and used 
for statistical analysis. α-SMA expression was determined by Positive Pixel Count (Aperio 
Imagescope version 10.2.2). Macrophages and neutrophilic granulocytes were counted 
manually in the interstitium. Since the influx of inflammatory cells does not occur during 
cold ischemia, we used the scores from the second biopsy for analysis. Glomeruli, the renal 
medulla and vessels were excluded from counting and surface area calculation. For α-SMA 
expression analysis, average score from all three biopsy time points were used. All scores 
were adjusted for biopsy surface area (BSA). 
 
Morphological damage 
To evaluate the degree of FGS, IF and vascular hyalinosis, paraffin sections (3 µm) were 
stained with Periodic Acid Schiff (PAS) and scored by a renal pathologist blinded for donor 
type and other clinical characteristics. A surface calculation using Aperio Imagescope was 
performed on all the sections. IF was defined as expansion of the interstitial space, with or 
without the presence of atrophied and dilated tubules and thickened tubular basement 
membranes. The glomeruli, renal papilla and vessels were excluded from the calculated 
fibrotic areas. The degree of IF was scored on a scale of 5: 0%, 0-10%, 10-25% 25-50%, 50-
75% and 75-100% of biopsy surface area. FGS was scored as % of total glomeruli. Vascular 
hyalinosis was scored as none, scarce, moderate, or severe. A mean score was calculated 
from the three different time points and adjusted for surface area. To calculate a mean 
score, at least three arteries had to be present.  
 
Arterial intima thickness 
Intima surface was expressed as a percentage of the media surface, to provide a 
standardized estimation of the severity of intima thickening independent of vessel size. A 
higher percentage represents a relatively thicker intima. For this purpose, all arteries 
present in the biopsies were analyzed in the α-SMA stained sections. For each vessel, media 
and intima were outlined to calculate individual surfaces using Aperio Imagescope. Intima 
surface was expressed as percentage of media surface. For each donor, the separate vessel 
scores of all three biopsy time points were mediated. At least values from three vessels 
were required to calculate an overall score. 
 
Donor kidney function measurements 
Through constant low-dose infusion of the radiolabeled tracer 125I-iothalamate the 
glomerular filtration rate (GFR) was measured in the living donor as described by Visser and 
Apperloo et al. four months prior to transplantation(34, 35). During the measurements, 
donors were seated in a quiet room in a semi supine position. After drawing a blank blood 
sample, the priming solution containing 0.04 mL/kg body weight of the infusion solution 
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(0.04 MBq of 125I-iothalamate and 0.03 MBq of 131I-hippurate per mL saline) plus an extra of 
0.06 MBq of 125I-iothalamate was given, followed by constant infusion at 12 mL/h. To attain 
stable plasma concentrations of both tracers, a 2-hour stabilization period followed, after 
which the clearance periods start. Clearances were measured over the next 2 hours and 
calculated as (U*V)/P and (I*V)/P, resp. U*V represents the urinary excretion of the tracer, 
I*V represents the infusion rate of the tracer and P represents the tracer value in plasma at 
the end of each clearance period. GFR was calculated from U*V/P or 125I-iothalamate and 
corrected for voiding errors by multiplying the urinary clearance of 125I-iothalamate with 
the ratio of the plasma and urinary clearance of 131I-hippurate. The day-to-day variability for 
GFR is 2.5%. 
 
Table 1. Characteristics of 131 living donors and 73 DBD donors at the day of their last pre-transplant 
visit to the out-patient clinic or last pre-transplant data reported by Eurotransplant 
Donor type DBD donors 
(n = 73) 
Living donors 
(n = 131) 
P 
Demographics    
Age at donation (years) 53 [44-57] 53 [45-59] 0.51 
Female donor, n (%) 65 46 0.006 
BMI at donation (kg/m2) 25 ± 4 26 ± 4 0.003 
Underlying illness    
History of hypertension (%) 26 20 0.31 
History of diabetes mellitus (%) 6 0 0.007 
Hemodynamic parameters    
SBP (mmHg) 130 ± 27 129 ± 15 0.18 
DBP (mmHg) 70 ± 13 77 ± 9 <0.001 
Renal Function parameters    
Serum creatinine (µmol/L) 73 ± 25 78 ± 15 0.002 
GFR (ml/min/1.73 m2) NA 117 ± 21  
Death    
Death: CVA 74 % NA  
Death: trauma/other 26 % NA  
Duration of brain death (min) 613 [478-740] NA  
 
Data are presented as mean ± SD, % or median [interquartile range]. Abbreviations: DBD, deceased brain dead; BMI, body 
mass index; SBP systolic blood pressure; DBP diastolic blood pressure; GFR, glomerular filtration rate; CVA: cardiovascular 
accident. P for difference was tested by the Mann-Whitney U test. 
 
Body surface area (BSA) was calculated as according to Dubois (36). GFR was normalized by 
dividing the raw sample by BSA and multiplying it with 1.73, giving GFR/BSA. 
 
Clinical data  
We measured body mass index (BMI), systolic blood pressure (SBP), diastolic blood 
pressure (DBP) and serum creatinine in the living donor prior to transplantation during the 
GFR measurements. For DBD donors these parameters were recorded from the 
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Table 2. Correlations of LVD and histopathological damage parameters based on renal biopsies of 
kidney transplant donors. 
Parameter 
LVD T1 
n = 99 
LVD T2 
n = 159 
LVD T3 
n = 152 
LVD mean 
ρ p Ρ p ρ p ρ P 
Macrophage intensity 
(number/10.000 µm2) 
0.24 0.02 0.27 0.001 0.03 0.78 0.22 0.03 
Mean arterial intima thickness  
(% of media thickness) 
0.22 0.04 0.041 0.62 0.08 0.32 0.14 0.07 
Glomerulosclerosis (% of total 
glomeruli) 
0.002 0.99 0.13 0.10 0.21 0.01 0.10 0.17 
Interstitial α-SMA (intensity) 0.03 0.76 0.12 0.15 0.09 0.30 0.10 0.17 
Mean vascular hyalinosis (number) 0.11 0.27 0.13 0.10 0.09 0.28 0.19 0.009 
Mean interstitial fibrosis (number) 0.07 0.49 0.07 0.40 0.16 0.06 0.12 0.09 
Interstitial neutrophilic 
granulocytes (number*10.000) T2 
  
0.20 0.01 
    
   Data are expressed as Spearman’s rho (ρ) and p-value. 
 
Statistical analysis  
Analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL). For comparison of 
two groups, Mann Whitney U test was performed in case of continuous variables, the Chi-
square test for dichotomous variables and the Fisher’s Exact test for the history of diabetes 
mellitus. Results are presented as mean ± SD (standard deviation). All eight 
histopathological injury parameters showed a skewed distribution. Biopsies of different 
donor types were not matched to analyze the difference in histopathological injury. To 
evaluate associations of these injury parameters with donor characteristics, Spearman’s 
correlation coefficients were calculated on the pooled donor data to determine which 
variables were significantly associated. Two-sided P-values of less than 0.05 were 
considered to indicate statistical significance. 
Results  
Donor characteristics 
The characteristics of DBD and LD are shown in table 1. The groups were similar with 
respect to age at donation, SBP and a history of hypertension. Females were 
overrepresented in the DBD group compared to the LD (65.4% vs. 45.8%). Compared to 
DBD donors, LD had significantly higher levels of serum creatinine (78±15 μmol/L vs. 73±25 
μmol/L, p=0.002). BMI and DBP at donation were significantly higher in the LD compared to 
DBD donors (BMI 26±4 kg/m2 vs. 25±4 kg/m2, p=0.003; DBP 77±9 mmHg vs. 70±13 mmHg, 
p<0.001).  
 
Correlations with donor characteristics 
Donor age was correlated with IF and FGS (ρ=0.5, p=0.02 and ρ=0.6, p=0.03 resp.) in all biopsies. 
No correlations of damage parameters with GFR prior to donation (living donors) were found. 
None of the histological damage parameters correlate with the use of antihypertensive drugs 
except for the use of calcium antagonists and IF (ß=0.48, p=0.03) in LD.  
CHAPTER 4 
60 







Lymphatic vessel density (lymphatic vessel/mm2) 7.7 ± 5.92 4.61 ± 3.14 0.001 
Interstitial α-SMA (intensity) 2.24 ± 2.09 1.55 ± 1.44 0.02 
Interstitial macrophages (number) 0.14 ± 0.1 0.09 ± 0.05 0.001 
Interstitial neutrophilic granulocytes (number*10.000) 0.33 ± 0.35 0.21 ± 0.27 0.007 
Glomerulosclerosis (% of total glomeruli) 0.38 ± 0.66 0.50 ± 2.92 0.72 
Interstitial fibrosis 0.76 ± 0.60 0.83 ± 0.49 0.59 
Vascular hyalinosis 0.44 ± 0.67 0.18 ± 0.42 0.003 
Arterial intima thickness (% of media thickness) 42.7 ± 29.4 36.5 ± 15.2 0.27 
Data are expressed as mean ± SD. IF, FGS and vascular hyalinosis are expressed in absolute numbers. P for difference was 
tested by the Mann-Whitney U test. 
 
Correlations of LVD with other histological damage parameters 
These correlations in the whole donor group are shown in table 2. LVD mean and LVD at T1 
and T2 was associated with macrophage intensity (ρ=0.22, p=0.03; ρ=0.24, p=0.02; ρ=0.27, 
p=0.001 resp.). LVD measured at T1 was associated with arterial intima thickness (ρ=0.22, 
p=0.04). LVD T3 was associated with FGS (ρ=0.21, p=0.01). Mean LVD was found to be 
associated with mean vascular hyalinosis (ρ=0.19, p=0.009). At T2, LVD was associated with 
neutrophilic granulocytes (ρ=0.20, p=0.01). Within the DBD biopsies, LVD was correlated 
with signs of arteriopathy such as hyalinosis (ρ=0.25, p=0.04), and with markers of 
interstitial injury such as IF (ρ=0.3, p=0.02).  
 
Difference in pre-existent damage between DBD and LD 
Data on al histopathological damage parameters are shown in table 3. The number of 
interstitial macrophages and α-SMA intensity was higher in DBD donors compared to LD 
(1.55±1.44 vs. 2.24±2.09, p=0.001; 0.14±0.1 vs. 0.09±0.05, p=0.02; resp.; figure 1). The 
number of neutrophilic granulocytes and vascular hyalinosis scores were higher as well in 
DBD donors (0.33±0.35 vs. 0.21±0.27, p=0.007; 0.44±0.67 vs. 0.18±0.42, p=0.003; resp.; 
figure 1). No significant differences in glomerulosclerosis, IF and arterial intima thickness 
between both donor types were found (figure 1). LVD was markedly higher in DBD donors 
compared to LD (7.70±5.92 vs. 4.61±3.14, p<0.001, figure 2), and were found around 
arteries and veins. Almost no lymph vessels were observed in interstitial space far from 
arterial adventitia. 











































Figure 1. Representative image of stained cortical kidney sections of a living and DBD donor, 
demonstrating increased in the α-SMA expression (A, B), number of interstitial macrophages (C, D), numbers of neutrophilic 
granulocytes (E, F) and vascular hyalinosis (G, H) in DBD donor biopsies. The extent of FGS (I, J) and interstitial fibrosis (K, L) 
showed an increase in some samples of DBD, however, when comparing the whole series of biopsies between LD and DBD, 
there was no significant difference.  
CHAPTER 4 
62 










LVD (lymphatic vessel/mm2) 8.11 ± 6.34 5.78 ± 2.80 0.71 
Interstitial α-SMA (intensity)  2.34 ± 2.13 1.95 ± 2.00 0.47 
Interstitial macrophages (number)  0.15 ± 0.09 0.12 ± 0.12 0.06 
Interstitial neutrophilic granulocytes (number*10.000)  0.37 ± 0.38 0.20 ± 0.15 0.27 
Glomerulosclerosis (% of total glomeruli) 0.43 ± 0.71 0.19 ± 0.44 0.17 
Interstitial fibrosis  0.92 ± 0.56 0.39 ± 0.53 0.001 
Vascular hyalinosis 0.50 ± 0.70 0.30 ± 0.57 0.25 
Arterial intima thickness (% of media thickness) 48.56 ± 33.29 28.75 ± 4.72 0.001 
Data are expressed as mean ± SD. IF, FGS and vascular hyalinosis are expressed in absolute numbers. P for difference was 
tested by the Mann-Whitney U test. 
 
Secondary analyses in DBD donors separated by cause of death 
In table 4, damage scores of the DBD donors are shown per cause of death. LVD was not 
significantly different in DBD donors that died from a CVA compared to trauma or other 
causes. IF and arterial intima thickness were higher in the group that died as a result of a 
CVA (0.92±0.56 vs. 0.39±0.53; 48.56±33.29 vs. 28.75±4.72, resp.; both p<0.05).  
Discussion 
To our knowledge, this is the first study showing that the number of lymphatic vessels is 
significantly higher in pretransplant kidney biopsies of DBD compared to LD. In line with the 
number of LVs, pro-fibrotic, vascular and inflammatory damage in the pretransplant DBD 
kidney biopsies were also higher. The prominent pre-existent renal damage in kidneys from 
DBD donors compared with kidneys from LD is supported by several other studies. 
However, this evaluation has not been performed in such a large cohort before, thereby 
providing a more complete understanding of the differences in donor kidney quality (6, 7).  
The role of lymphangiogenesis in organ transplantation is still under debate. Upon renal 
transplantation, lymphangiogenesis has been observed; however, little is known about the 
role of lymphangiogenesis at time of donation. LVD was not different in biopsies collected 
from transplanted kidneys with interstitial fibrosis and tubular atrophy, independently of 
rejection (25). However, more LVs around cellular infiltrates were correlated with superior 
graft function at one year after renal transplantation (24). In our study, interstitial (mostly 
periarterial region) LVD in (pre)transplant biopsies was associated with arteriopathy and 
tubulointerstitial injury and not with fibrotic parameters. The living donors were somehow 
selected, since they had higher diastolic pressure, lower kidney function and higher BMI 
compared to the DBD donors. In their kidneys, this is histologically reflected by the high 
values of glomerulosclerosis, IF and arterial intima thickness. Despite this, all inflammatory 
parameters and LVD were low in these kidneys. This already suggests that pre-existent 
fibrotic responses are rather independent of inflammation and lymphangiogenesis. As CVA 
is the consequence of existing vasculopathy, of which vascular hyalinosis is an important 
sign, we expected to find a difference in hyalinosis between the two DBD donor types but  
 

































Figure 2. Representative image of double staining for PAS and D2-40 (lymphatic vessels) in the 
cortical region of kidney biopsy sections. 
 
our analysis did not demonstrate that. This is possibly due to the low number of trauma-
DBDs. On the other hand, the correlation we found between vascular hyalinosis and mean 
LVD seems reasonable. Hyalinosis is a sign of vascular leakageand fluid drainage, and on the 
other hand, accumulation of interstitial fluid and tissue swelling is one of the most potent 
lymphangiogenic stimuli in order to increase the key functional task of LVs in draining that 
interstitial fluid (26). Our data suggest that lymphangiogenesis, as part of a complex 
tubulointerstitial tissue remodeling program, is already present in donor biopsies prior to 
implantation. Whether interventional therapy aiming at the modulation of lymphatic 
numbers and/or functions can improve functional outcome after transplantation remains to 
be determined. In line with several other studies we found that donor age is correlated 
with IF and FGS (15, 17, 23). Interestingly, we found a difference in vascular hyalinosis 
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between the two types of DBD donors. This can not completely be the result of the 
difference in brain death origin. Perhaps other clinical factors which we did not collect, such 
as the number of antihypertensives used, play a role. No significant differences were found 
between LVD in DBD donors that died as a result of a CVA compared to DBD donors that 
died due to a trauma. However, the increased intensity of IF and arterial intima thickness in 
DBD donors that died as a result of a CVA compared to DBD donors that died of trauma, 
stresses the importance of these morphological damage that originated before brain death. 
This is illustrated by the observation that no significant difference in these parameters 
between DBD and LD are present, while LVD is significantly higher in DBD.  
Several limitations of our study deserve acknowledgement. First, it is based on one single 
European center with possible region-specific demographic characteristics. Our center does 
not include an absolute cutoff for donor age; however, only 22.5% of the donors were aged 
above 60 years. Only 11% of the donors had a BMI exceeding 30 kg/m2. Since in our center 
kidneys from LD with a history of diabetes are not used, one might question whether the 
significantly higher score of vascular hyalinosis in DBD donors is a reflection of diabetic 
vasculopathy. However, we did not find higher scores of glomerulosclerosis and arterial 
intima thickness in the DBD donors. Taking our observations together, some of the results 
we found in our single center transplant population are comparable to those of other 
centers while some new findings regarding LVD and the histopathology in DBD were 
presented as well. The different donor types in our study population make it difficult to 
make overall comparisons with other centers. However, our results highlight the 
multifactorial origin of histological damage in kidney transplant biopsies. 
In conclusion, this analysis, which incorporates and confirms the separate observations of 
previous studies, includes several new observations. Our study demonstrates that LVD, α-
SMA, macrophages, neutrophilic granulocytes and vascular hyalinosis are increased in the 
DBD donor at time of donation compared to living donors. We showed the relevance of LVD 
in pre-existent renal damage in kidney transplantation biopsies, which was mainly peri-
adventitial localized, mostly seen in DBD-CVA donor kidneys and associated with hyalinosis 
and renal inflammation, but not with fibrosis. Validation of LVD in the assessment of kidney 
quality before transplantation needs to be determined prospectively in an independent 
large cohort of kidney transplant biopsies. Furthermore, regarding the DBD donors, it needs 
to be evaluated whether a separate scoring approach predicting transplant outcome is 
warranted.  
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Some disease entities, in which there is a temporary deterioration in kidney function and/or 
development of proteinuria, show an apparent complete functional remission when the 
initiating trigger has been removed. It was initially thought that transient kidney function 
impairment was harmless; however, there is now accumulating evidence that these 
patients are more prone to develop kidney damage later in life. We investigated to what 
extent renal functional and structural changes in a rat model of Angiotensin II (Ang II)-
induced hypertensive renal disease are reversible after cessation of disease induction, 
thereby providing us with data which may explain residual sensitivity to damage. Severe 
hypertension and proteinuria with declined creatinine clearance occurred after 3 weeks of 
Ang II infusion. At the structural level, Ang II infusion resulted in glomerular and tubular 
structural changes, interstitial inflammation and fibrosis and lymphangiogenesis. Eight 
weeks after cessation of Ang II, all clinical parameters, pre-fibrotic changes such as 
myofibroblast transformation and increase in lymph vessel number (lymphangiogenesis) 
returned to control values. However, glomerular desmin expression, glomerular and 
periglomerular macrophages and interstitial collagens remained present after eight weeks. 
These dormant abnormalities may indicate that after transient renal function decline, 
structural changes in the kidney are still present. 




Virtually all progressive renal diseases, independent of their primary origin [1], lead to end-
stage renal fibrosis. Next to this, aging is also a risk factor in the development of kidney 
disease [2,3]. End-stage renal disease (ESRD) is a life threatening condition eventually 
demanding dialysis or renal transplantation. Renal fibrosis is characterized by excessive 
accumulation of extracellular matrix components and macrophages in the renal interstitial 
space [4]. The deposition of matrix leads to deterioration of the normal architecture of the 
kidney, thereby hampering its crucial functional aspects [1]. Pharmaceutical interventions 
used in renal diseases, such as inhibitors of the renin-angiotensin-aldosterone system 
(RAAS), aim at cessation or slowing down the progressive nature of renal fibrosis [5-7]. In 
certain conditions, in which the kidney suffers for a limited period of time from 
hypertension and proteinuria, there appears to be a remarkable renal capacity of self-
repair. When the initial trigger is removed, the kidneys retain their normal functional 
capacity. For example in patients with acute kidney injury (AKI), which is characterized by 
an abrupt decline in renal function, complete renal recovery can be present. However, 
recent data indicate that these patients are more vulnerable for the development of renal 
disease [8-11]. This raised the question to whether the repair mechanisms after short-term 
renal disease have been incomplete, thereby resulting in increased vulnerability to 
subsequent renal triggers.  
Angiotensin (Ang) II infusion is a widely employed experimental model to study transient 
renal disease [12-14]. The model is characterized by severe hypertension, followed by 
massive proteinuria and with, at the structural level, glomerular and interstitial damage. 
After withdrawal of Ang II infusion, the blood pressure returns to control values and 
proteinuria regresses spontaneously and completely. The model more or less mimics 
human conditions in which the kidney is suffering from hypertension and/or proteinuria for 
a limited period of time.  
In this study we aimed at getting a better insight into the processes of incomplete recovery 
after initial structural changes in the kidney, whilst clinical parameters show complete 
restoration. For that purpose rats were transiently treated with Ang II via osmotic 
minipumps. The pumps were removed and the rats were studied for functional and 
structural parameters for an extended period of time. 
Material and Methods 
Animal study and design 
Twenty male Wistar rats (240 - 280 gram, Harlan, Horst, the Netherlands) were housed at 
the animal research facility under standard conditions with a 12h light-dark cycle and free 
access to drinking solution and standard rat chow. After one week of adaption and two 
weeks of daily blood pressure measurement training, osmotic minipumps (model 2004, 
Alzet, Cupertino, CA, USA) were placed intraperitoneally via an abdominal midline incision 
under general anesthesia (2% Isoflurane/O2) to infuse either Angiotensin II (435 ng/kg/min, 
n = 10; Sigma-Aldrich Corporation, St. Louis, MO, USA) or vehicle (0.9% NaCl, n = 10). After 
three weeks of continuous infusion, pumps were removed under general anesthesia. In the 
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same procedure an open kidney biopsy was obtained, to determine the extent of renal 
structural changes. In this way every rat served as its own control. After surgical removal of 
a small part of the upper pole from the left kidney, gelfoam was applied to achieve 
hemostasis. Post-operatively, all rats received one (after pump implantation) or three (after 
biopsy) subcutaneous injection(s) of 50 μg/kg buprenorphin (Schering-Plough, Houten, the 
Netherlands) for analgesic purposes and were allowed to recover from surgery at 37°C in a 
ventilated incubator. Of the former Ang II-infused rats, 7 out of 10 rats survived the kidney 
biopsy procedure and survived till the end of the experiment, whereas this was 10 out of 10 
for control rats. The loss of Ang II rats was a consequence of failed hemostatis after taking 
kidney biopsies under severe hypertensive conditions.  
On a weekly basis, body weight was measured and rats were placed in metabolic cages for 
collection of 24h-urine. Blood samples were collected at baseline, during the kidney biopsy, 
4 weeks after biopsy and at termination. Urinary concentration of protein was determined 
using the pyrogallol red molybdate method [15]. Plasma and urine creatinine, urea and 
sodium levels were determined by standard assays from Roche on the Roche Modular 
(Roche, Diagnostics GmbH, Mannheim, Germany) according to routine procedures in our 
clinical chemical laboratory (UMCG). During infusion, systolic blood pressure was measured 
every week in conscious animals using the tail-cuff method (Apollo 179; IITC Life Science, 
Woodland Hills, California, USA). The mean of three consecutive measurements was taken 
as the final value. At termination, eight weeks after cessation of Ang II or 0.9% NaCl 
infusion, rats were anesthetized (2.0% isoflurane in O2). The aorta was cannulated and 
blood samples were taken. Kidneys were harvested after perfusion with 0.9% NaCl. Coronal 
kidney slices were fixed in 4% paraformaldehyde and paraffin embedded for 
immunohistochemical analysis or immediately snap frozen in liquid nitrogen and stored at -
80°C for molecular analysis. Experimental procedures were in accord with institutional and 
legislator regulations and approved by the Institutional Animal Care and Use Committee of 
the University of Groningen (IACUC-RuG) (DEC number: 6062A).   
 
Qualitative Real-Time Polymerase Chain Reaction 
Quantitative real-time PCR (q-PCR) was performed for renin, OPN, Kim-1, α-SMA, Collagen I, 
Collagen III, Collagen IV, Collagen V, TGF-beta and Podoplanin. RNA was extracted from 
snap frozen kidney tissue, containing both cortex and medulla, using the TRIzol method 
(Invitrogen, Carlsbad, CA, USA). RNA concentrations were measured by a nanodrop UV-
detector (Nanodrop Technologies, Wilminton, DE, USA). Complementary DNA (cDNA) was 
synthesized using Superscript II RT with random hexamer primers (Invitrogen, Carlsbad, CA, 
USA). Gene expression levels (Applied Biosystems, Foster City, CA, USA) were measured by 
qualitative realtime-PCR (qRT-PCR) based on the Taqman methodology. HPRT was used as a 
housekeeping gene with the following primers (Integrated DNA Technologies, Coralville, IA, 
USA) and probe (Eurogentec, Maastricht, the Netherlands): Forward: 5'-GCC CTT GAC TAT 
AAT GAG CAC TTC A-3’, Reverse: 5'-TCT TTT AGG CTT TGT ACT TGG CTT TT-3’ and Probe: 6-
FAM 5'-ATT TGA ATC ATG TTT GTG TCA TCA GCG AAA GTG-3' TAMRA. The other primers 
were obtained from Applied Biosystems as Assays-on-Demand (AOD) gene expression 
products. The AOD ID’s used were: Renin Rn00561847_m1, SPP1 (OPN) Rn00563571_m1, 
Havcr1 (Kim-1) Rn00597703_m1, Acta2 (α-SMA) Rn01759928_g1, Col1a1 (Collagen I) 
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Rn01463648_m1, Col3α1 (Collagen III) Rn01437683_m1, Col4a1 (Collagen IV) 
Rn01482927_m1, Col5a1 (Collagen V) Rn00593170_m1, TGF-β1 (TGF-beta) 
Rn00572010_m1 and PDPN (Podoplanin) Rn00571195_m1. The qPCR reaction mixture 
contained 20 ng cDNA template and 5 ul mastermix. Nuclease-free water was added to a 
total volume of 10 µl. All assays were performed in triplicate. The thermal profile was 15 
minutes at 95°C, followed by 40 cycles of 15 seconds at 95°C and 1 minute at 60°C. 
Consequently, the gene expression was normalized by calculating the difference in Ct from 
the Ct of the reference gene HPRT (∆ CT). The average Ct-values for the target genes were 
subtracted from the average housekeeping gene Ct-values to yield the delta Ct. The results 
were expressed as 2-ΔCt.  
 
Immunohistochemistry (IHC) and immunofluorescent  
For immunostaining, sections were stained with periodic acid-schiff (PAS) and evaluated for 
focal segmental glomerular sclerosis (FSGS). Furthermore, we used primary antibodies for 
Kidney Injury Molecule 1 (Kim-1) (rabbit anti‐Kim‐1 peptide 9, 1:400, gift V. Bailly, Biogen 
Inc, Cambridge, MA, USA), osteopontin (mouse anti-OPN, clone MPIIIB10, 1:300, 
Developmental Hybridoma Studies Institute, Iowa City, IA, USA), macrophages (mouse 
anti‐CD68 ED1, MCA341R AbD, 1:750, Serotec Ltd, Oxford, UK), Desmin (mouse 
anti‐desmin, NCL‐DES‐DER11, 1:500, Novocastra, Rijswijk, the Netherlands), α-Smooth 
Muscle Actin (mouse anti‐SMA, clone 1A4 A2547, 1:10.000, Sigma, Zwijndrecht, the 
Netherlands), collagen I (goat anti‐type 1 Collagen, 1310‐01, 1:100, Southern Biotech, 
Birmingham, AL, USA), collagen III (goat anti‐type 3 Collagen, 1330‐01, 1:75, Southern 
Biotech, Birmingham, AL, USA), Podoplanin (rabbit anti-Podoplanin, 11-035, 1:100, Angio 
Bio, Del Mar, CA, USA) and Rat endothelial cell antigen-1 (RECA-1) (mouse anti-RECA-1, 
HM3012, 1:50, HyCult Biotechnology, the Netherlands) to perform IHC. To make sure that 
our Podoplanin antibody was specific for lymph vessels (LVs) only, we performed an 
immunofluorescent (IF) double staining with primary antibodies for Podoplanin (same 
concentration as IHC), LYVE-1 (rabbit anti-LYVE-1, 1:300, gift Prof. D. Jackson, John Radcliffe 
University Hospital, Oxford, UK) and VEGFR-3 (goat anti-VEGFR-3, AF743, 1:40, R&D system 
Inc, Minneapolis, MN, USA). First, sections were deparaffinized and washed with phosphate 
buffered saline (PBS, pH 7.4). For Kim-1, osteopontin, ED1, desmin and α-SMA, overnight 
antigen retrieval was performed in 0.1 M Tris/HCl buffer, pH 9.0, at 80°C. For collagen I, 
collagen III, and Podoplanin, antigen retrieval was performed using a citrate, pH 6.0, an 
EDTA, pH 8.0, and an EDTA, pH 9.0 buffers respectively. The solution was heated for 15 
minutes in microwave oven at maximum power. Sections were again washed with PBS and 
endogenous peroxidase was blocked by incubation with 0.3% H2O2 in PBS for 30 minutes. 
Then, sections were incubated with primary antibodies for 60 minutes at room 
temperature. Binding was detected using sequential incubation with primary antibodies 
associated peroxidase-labeled secondary and tertiary antibodies (Dakopatts, Glostrup, 
Denmark) for 30 minutes. All antibodies were diluted with PBS containing 1% Bovine Serum 
Albumin (BSA) and 1% normal rat serum was added to the secondary and tertiary antibody 
dilutions. Peroxidase activity was developed using 3,3’-diaminobenzidine tetrachloride 
(DAB) for 10 minutes containing 0.03% H2O2. Counterstaining was performed using 
Mayer’s hematoxylin and for some subsequent PAS staining was used. For RECA-1, frozen 
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sections were used and processed via the normal IHC procedure with an AEC 
counterstaining. Appropriate isotype and PBS controls were consistently negative. 
 
Analysis of histopathological changes 
Kidney sections were scanned using an Aperio Scanscope GS (Aperio Technologies, Vista, 
CA, USA). The extent of proximal tubular damage (Kim-1 and OPN), glomerular podocyte 
stress (desmin), fibrotic changes (α-SMA, collagen I and III) (excluding vessels) was 
quantified using computer-assisted analysis with Aperio Imagescope (Version 9.1, Aperio, 
Vista, CA, USA). For α-SMA, osteopontin, Kim-1 and collagen I and III, the ratio between 
positive pixels in the cortex and the total cortical surface area was used. For desmin the 
ratio between glomerular positive pixels and total cortical glomerular area was calculated. 
To obtain a measure of inflammation, the number of interstitial, periglomerular and 
glomerular macrophages (ED1-positive cells) was counted manually using light microscopy 
and a mean score of thirty randomly selected renal cortical fields or fifty glomeruli, both 
per animal, was obtained. For LVs, thirty renal cortical fields were selected and the 
lymphatic vessel density (LVD) was quantified by counting manually the podoplanin-
positive interstitial vascular profiles per medium-power field. After excluding glomeruli and 
large vessels the mean percentage of RECA-1 positive peritubular capillaries per five cortical 
areas was determined with Image J (Image J 1.46r, National Institutes of Health, Bethesda, 
MD). Histopathological analysis was performed in a blinded fashion.  
 
Immunoblot analysis 
Protein lysates were prepared from tissue cryosections (10 times, 10 µm) in RIPA buffer 
(Thermo Scientific) supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich). 
Lysates were homogenized using sonication. Protein concentrations were determined using 
a DC protein assay (Bio-Rad, Hercules, CA, USA) after which 8µg of protein was spotted in 
triplicate on a Tris buffered saline (TBS) pre-soaked nitrocellulose membrane using a 96-
well dot-blot apparatus (Bio-Rad). To reduce non-specific binding, spotted membranes 
were blocked in TBS + 0.5% Tween20 (Sigma-Aldrich) containing 5% milk powder. Spotted 
membranes were stained with primary antibodies directed against collagen type I (1:1000, 
ab93095, Abcam) or collagen type III (1:2000, ab6310, Abcam) diluted in TBS-Tween20 
containing 5% milk powder. All washing steps were performed in TBS-Tween20. Protein 
bands were visualized using chemiluminescence and a ChemiDoc imaging system (Bio-Rad). 
Image analysis was performed using the Dot Blot analyser plugin for ImageJ, whereby 
collagen expression of control rats at time of biopsy was used as a reference.  
 
Statistical analysis 
Data are expressed as the mean ± standard error of the mean (SEM). Statistical significance 
was accepted at p<0.05. Statistical analyses were performed using Mann-Whitney U tests 
or, when testing repeated measurements, two-way ANOVA tests. For correction of multiple 
comparisons a Bonferroni post-hoc analysis was performed. Data were analyzed and 
graphed using GraphPad Prism (Version 5.00, GraphPad, San Diego, CA, USA).  
 
 




Rat characteristics – body weight, systolic blood pressure and sodium excretion 
At baseline, there were no significant differences in body weight between Ang II-infused 
rats and NaCl-infused controls (data not shown). Throughout the infusion period, body 
weight of all Ang II-infused rats was significantly reduced as compared to NaCl-infused 
controls (321.4 ± 18.1 grams vs. 393.3 ± 7.7 grams, p<0.001). After cessation of Ang II 
infusion, rats gained weight and at the end of the study former Ang II-infused rats were 
significantly heavier when compared to their controls (p<0.05). Three weeks of Ang II 
infusion progressively increased systolic blood pressure 1.5-fold compared to NaCl-infused 
rats (212 ± 10.43 mmHg vs. 146 ± 1.4 mmHg, p<0.001, Figure 1A). After withdrawal of Ang 
II, blood pressure immediately returned to baseline values (139 ± 4.0 mmHg vs. 134 ± 4.7 
mmHg) and all rats stayed normotensive till the end of the experiment. Infusion with Ang II 
significantly reduced mRNA levels of renin compared to control (p<0.05, data not shown). 
Urinary sodium excretion was higher in Ang II-infused rats; however this was not significant 
(2.7 ± 0.2 mmol/24h vs. 2.1 ± 0.2 mmol/24h).  
 
Spontaneous recovery of Ang II-induced proteinuria and renal function loss 
There was no difference in urinary protein levels and renal function - reflected by creatinine 
clearance and plasma urea - for both groups at baseline (Figure 1). Under infusion of Ang II, 
rats gradually developed proteinuria with a significant increase of urinary protein levels 
already after one week of Ang II infusion (p<0.01) and an 1.9-fold increase after three 
weeks (51.4 ± 6.3 mg/24h vs. 14.7 ± 2.0 mg/24h, p<0.01) (Figure 1A). After three weeks of 
Ang II infusion, all rats had an impaired renal function as evidenced by a 59% reduction in 
creatinine clearance (2.0 ± 0.5 mL/min vs. 4.9 ± 0.6 mL/min, p<0.001) (Figure 1B) and a 1.9-
fold increase in plasma creatinine levels (37.7 ± 8.4 μmol/L vs. 20.1 ± 1.0 μmol/L, not 
significant) (Figure 1C). Furthermore, Ang II infusion caused a 2.2-fold increase in plasma 
urea levels compared to control rats (15.3 ± 3.5 mmol/L vs. 7.0 ± 0.3 mmol/L, p<0.001) 
(Figure 1D). Withdrawal of Ang II infusion resulted in a spontaneous and total recovery of 


































Figure 1. Ang II induces hypertension, renal function loss and proteinuria with spontaneous recovery 
after Ang II withdrawal 
Ang II infusion increased systolic blood pressure (A) and urinary protein levels (B). Furthermore Ang II infusion attenuated 
renal function as evidenced by a decrease in creatinine clearance (C) and an increase in plasma creatinine (D). Ang II infusion 
also caused an increase in plasma urea levels (E). When Ang II infusion was stopped, functional renal parameters of all rats 
turned to control values again. (##p<0.01, ###p<0.001 vs. control) 
 
Effects of Ang II on tubular damage and glomerular desmin expression  
Ang II infusion induced tubular dilatation and atrophy as reflected by a significant increase 
in Havcr1 mRNA and KIM-1 protein expression (p<0.001) (Figure 2A and 2B) and 
osteopontin (OPN) mRNA and protein expression (p<0.001 and p<0.001) (Figure 3A and 3B) 
when compared to control rats. A complete reversibility of tubular damage was seen eight 
weeks after cessation of Ang II, evidenced by a reduction to control levels of both Havcr1 
mRNA and KIM-1 protein expression (p<0.001), as well as SPP1 mRNA expression (p<0.001). 
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Control rats showed a slight increase in SPP1 mRNA (p<0.01) and OPN protein (p<0.05) 
expression during the course of the study. At time of sacrifice, there was no difference in 
OPN protein expression between Ang II-infused rats and control rats. Glomerular desmin 
protein expression was increased 7.4-fold after three weeks of Ang II infusion (p<0.01) 
(Figure 4A). There was no recovery of desmin expression after cessation of Ang II infusion 
and desmin protein expression of former Ang II-infused rats even increased over the weeks 
when compared to their biopsy levels (p<0.05). Glomerular desmin expression of NaCl-
infused rats also progressed over the weeks (p<0.001). At time of termination, Ang II-
infused rats still had significantly higher levels of desmin protein expression when 
compared to control rats (p<0.05). Three weeks of Ang II infusion did not result in focal 
segmental glomerular sclerosis (data not shown).  
 
Decreased interstitial but increased periglomerular and glomerular macrophage influx after 
cessation of Ang II infusion 
As expected, Ang II infusion increased the number of ED1 positive cells in the renal 
interstitium compared to controls (5.2-fold increase; 18.8 ± 4.8 vs. 3.6 ± 0.5, p<0.001) 
(Figure 5A). When Ang II infusion was ceased, the number of interstitial macrophages 
declined (p<0.01) but was still elevated when compared to control rats (p<0.05). Ang II 
infusion also significantly increased periglomerular macrophage numbers (2.91 ± 0.3 vs. 1.7 
± 0.2, p<0.01), which slightly increased after stopping Ang II infusion (Figure 5B). This was in 
contrast to macrophage influx in glomeruli, which significantly decreased under Ang II 
infusion (0.6 ± 0.1 vs. 1.2 ± 0.2, p<0.05), but significantly increased eight weeks after 
stopping of Ang II infusion (2.0 ± 0.3 vs. 1.5 ± 0.2, p<0.001) (Figure 5C).  
 
Interstitial fibrotic lesions after Ang II infusion, moderate recovery 
Ang II infusion induced interstitial lesions, characterized by increased mRNA and protein 
expression of the pre-fibrotic marker α-SMA (p<0.001) (Figure 6A and 6B). Eight weeks  
after stopping Ang II infusion, levels of α-SMA mRNA (p<0.05) and protein (p<0.001) 
expression spontaneously returned to control levels. This Ang II-induced interstitial 
myofibroblast transformation was accompanied by increased fibrotic damage. Both 
Collagen I (p<0.05) and III (p<0.001) mRNA expression was upregulated under Ang II-
infusion (Figure 7A and 8A). Eight weeks after stopping Ang II infusion mRNA expression of 
both collagens returned to the same level as their controls. Protein expression of Collagen I 
and II did not increase after three weeks of Ang II infusion (Figure 7B and 8B). 
Immunohistochemical and dotblot analysis showed an increased formation of Collagen I 
and III proteins after withdrawal of Ang II infusion (p<0.05) (Figure 7B and 8B). Control rats 
also showed an increase in Collagen I and Collagen III (p<0.05) protein expression over the 
weeks (Figure 7B and 8B). In line with Ang II-induced upregulation of Collagen I and III 
mRNA expression, also mRNA expression of TGF-β (p<0.01), Collagen IV (p<0.05) and V 
(p<0.05) mRNA was significantly increased under Ang II infusion. Eight weeks after stopping 
Ang II infusion, expression levels of TGF-β, Collagen IV and V mRNA were decreased to 






























Figure 2. Effects of Ang II infusion and withdrawal on tubular damage 
Kim-1 mRNA (A) and protein (B) levels were increased by Ang II infusion. After stopping Ang II infusion, recovery of proximal 
tubular damage was established, evidenced by control levels of Kim-1 mRNA and protein levels in Ang II infused rats. 
Representative photomicrographs of Kim-1 stained renal sections (C). (### p<0.001 vs. control at time of biopsy; ***p<0.001 
vs. Ang II at time of biopsy) 
 
 
Regression of Ang II-induced lymph vessel formation 
Under Ang II infusion the mRNA expression level of PDPN, a marker of lymphatic vessels 
(LV), was upregulated; however this was not significant (Figure 10A). Stopping Ang II 
infusion resulted in a decrease of PDPN mRNA expression to control levels. Ang II infusion 
induced a 2-fold increase in number of LVs (4.1 ± 0.4 vs. 2.2 ± 0.4, p<0.01) (Figure 10B). At 
termination, the number of LVs of former Ang II infused rats regressed to control levels 
(p<0.001). Ang II infusion had no effects on the number of peritubular capillaries (Figure 
10C).  
Discussion 
Following transient renal function decline induced by Ang II infusion, all functional 
parameters – blood pressure, kidney function and proteinuria – spontaneously recover 
within one week and remain normal throughout the follow-up period of eight weeks. At the 
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structural level, we noted the complete reversibility of tubular damage and changes 
associated with myofibroblast transformation (α-SMA expression). Furthermore, we are the 
first to show that newly formed lymph vessels in the renal interstitium are able to undergo 
spontaneous regression. However, glomerular desmin expression and thin interstitial 























Figure 3. Effects of Ang II on OPN expression 
OPN mRNA (A) and protein (B) levels were increased by Ang II infusion. After stopping Ang II infusion OPN mRNA and protein 
levels returned to control levels. In time, OPN protein expression of control rats significantly increased. Representative 
photomicrographs of OPN stained renal sections (C). (## p<0.01, ### p<0.001 vs. control at time of biopsy; ***p<0.001 vs. Ang 











Figure 4. AngII infusion causes persistent glomerular damage 
Ang II infusion increased desmin protein levels (A). At sacrifice there was a significant increase of desmin protein in former AngII-
infused rats and surprisingly in control rats as well. Compared to control rats, glomerular damage of AngII-infused rats was 
significantly higher after stopping AngII infusion. Representative photomicrographs of desmin stained renal sections (B). (## 
p<0.01, ### p<0.001 vs. control at time of biopsy; *p<0.05 vs. AngII at time of biopsy; $ p<0.05 vs. control at time of sacrifice) 
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dotblot analysis. This was accompanied by an increased number of glomerular and 
periglomerular macrophages. This discrepancy between functional and structural 
parameters indicates that subclinical renal damage is still present after despite complete 
functional recovery. After withdrawal of Ang II, blood pressure returned to control values 
and rats resided normotensive till the end of the experiment. In previous studies it was 
found that transient exposure to Ang II can lead to the development of a renewed or 
































Figure 5. Decreased interstitial inflammation, increased glomerular macrophages after cessation of 
Ang II 
Ang II increased the influx of interstitial macrophages. After Ang II withdrawal, the number of interstitial ED1 positive cells 
decreased, but was still elevated versus control rats (A). For glomerular macrophages the opposite was found, with a decrease of 
macrophages per glomerulus after Ang II. After stopping infusion, Ang II-infused rats showed an increase in glomerular 
macrophages (B). Representative photomicrographs of ED-1 positive cells in interstitium (C) and glomeruli (D). (# p<0.05, ### 
p<0.001 vs.control at time of biopsy; **p<0.01, ***p<0.001 vs. Ang II at time of biopsy; $ p<0.05 vs. control at time of sacrifice)  
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Salt-sensitive hypertension was described when after short-term exposure to Ang II 
Sprague Dawley rats subsequently were exposed to a high salt diet [18]. However, in the 
same study rats placed on a low salt diet remained normotensive, comparable with what 

























Figure 6. Complete reversion of Ang II-induced pre-fibrotic changes 
Ang II infusion increased α-SMA mRNA (A) and protein (B) expression. At time of sacrifice, mRNA levels of Ang II-infused rats 
returned to control values. The same pattern holds through for α-SMA protein expression, with a complete reversion of pre-
fibrotic changes after cessation of Ang II. Representative photomicrographs of α-SMA stained renal sections (C). (##p<0.01, 
###p<0.001 vs. control at time of biopsy; *p<0.05, ***p<0.001 vs. Ang II at time of biopsy) 
 
The absence of hypertension in our model provides us with the opportunity to study renal 
residual changes after a temporary insult. Where others have demonstrated that two 
weeks of Ang II infusion at a lower dose already is sufficient to induce renal damage [19,20], 
we infused Ang II at a dose of 435 ng/kg/min for the duration of three weeks. This might 
explain the high levels of hypertension, urinary protein excretion and degree of renal 
structural changes demonstrated in the present study. However, a previous publication 
from our group with the same dose and infusion time of Ang II in Sprague-Dawley rats 
shows comparable functional and structural renal changes [21]. Both in rats and in humans 
renal functional and structural damage spontaneously develops as a consequence of aging 
[3,22-27]. In the current experiment, we potentially found slight effects of aging with a 
decrease in creatinine clearance and an increase in urinary protein excretion, plasma urea 
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levels, glomerular desmin protein expression and interstitial collagen protein expression of 
control rats at time of termination when compared to their own baseline values. It was 
demonstrated that in Wistar rats, glomerular changes and proteinuria gradually develop as 
a consequence of aging [28]. However, aging might not completely explain the findings of 
increased renal structural changes in our control rats. An additional explanation for renal 
functional and structural decline over the weeks can be induced by the implementation of 

























Figure 7. Decrease in Collagen I mRNA expression after stopping Ang II infusion, ongoing deposition 
of proteins 
Ang II infusion increased Collagen I mRNA (A) expression. After withdrawal of Ang II, Collagen I mRNA levels returned to 
control values again. Protein expression of Collagen I was unaffected after infusion with Ang II, however eight weeks after 
cessation of Ang II protein levels of Collagen I increased versus its own biopsy (B). Representative photomicrographs of 
Collagen I stained renal sections (C). (#p<0.05 vs. control at time of biopsy; *p<0.05 vs. Ang II at time of biopsy, ***p<0.001 vs. 
Ang II at time of biopsy) 
 
An incomplete resolution of Ang II-induced renal functional and structural changes, with 
still evidence of injury and higher levels of serum creatinine after stopping Ang II has been 
shown before [18]. We now demonstrate that despite the fact that urinary protein levels 
return to baseline values, podocyte stress as evidenced by glomerular desmin expression 
[29], and increased influx of periglomerular and glomerular inflammatory cells is still 
present eight weeks after cessation of Ang II. The glomerular deposition of desmin and 
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intraglomerular inflammation can cause foot process fusion, with an increased risk of 
redeveloping proteinuria [30,31]. The relevance of periglomerular infiltrates is 
substantiated by Heymann et al. who found that induced periglomerular mononuclear 
infiltrate was associated with parietal podocyte damage [32].   
Furthermore, we previously have demonstrated that depletion of glomerular macrophages 
in a rat renal ablation model led to decreased glomerular mesangial expansion, indicating 
that glomerular macrophages are involved in the initiation and progression of glomerular 
damage [30]. Whether the low numbers of glomerular macrophages in the present model 

























Figure 8. Decreased Collagen III mRNA expression after stopping Ang II infusion, increased protein 
levels when compared to control rats 
Both Collagen III mRNA (A) and protein (B) expression was increased under Ang II infusion. After stopping Ang II, Collagen III 
mRNA expression decreased to control levels. At time of sacrifice, Collagen III protein levels of Ang II-infused rats were 
significantly increased when compared to control rats. Collagen III protein expression of control rats was significantly elevated 
at time of sacrifice when compared to their biopsies. (B). Representative photomicrographs of Collagen III stained renal 
sections (C). (#p<0.05, ###p<0.001 vs. control at time of biopsy; **p<0.01 vs. Ang II at time of biopsy, $p<0.05 vs. control at 
time of sacrifice) 
 
The increased glomerular desmin expression in the present study is in line with enhanced 
collagen deposition. Wedemonstrated that after three weeks of Ang II infusion mRNA 
expression of collagens is significantly increased, which was followed by an increased 
protein expression at the end of the experiment, despite cessation of Ang II infusion. It of 
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course takes time for collagen deposition to take place but it also might well be that this 
discrepancy is due to sufficient enzymatic degradation of collagens in the first phase, 
whereas the remaining interstitial collagen deposition at the end of the experiment is a 
consequence of the formation of insoluble collagen crosslinks, with subsequent 
extracellular matrix (ECM) formation [34,35]. When the remaining fibrotic ECM is exposed 
to de novo stimuli including aging related changes, the extent of defense and repair of this 
damage is incomplete and likely to accumulate over time. This has been shown to result in 
structural and functional changes, with significant effects on cell adhesion, proliferation and 
also altered cell signaling as a consequence [36]. Cytokines, growth factors and reactive 
oxygen species in combination with fibrotic ECM formation are likely to be of great 
significance in the development and progression of CKD [37]. Fibrotic ECM is known to 










Figure 9. Normalization of mRNA expression of fibrotic markers after cessation of Ang II infusion 
mRNA expression of the fibrotic markers TGF-beta, Collagen IV and Collagen V was upregulated under Ang II infusion (A, B, C). 
Eight weeks after stopping Ang II infusion, mRNA levels of all markers returned to control levels again. (#p<0.05, ##p<0.01 vs. 
control at time of biopsy; *p<0.05, **p<0.01 vs. Ang II at time of biopsy) 
 
Lymph vessel formation is a key event in renal interstitial fibrosis [39]. Inflammation-
induced lymphangiogenesis is described in multiple human diseased conditions [40-43] as 
well as in animal studies [44,45]. We are the first to show that newly formed renal lymph 
vessels can undergo spontaneous regression. Opposed to findings of persisting lymphatic 
vessels in a model of chronic airway inflammation [41], we found that eight weeks after 
cessation of Ang II both Podoplanin mRNA and protein expression returned to control 
levels. In pulmonary fibrosis it is shown that Ang II contributes to progression of the disease 
[46] and that both Angiotensin II type 1 and 2 receptors and LVs play an important role in 
organ remodeling and fibrosis [47]. In the kidney, lymphangiogenesis occurs after 
established proteinuria and prior to collagen deposition, fibrosis and macrophage influx in a 
rat model of unilateral adriamycin nephrosis and ACE inhibition significantly prevents this 
new lymph vessel formation [39,48]. In addition, one of the commonly found events in 
proteinuria-associated diseases is renal interstitial oedema and swelling, and that has been 
shown to be an important factor in provoking lymphangiogenesis [39]. It might be that 
during the process of renal remission growth factors involved in stimulating 
lymphangiogenesis such as VEGF-C and D [49] are absent which eventually lead to 
lymphatic endothelial cell apoptosis and LVs regression. Despite dynamic changes in lymph 
vessel formation, the number of peritubular capillaries was unaltered in our model.  
A decreased expression of the proinflammatory cytokine osteopontin (OPN) is presumably 
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a consequence of normalization of the blood pressure and proteinuria in our experiment. 
OPN plays a crucial role in the development of Ang II-induced renal damage [50,51] by 
inducing inflammation, oxidative stress and fibrosis [50]. Interestingly, it was shown 
recently that OPN can also directly induce lymphangiogenesis [52]. Ang II infusion increased 
OPN mRNA and protein expression and eight weeks after cessation of Ang II the renal OPN 
expression levels were decreased to control levels. A decrease in OPN expression not only 
leads to renal structural improvement, but is also accompanied by enhanced renal function 
[53]. Suppression of OPN expression, by e.g. IL-1 receptor antagonist treatment or RAAS 
inhibition, reversed OPN-induced loss of renal function, macrophage influx and severe 
histological damage [54,55]. All these results indicate that the decreased level of OPN 
expression might contribute to the reversibility of the Ang II-induced pre-fibrotic damage 























Figure 10. Regression of lymph vessels after Ang II withdrawal 
Ang II infusion increased mRNA expression of Podoplanin, however this was not significant (A). Ang II-induced 
lymphangiogenesis was evidenced by an increase in lymph vessel formation (B), with spontaneous regression to control levels 
eight weeks after withdrawal of Ang II. Representative photomicrographs of Podoplanin stained renal sections (C). (##p<0.01 
vs. control at time of biopsy; ***p<0.001 vs. Ang II at time of biopsy) 
 
The present study has strengths and limitations. The experimental set-up with every rat 
functioning as its own control, by comparing renal functional and structural damage at time 
of biopsy versus termination after a follow-up period of 8 weeks, makes the study unique 
and powerful. Furthermore, a lot of different parameters for renal function and structural 
changes were determined to get insight into the process of the development of renal 
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damage, spontaneous recovery and remaining damage. A limitation of the study is the 
method used to assed renal function. Creatinine clearance is widely used to assess renal 
function in experimental renal disease [56], however an important complications to this 
technique is tubular creatinine secretion, which also in rats leads to an overestimation of 
the real GFR to various extent [57, 58]. Additional experiments are needed to sort out the 
effects of angiotensin II infusion on tubular creatinine excretion. The lack of inclusion of 
control rats for the biopsy procedure makes the interpretation of increased renal damage 
parameters in control rats difficult.  
In conclusion, despite full restoration of renal function, renal structural abnormalities 
induced by Angiotensin II infusion are only partially restored, with remaining glomerular 
desmin expression, increased influx of periglomerular and glomerular macrophages and 
interstitial collagen deposition. This incomplete structural restoration of damage indicates 
that ongoing scarring takes place after initial injury to the kidney, despite absence of clinical 
signs and symptoms of renal disease. Further studies need to be conducted to identify the 
most important players in this process and to investigate to what extent this remaining 
damage has consequences for long-term renal outcome.  
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Proteinuria is an important cause of progressive tubulointerstitial damage. Whether 
proteinuria could trigger a renal lymphangiogenic response has not been established. 
Moreover, the temporal relationship between development of fibrosis, inflammation and 
lymphangiogenesis in chronic progressive kidney disease is not clear yet. Therefore, we 
evaluated the time course of lymph vessel (LV) formation in relation to proteinuria and 
interstitial damage in a rat model of chronic unilateral adriamycin nephrosis. Proteinuria 
and kidneys were evaluated up to 30 weeks after induction of nephrosis. LVs were 
identified by podoplanin/VEGFR3 double staining. After 6 weeks proteinuria was well 
established, without influx of interstitial macrophages and myofibroblasts, collagen 
deposition, osteopontin expression (tubular activation) or LV formation. At 12 weeks, a ~3-
fold increase in cortical LV density was found (p<0.001), gradually increasing over time. This 
corresponded with a significant increase in tubular osteopontin expression (p<0.01) and 
interstitial myofibroblast numbers (p<0.05), whereas collagen deposition and macrophage 
numbers were not yet increased. VEGF-C was mostly expressed by tubular cells rather than 
interstitial cells. Cultured tubular cells stimulated with FCS showed a dose-dependent 
increase in mRNA and protein expression of VEGF-C which was not observed by human 
albumin stimulation. We conclude that chronic proteinuria provoked lymphangiogenesis in 
temporal conjunction with tubular osteopontin expression and influx of myofibroblasts, 
that preceded interstitial fibrosis. 




Proteinuria is a noticeable risk factor for development of chronic kidney disease (CKD) and 
its reduction has renoprotective effects, slowing down progression to end-stage renal 
disease (ESRD) (1–3). Proteinuria is not only a marker of renal failure progression, but is 
directly involved in the pathogenesis of tubulointerstitial fibrosis in the kidney as well (4). 
Proximal tubular epithelial cells, experimentally exposed to pathologically high 
concentrations of plasma proteins, display several biologic responses, including 
profibrogenic signalling, inflammation, apoptosis, production of reactive oxygen species 
and epithelial dedifferentiation, which ultimately contribute to tubulointerstitial fibrosis (5-
8). With progression of the disease, macrophages become gradually involved in lesions, and 
this enhances proteinuria-induced renal structural changes into macrophage-dependent 
interstitial fibrosis (9,10). Tubulointerstitial fibrosis is important in long-term renal 
prognosis since it determines renal function and predicts the outcome better than any 
other histopathological finding (11,12). The extent of proteinuria-induced tubulointerstitial 
changes limits the efficacy of antiproteinuric and renoprotective treatment with renin–
angiotensin system (RAS) blockers (13), even when the changes are still within the pro-
fibrotic range, highlighting the importance of tubulointerstitial damages in response to 
therapy in proteinuric patients. This warrants better exploration of the (pro-)fibrotic 
response to proteinuria. 
Lymphatic vessels contribute to the drainage of extravasated proteins, excess fluid and 
macromolecules from interstitial tissue and return them to the blood circulation via the 
lymph, playing a crucial role in tissue fluid balance and homeostasis (14,15). They are also 
essential for immune defense by carrying antigens and antigen-presenting cells from the 
interstitium to the lymph nodes, a critical step for the development of an immune response 
(16). The growth of lymphatic vessels (lymphangiogenesis) has been shown to be actively 
involved in adult tissues during various diseases such as inflammation, obesity, 
hypertension, tumour metastasis, organ transplantation and lymphedema (17), and very 
recently shown to be involved in development of fibrosis, at least in pulmonary fibrosis 
(18). Renal lymphangiogenesis has been reported in transplanted kidneys (19,20), and in 
nephropathies with interstitial fibrosis. Lymphangiogenesis generally correlated with the 
degree of tissue fibrosis rather than inflammation (21). Recently, transforming growth 
factor-β (TGF-β) has been shown to induce VEGF-C expression in tubular epithelial cell, 
which promote lymphangiogenesis (22). Whether proteinuria could trigger a renal 
lymphangiogenic response has not been established. Studies up to now are mostly cross-
sectional, and the temporal relationship between development of fibrosis, inflammation 
and lymphangiogenesis in chronic progressive kidney disease is not clear yet. To resolve 
these relationships, we performed a time-course study, up to 30 weeks, in adriamycin 
nephropathy in rats. We used a unilateral model to minimize possible effects of uremic 
condition and renal tissue oedema. Our study reveals that the formation of renal interstitial 
lymph vessels occurs after established proteinuria. The new lymphatic vessels are formed 
prior to collagen deposition and fibrosis, macrophage influx and in conjunction with the 
tubular osteopontin expression and VEGF-C production. 
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Materials and Methods 
Animal Experimental Protocol 
Unilateral adriamycin nephrosis was established in male Wister rats weighing 275–300 g, 
using a technique described previously (23). Briefly, the left kidney was approached by 
means of an abdominal midline incision under isoflurane anesthesia (1.5% isoflurane in O2). 
An adjustable clamp was placed around the aorta above the left renal artery. Then, an 
injection of adriamycin (1.5 mg/kg) was performed in the tail vein. 12 minutes later, once 
adriamycin had been eliminated from the circulation (24), the clamp was removed. Rats in 
control group underwent the same surgical procedure with saline injection. Rats were 
placed in metabolic cages for 24-h urine collection bi-weekly, and proteinuria was 
determined in urine samples by a BNII third-generation nephelometer (Dade Behring, 
Mannheim, Germany). At different time points (week 6, 12, 18, 24, and 30) after the 
injection of adriamycin, 6 rats were sacrificed, and kidneys were harvested after perfusion 
with saline. In a separate bilateral adriamycin experiment, an intervention was done from 
week 6 to week 12 by the ACE inhibitor Lisinopril (75 mg/l drinking water) in combination 
with low salt (0.05%) diet (n= 7 rats). Control adriamycin rats just received low salt diet 
from week 6 to week 12 (n =6 rats). At week 12, 24-hours urine was collected in metabolic 
cages, animals were sacrificed and kidneys preserved for histology. 
All experimental protocols for animal studies followed the national guide for the care and 
use of laboratory animals, and were approved by the local Animal Ethic Committee of the 
University of Groningen. 
 
Immunohistochemistry and Immunofluorescence 
Stainings were performed on both paraffin-embedded and cryo sections. Three-micron 
thick formalin-fixed paraffin sections were deparaffinized in xylene and rehydrated. Antigen 
retrieval was done for 10 min in citrate buffer, PH: 6.0 or 10 mM Tris–1 mM EDTA buffer, 
PH: 9.0 in a microwave oven, and endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxide. Four-micrometer thick frozen sections were fixed in acetone and 
treated with 0.03% hydrogen peroxide. Sections were pretreated with normal goat, rabbit 
or mouse serum, and subsequently incubated for 1 hr with the following primary 
antibodies: rabbit anti-LYVE-1 (Kind gift from Prof. David Jackson, John Radcliffe University 
Hospital, Oxford, UK), mouse anti-rat Podoplanin (Angio Bio, Del Mar, USA), Goat anti-
mouse VEGFR3 (R&D system, Inc), mouse anti rat CD68 (Clone ED1, AbD Serotec, UK), 
rabbit anti-rat VEGF-C (RELIATech, GmbH, Germany), mouse anti-α-SMA (clone 1A4; Sigma), 
rabbit anti-collagen type I and rabbit anti-collagen type III (both from Biogenesis, Poole, 
UK). Binding of primary antibodies was detected by incubating the sections for 30 min with 
secondary antibodies diluted in PBS +1% normal rat serum: HRP-conjugated rabbit anti-
mouse, biotinylated rabbit anti-mouse, FITC-conjugated rabbit anti-mouse, HRP-conjugated 
rabbit anti-goat, HRP and FITC-conjugated goat anti-rabbit and goat-anti mouse (all from 
DAKO, Belgium). As negative controls, the primary antibodies were omitted and replaced by 
PBS with normal rat serum. HRP and BIOT activity was visualized using the TSATM 
Tetramethylrhodamine System (PerkinElmer LAS Inc., USA) and FITC-conjugated 
streptavidin (Invitrogen) respectively. DAPI (Vector Laboratories, Inc) was used to stain 
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nuclei. For paraffin sections, bound antibodies were visualized by the peroxidase substrate 




Focal glomerulosclerosis (FGS), interstitial macrophages, myofibroblasts, osteopontin, 
collagen I and III were measured as described previously (23). Briefly, interstitial 
macrophages (ED1 positive), myofibroblasts (α-SMA positive), osteopontin, collagen I and 
III immunostainings were evaluated in 50 cortical tubulointerstitial images per slide using 
computerized image analysis (Advanced QUIPS, Leica Imaging Systems, Cambridge, UK) on 
blinded sections. The sections were semiquantitatively scored for focal glomerulosclerosis 
in a blinded fashion by determining the level of mesangial expansion and focal adhesion in 
each quadrant in a glomerulus and expressed on a scale from 0 to 4 (25). In total, 50 
glomeruli per kidney were analyzed, and the total FGS score was calculated by multiplying 
the score by the percentage of glomeruli with the same FGS score. The sum of these scores 
gives the total FGS score with a maximum of 400. 
 
Double Immunofluorescence Protocol for Lymph Vessel Identification and Quantification 
For identification of lymph vessels we applied a double immunofluorescence protocol, 
using two primary antibodies against podoplanin and VEGFR3. After acetone fixation, 
frozen sections were blocked by 0.03% H2O2, followed by 20 minute incubating with 
appropriate normal serum. Then, sections were treated with mouse anti-rat podoplanin 
and goat anti-mouse VEGFR3 primary antibodies for 1hr in room temperature. After 
washing three times with PBS (Phosphate buffered saline), FITC and HRP-conjugated 
secondary antibodies applied for 30 minutes to give each marker different colors. After 
staining, the sections were scanned using a Tissue FAXS acquisition system (Tissue Gnostics, 
Austria) based on a Zeiss Axio Observer Z1 (Zeiss, Germany). Microscopic fluorescence 
imaging was performed at the UMCG Microscopy and Imaging Center (UMIC), which is 
supported by the Netherlands Organisation for Health Research and Development (ZonMW 
grant 40-00506-98-9021). Double stained vessel structures which were positive for both 
markers (merged colors) counted as lymph vessels and measured by using a homemade 
macro on ImageJ 1.41 (Rasband, W.S., U.S. National Institutes of Health). A total of 30 fields 
per kidney cortex were evaluated and the lymphatic vessel density (LVD) was quantified as 
number of double positive (Podoplanin+/VEGFR3+), interstitial vascular profiles per 
medium-power field (20x objective). The surface area of lymph vessels were also evaluated 
using Image J program, and lymph vessel size was differentiated into four size categories, 
namely: very small, small, medium- sized and larger lymph vessels. 
 
Tubular Epithelial Cell Culture 
Human HK-2 cells (proximal tubular epithelial cell line) from American Type Culture 
Collection (ATCC, Manassas, VA, USA)were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM)and Ham’s F-12 medium (Invitrogen-Gibco), supplemented with Insulin (5 mg/ml), 
Transferrin (5 mg/ml), Selenium (5 ng/ml),hydrocortison (36 ng/ml), Epidermal Growth 
Factor (EGF)(10 ng/ml), penicillin (50 U/ml) and streptomycin (50 mg/ml). The cells were 
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cultured in 12-well plates until 90% confluency, and then starved for two days without EGF. 
We stimulated the cells afterwards with different concentrations of FCS (Fetal Calf Serum, 
from Sigma-Aldrich), 5, 10 and 20% for 24 hours. Supernatant was collected for ELISA 
measurement, cells were washed with PBS (phosphate-buffered saline), and RNA was 
isolated for RTPCR.  
 
RNA Extraction and Real-Time 
PCR Total RNA was extracted using RNeasy Micro kit (Qiagen), and cDNA was synthesized 
using QuantiTect Reverse Transcriptase Kit (Qiagen) according to the manufacturer 
guidelines. The VEGF-C primer was QuantiTect Primer Assay (Qiagen, QT00175301), and as 
housekeeping gene, Glyceraldehyde 3- phosphate dehydrogenase (GAPDH) was used. Real-
time PCR was performed using CFX384TM Real-Time System (Bio Rad) with SYBR Green 
assay (SensiMixTM, Bioline). Mean Ct values of samples were normalized to the GAPDH 
value (ΔCt), and relative results were expressed as 2-ΔCt. 
 
VEGF-C ELISA Measurement 
The level of VEGF-C protein secreted into cell culture supernatant was measured by Human 
VEGF-C Immunoassay kit (R&D Systems, Wiesbaden-Nordernstadt, Germany), according to 
manufacturer’s instructions. Supernatant was collected from HK-2 cells stimulated by FCS. 
Medium alone, and medium +20% FCS were used as controls. Three individual experiments 
induplicate were carried out. 
 
Statistical Analysis 
Statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL) and figures were 
made using GraphPad Prism 5.0 (GraphPad Software Inc, La Jolla, CA). Differences among 
groups were tested using two-way ANOVA with Tukey post-hoc analysis. Similar test was 
performed for non-parametric values after log transformation. Since many kidneys had FGS 
score of zero, the difference was tested with Kruskal-Wallis test with Dunn’s post-hoc 
analysis. P<0.05 was considered statistically significant. 
Results 
Clinical Parameters 
Proteinuria was significantly increased in adriamycin-injected rats, compared to saline-
injected controls. It was significantly increased as of 3 weeks (data not shown), and reached 
a plateau of ~200–250 mg/24 h at twelve weeks after induction of nephrosis (Fig. 1A). FGS 
developed over time, with statistical difference from control as of 12 weeks (Fig. 1B). Rats 
in control groups developed a mild proteinuria over time, attributed to the normal process 
of aging. Serum creatinine concentrations, systolic blood pressures (SBP) and body weights 



























Figure 1. Development of proteinuria (A) and focal glomerulosclerosis (B) over time in unilateral 
Adriamycin-induced nephropathy. (*p<0.05, **p<0.01, ***p<0.001); (A) versus week 0; (B) versus week 6. 
 
Lymph Vessel Number Increased in Conjunction with Tubular Activation but before 
Interstitial Fibrosis 
Kidneys from adriamycin-injected rats showed the development of podoplanin-positive 
cells and vessel-like structures in the cortical interstitium (Fig. 2B and C), which were not 
seen in saline-injected control rats. In control renal tissues podoplanin-positive lymph 
vessels were only seen in close conjunction with larger arteries, mostly in deeper cortical 
regions (Fig. 2A). This strongly suggested the development of a podoplanin-positive 
lymphatic network in the cortical tubulointerstitial compartment over time in proteinuric 
adriamycin rats. To be sure that these podoplanin-positive cells and vessel-like structures 
resembled lymphatic endothelium, we performed double staining for podoplanin with two 
other well-established markers for lymphatic endothelium namely VEGFR3 and LYVE-1. 
Indeed, almost all (more than 95%) interstitial podoplanin-positive cells and vessels were 
also positive for VEGFR3 and LYVE-1 (Fig. 2D–I), proving them to be lymphatic endothelial 
cells. Fig. 3A shows the absence of a lymphangiogenic response at 6 weeks after adriamycin 
injection, although proteinuria was already established with values around, 100 mg/24 h. At 
6 weeks no tubular activation (evidenced by tubular osteopontin expression), no interstitial 
accumulation of α-SMA positive myofibroblasts or interstitial influx of ED-1 positive 


































Figure 2. Identification of tubulointerstitial lymph vessels.  
Podoplanin positive tubulointerstitial vessel-like structures (indicated by black arrows) were present in the kidneys of saline-
injected rats adjacent to large and middle-size arteries (A), and barely observed in cortical interstitial area, even in proteinuric 
kidneys at week 6 (B), however were clearly induced in the kidneys of adriamycin-injected rats at 12 weeks (C). Interstitial 
localization of these podoplanin-positive vessels becomes clear by the recognition of PAS positive tubules. Double staining for 
podoplanin and LYVE- 1 (D–F) and for podoplanin and VEGFR3 (G–I) confirmed interstitial podoplanin positive structures to be 
lymphatic endothelial cells, both in large and small lymphatic vessels. (Bar = 100 mm). 
 
At week 12 a clear increase in lymphatic was observed, significantly different from week 6 
(Fig. 3A, p<0.001). Evaluation of other tubulointerstitial parameters revealed tubular 
activation (Fig. 3B, osteopontin week 12 versus week 6, p<0.01). Interstitial myofibroblasts 
were significantly increased at week 12 compared to week 6 as well (Fig. 3C, p<0.03), but 
interstitial macrophages (Fig. 3D), and interstitial fibrosis, evidenced by the interstitial 
collagens type I and type III were not yet increased at week 12 (Fig. 3E and F). From week 
12 to week 30 a further increase of lymph vessels was found (Fig. 3A). Along, tubular 
activation (osteopontin), and interstitial accumulation of myofibroblasts and macrophages 
was observed (Fig. 3B–D). At weeks 24 and 30 interstitial  
 




































Figure 3. Quantitative immunohistochemical analysis of tubulointerstitial damage markers in 
proteinuric, non-proteinuric and saline-injected rats over time. 
Lymphangiogenesis (A), measured as lymph vessel number per medium power field (MPF/200x); osteopontin staining (B), 
quantified as % positive staining per cortical field; myofibroblasts (C), quantified as % positive staining for α-smooth muscle-cell 
actin percortical field; interstitial (ED-1)-positive macrophages (D), numbers per cortical field; interstitial collagen type I deposition 
(E), quantified as % staining per cortical field; and interstitial collagen type III deposition (F), quantified as % staining per cortical 
field (*p<0.05, **p<0.01, ***p<0.001 versus week 6, and for collagen III only week 12 versus week 30 was significant) 
 
collagen I significantly increased compared to week 6 (Fig. 3E, both time points p, 0.01). Collagen 
III did only show a significant increase at week 30 compare to weeks 12 (Fig. 3F). In the control 
groups all interstitial parameters showed minor non-significant increase related to ageing of the 
animals. (Fig. 3A–F). These temporal data support a tubulointerstitial lymphangiogenic response 
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secondary to proteinuria, in conjunction with tubular activation by osteopontin expression and 
myofibroblast accumulation, however preceding interstitial inflammation (macrophage influx) and 
interstitial fibrosis. These findings are exemplified in Fig. 4. 
 
Size Distribution of Lymphatic Vessels Showed the Growth of Newly Formed LV Over Time 
We analyzed surface area of all quantified lymphatic vessels in the kidneys from all 
adriamycin-injected rats. Based on the size distribution we divided them into four 
categories as shown in Figure 5. The distribution at 6 weeks showed the presence of small, 
middle-size and large lymph vessels. These are the already existing vessels present in close 
conjunction with larger arteries. No very small lymphatic structures are found at week 6, 
indicating the absence of new lymph vessel formation at week 6. At week 12, a significant 
increase is found in very small, small and medium-sized lymph structures (varying from 
single cells to very small vessel structures), indicating the occurrence of lymphangiogenesis 
and some size growth/maturation of lymph vessels. Between week 12 and 24 
lymphangiogenesis continues, based on a further increase in very small lymphatic 
structures. In this time frame however, no growth/maturation of small, middle-size and 
large lymph vessels occurred. In the last phase, from week 24 to week 30, 
lymphangiogenesis decreased, whereas growth/maturation significantly increased. We 
conclude that growth, i.e. widening of vessel diameter, occurred mainly between weeks 6–
12 and 24–30, whereas new lymph vessel formation takes place from week 6–24. 
 
Lymphangiogenesis is seen in Conjunction with VEGF-C Positive Tubular Cells 
Since VEGF-C has been described as a major lymphangiogenic factor in renal pathologies 
(16, 17), we stained renal tissues from adriamycin-injected rats at 12 weeks for VEGF-C. 
Many proximal tubules clearly showed VEGF-C expression in a basolateral fashion (Fig. 6, 
left panel). Podoplanin-positive lymph vessels were observed in close conjunction with 
tubuli positive for VEGF-C (Fig. 6, lowest panel). VEGF-C expression was also observed in a 
number of interstitial cells. To identify these VEGF-C positive interstitial cells we performed 
various double stainings for VEGF-C with α-SMA (myofibroblasts), ED-1 (macrophages), NG2 
(pericytes), FSP-1 (fibroblasts), or CD31 (PECAM, endothelial cells). Although low 
percentages of all these different cell types (all, 5%) showed some double positivity with 
VEGF-C, the majority of these cells did not express VEGF-C (Fig. 6. as an example just ED1 
(middle panel) and α-SMA (top panel) is shown). Thus, we were not able to identify the 
phenotype of most interstitial cells which showed VEGF-C positive staining. Since however, 
main VEGF-C expression was observed in tubular epithelial cells and also the newly formed 
lymph vessels were mainly found closely to VEGF-C positive tubules (Fig. 6), our data 
suggest tubular VEGF-C to be involved in the lymphangiogenesis response. 
 
Expression of VEGF-C by Tubular HK-2 Cell Stimulated with FCS in Dose-dependent Manner 
Since we showed tubular activation (osteopontin) and tubular VEGF-C expression at week 
12 in response to prolonged proteinuria, we decided to test in vitro the capability of tubular 
epithelial cells to express and secrete VEGF-C during serum stimulation. We thus incubated 
growth arrested HK-2 proximal tubular epithelial cells with an increasing dose of fetal calf 
serum. By qPCR we found a dose-dependent induction of VEGF-C (Fig. 7A). 












































Figure 4. Interstitial lymph vessel induction precedes interstitial fibrosis. 
Double staining of podoplanin (lymph vessels) with the interstitial collagens types I and III shows the induction of lymph 
vessels from 12 weeks onwards, whereas interstitial fibrosis is only evident at week 30. (Bar = 100 mm). 
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By ELISA we measured a dose-dependent increase of VEGF-C in the supernatant, whereas 
control media in the absence of cells was completely negative (Fig. 7B). These in vitro 
experiments show that proximal tubular epithelial cells are able to induce VEGF-C mRNA 



















Figure 5. Quantification of surface area of all lymph vessels counted in proteinuric kidneys over time. 
All double positive lymph vessels have been divided into four categories based on their size. At 6 weeks, small, middle-size 
and large lymph vessels were present in close association with larger blood vessels, however there were almost no very small 
LV, indicating no lymph vessel formation. Over time, the number of very small LV significantly increased up to week 24. 
Besides, the number of small, middle-size and large LV increased between weeks 6–12 and/or between weeks 24–30, 
implying growth and enlargement of LV in these time frames. (**p<0.01; ***p<0.001). 
 
Anti-proteinuric Intervention Prevented Tubulointerstitial Lymphangiogenesis 
To test whether the tubulointerstitial lymphangiogenic response was indeed secondary to 
proteinuria, in a separate experiment we treated adriamycin nephrotic rats from week 6 to 
week 12 with an ACE-inhibitor lisinopril under low salt diet. Control adriamycin rats were 
just on low salt diet from week 6 to week 12. Interestingly, the lymphangiogenic response 
seen in the control adriamycin rats was almost completely blunted upon the anti-
proteinuric treatment by adding the ACE inhibitor (Fig. 8). Efficacy of the treatment is 
shown by an almost complete normalization of urinary protein excretion in the low 
salt/ACE inhibitor group. This intervention study clearly shows that an effective reduction in 
proteinuria prevented the interstitial lymphangiogenic response. 
Discussion 
In this report we show in a unilateral adriamycin model in the rat that early, established, 
proteinuria is not associated with lymphangiogenesis. However, chronic proteinuria by tubular 
activation triggers new lymph vessel formation in the kidney, concomitantly with a pro-fibrotic 
response and osteopontin expression, and prior to the development of interstitial fibrosis. 
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Tubular expression of VEGF-C in close conjunction with newly formed lymph vessels, together 
with in vitro tubular cell-derived VEGF-C production upon serum stimulation, suggest a role for 
activated tubular cells in the induction of new lymph vessel formation, secondary to 
proteinuria. In line with this, antiproteinuric treatment by ACE inhibition significantly prevented 
renal new lymph vessel formation compared to non-treated proteinuric rats. 
Recent studies have shown a considerable heterogeneity in the expression of endothelial 
markers of lymphatic vessels in different physiological and pathologic conditions [26]. 
Despite this, LYVE-1 (lymphatic vessel endothelial hyaluronan receptor 1), VEGFR-3 
(vascular endothelial growth factor receptor 3), Prox1 (Prosperorelated homeobox 
transcription factor 1), and Podoplanin are among the most useful markers for microscopic 
imaging of lymph vessel, however, none is an ideal choice. To avoid misleading 
interpretation, use of multiple markers for lymph vessel staining has been proposed (27). 
Therefore, we performed an immunofluorescent double-staining protocol using VEGFR-3 
and Podoplanin for visualization of lymphatic endothelium. In the cortex of normal human 
and rodent kidneys, lymphatic vessels are restricted to the peripheral adventitia of large 






















Figure 6. Double immunofluorescence staining for VEGF-C with α-SMA (myofibroblast), ED1 
(macrophages), and with podoplanin (lymph vessels).  
Most podoplanin positive lymph vessels were observed close to tubules (mostly proximal) which showed VEGF-C expression at 
12weeks (arrows). After double staining for macrophages and myofibroblast, most of these interstitial cells were negative for 
VEGF-C. (Bar = 100 mm). 
 
in the medulla (20, 21). In our study, lymphatic vessels were indeed adjacent to arteries in 
control kidneys, while in proteinuric kidneys from 12 weeks onwards massive proliferation 
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of lymphatic vessels was observed especially in cortical tubulointerstitium but not in 
medullary region, fully in agreement with the expression of the lymphangiogenic factors 
VEGF-C and osteopontin by proximal tubules in cortical regions. Proteinuria is associated 
with the activation of several molecular pathways which ultimately lead to tubulointerstitial 
inflammation and fibrotic interstitial damage (28). Several in vivo and in vitro studies 
consistently have shown that plasma protein-associated factors can provoke direct tubular 
activation, and can induce the synthesis of several cytokines and chemokines, like 
endothelin-1 (ET-1), monocyte chemoattractant protein-1 (MCP-1), IL-8 and RANTES 
(regulated upon activation normal T-cell expressed and secreted), which all recruit 
inflammatory cells to the site of injury (5,8,29,30). Of particular interest among them is 
osteopontin. In addition to its multi-functional properties, very recently Liersch R. et al. 
identified osteopontin as a new lymphangiogenic factor in melanoma cell line [31]. 
Although we did not prove this in our study, it could be very well that OPN plays a role in 
renal lymphangiogenesis in our model, which is subject of future studies. 
Infiltration of mononuclear cells in the pathogenesis of progressive renal injury has been well 
documented. Macrophages are closely engaged in the production of several cytokines and growth 
factors which contribute to ongoing tissue damage (32). Several other cell types such as dendritic 
cells, neutrophils, mast cells and fibroblasts have been shown to secrete major lymphangiogenic 
growth factors, such as VEGF-C and -D, in inflammation- induced lymphangiogenesis (33,34). 
However, the role of macrophages has been highlighted mostly. Emerging evidence suggests that 
macrophages participate in lymphangiogenesis via two ways: secreting lymphangiogenic growth 
factors, and transdifferentiation into lymphatic endothelial cell (35,36). In our present study 
interstitial macrophage numbers increased significantly by 18 weeks, while at 6 and 12 weeks 
there was no prominent infiltration of macrophages as compared to controls. However, at 12 
weeks with no significant increase of macrophage number, lymph vessel density sharply 
increased. Also a double staining for VEGF-C with macrophages (ED-1) showed the large majority 
(>95%) of them are not positive for this growth factor, suggesting that ED-1 positive cells, at least 
in our model, are not the main cells for secreting VEGF-C, which is in line with recent report in 










Figure 7. Human proximal tubular epithelial cells (HK-2) express VEGF-C upon serum stimulation in a 
dose-dependent fashion. After incubation of HK-2 cells by fetal calf serum, a dose-dependent induction of VEGF-C was 
observed both at mRNA level by RT-qPCR (A) and at protein level measured by ELISA in culture supernatant. mRNA induction 
(A) is expressed as increase in VEGF-C mRNA message compared to cells cultured in the absence of fetal calf serum. Graph 
represents three independent experiments performed in duplo. The VEGF-C ELISA (B) has been performed twice in duplo. 
Graph shows one representative example, with bars being the mean of duplicates. M (cell culture medium) and 20+M (20% 
FCS in medium without incubation with cells) were measured as controls (B). (*p<0.05; **p<0.01). 
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This implies that lymphangiogenesis is an early response, before influx of macrophages and 
development of inflammation, at least in renal proteinuric conditions, indicating different 
mechanism(s) for new LV formation in this model from well-characterized inflammation-
induced lymphangiogenesis. 
Lymphangiogenesis has been also reported in the remnant kidney model of renal fibrosis in 
rat (37), and in human renal biopsies where lymph vessel number was striking in 
tubulointerstitial fibrotic areas (21). In our experiment, lymphangiogenesis significantly 
increased at week 12 without increase in interstitial collagen I and III deposition. These 
findings provide strong evidence that fibrosis and lymphangiogenesis are not always closely 
interconnected events, and are more in line with a profibrotic signalling mechanism in 
inducing lymphangiogenesis. Conflicting reports about the relation of lymphangiogenesis, 
fibrosis and TGF-β have been published and TGF-β shown as an inhibitor of lymphatic 
endothelial cell proliferation (38-40). Recently in the kidney UUO model, TGF-β has been 
proved to induce VEGF-C expression by tubular epithelial cell which promote 
lymphangiogenesis (22). Upregulation of TGF-β1 has been reported in human Proximal 
Tubular Epithelial Cells (PTEC) stimulated by human albumin serum (HAS), however the 
amount of TGF-β1 production was dependent on cell line (41). Since TGF-β1 is a strong 
inducer of myofibroblasts, and in our study interstitial α-SMA positive myofibroblasts 
followed the same kinetics as lymph vessel density, we speculate that VEGF-C induction by 
TGF-β1 in tubular epithelial cells could be the mechanism of lymphangiogenesis in our 
proteinuric model. However, some other TGF-β1-independent mechanisms, like 
osteopontin, could be involved as well. We did not investigate in detail which urinary 
proteins could induce tubular VEGF-C. We showed that plasma proteins (in fetal calf serum) 
are able to induce VEGF-C expression. We however were unable to induce VEGF-C in 
tubular cells by purified human albumin (data not shown). In line with this observation, in 
human minimal change nephropathy biopsies from patients with a selective albuminuria, 
lymph vessel formation was not observed, whereas in unselective proteinuric 
glomerulopathies, such as IgA nephropathy and membranous glomerulopathy, interstitial 
lymph vessels were induced (21).We thus speculate that albumin-unrelated proteins induce 
VEGF-C in tubular cells. In addition, the amount of filtered plasma proteins and proteinuria, 
and the duration of proteinuria may be important for tubular activation and induction of 
VEGF-C, since significant LVs formation was observed at 12 weeks, when proteinuria had 
established and osteopontin, as a marker of tubular activation, increased. It could be 
postulated that time and duration of contact between filtered plasma proteins with tubular 
epithelial cells is an important factor to activate these cells for VEGF-C production and also 
for osteopontin expression. This suggestion is strongly corroborated by our finding that 
upon effective intervention on proteinuria; lymph vessel formation was almost completely 
prevented. Although VEGF-C is the best characterized growth factor inducing 
lymphangiogenesis, we cannot claim that this growth factor is the sole lymphangiogenic 
mediator in our model, as many other mediators has been shown to be involved in 
lymphangiogenesis. Besides an eventual role for tubular osteopontin, several growth 
factors and cytokines are ultrafiltered from plasma into tubular fluid in proteinuria which 
normally are restricted from transglomerular passage (12), and some of them like 
hepatocyte growth factor (HGF) and platelet-derived growth factor (PDGFBB), have been 
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reported to have a potential lymphangiogenic ability (42). There are other possibilities for 
the mechanism of renal lymphangiogenesis by proteinuria.  
One of the key mechanisms in the pathogenesis of proteinuria-associated injury is nuclear 
factor-kB (NF-kB), which upon stimulation evoking several proinflammatory responses (43). 
NF-kB also plays a role in molecular mechanism of inflammation-induced 
lymphangiogenesis (44), which provides some evidence of underlying possible mechanism 
in proteinuria-driven lymphangiogenesis. Edema in renal interstitium is another 
consequence of proteinuria (45). Disruption of renal lymphatic circulation was shown 
experimentally leads to retention of protein and fluid in interstitium, severe proteinuria, 
fibrosis, and renal cell apoptosis, which caused chronic renal failure (15,46). On the other 
hand, inducing lymphangiogenesis, by using recombinant VEGF-C, has been reported to 
profoundly decrease interstitial fluid in experimental lymphedema (47), suggesting a 
beneficial effect of provoking lymphangiogenesis in ameliorating tissue edema. In our main 
experiment, we used unilateral adriamycin-induced proteinuric model to largely exclude 
effects of edema on lymphangiogenesis. Besides, the unilateral adriamycin approach 
prevents development of a uremic condition in the animals, thereby excluding eventual 























Figure 8. Antiproteinuric intervention strongly prevents renal lymphangiogenesis.  
Lymphatic vessel number was significantly higher in the kidneys of proteinuric rats than in rats receiving anti-proteinuric 
treatment. Representative images of interstitial lymphatic vessels (arrows) in the kidney of proteinuric (A) compared to 
treated animals (B). Quantification showed a significant reduction of lymph vessel number upon antiproteinuric treatment (C), 
whereas efficacy of ACE inhibition on proteinuria is shown in D. Dashed line shows the mean number of cortical lymphatic 
vessels in kidneys of healthy rats. (Bar = 100 mm, **p<0.01, ***p<0.001). 
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In transplantation, some experiments showed that lymphangiogenesis is detrimental by 
promoting migration of antigen-presenting cells (APCs) to the draining lymph node and 
initiating immune responses. Blocking lymphangiogenesis increased graft survival and 
better outcome afterwards, at least in experimental cardiac, corneal and islet 
transplantation [48–50]. In contrast, in experimental chronic and acute skin inflammation 
models lymphangiogenesis was beneficial by promoting lymph flow and reducing edema, 
suggesting a promising therapeutic strategy (51, 52). Whether blocking lymphangiogenesis 
during proteinuria would have been beneficial effects for interstitial changes is not 
investigated in the current study and subject for further research. 
In conclusion, our study for the first time showed that proteinuria can trigger renal 
lymphangiogenesis before development of interstitial fibrosis. Moreover, our data suggest 
lymphangiogenesis is induced by proteinuria-driven tubular activation, osteopontin 
expression and/or VEGF-C synthesis. The degree and duration of proteinuria seems crucial 
to activate tubular epithelial cell for production of osteopontin and VEGF-C. Future 
lymphangiostatic intervention studies will reveal the possible renoprotective effect of 
targeting lymphangiogenesis in proteinuric disease and the relation between 
lymphangiogenesis and development of fibrosis. 
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The Rho kinase pathway plays an important role in epithelial dedifferentiation and 
inflammatory cell infiltration. Recent studies suggest that inflammation promotes 
lymphangiogenesis, which has been associated with renal allograft rejection. We 
investigated whether targeted inhibition of the Rho kinase pathway in proximal tubular 
cells reduces inflammation and lymphangiogenesis in acute renal allograft rejection.  
The Rho kinase inhibitor Y27632 was coupled to lysozyme (Y27632-lysozyme), providing a 
kidney-specific conjugate that can release its drug in proximal tubular cells. Isogenic (Fisher-
Fisher, n=18), or allogenic (Fisher-Lewis, n=24) kidney transplantations were performed, 
with the contralateral kidney remaining in situ. To elicit acute rejection, no 
immunosuppressive treatment was given. Animals were treated daily with Y27632-
lysozyme (10 mg/kg/day i.v.) or vehicle (saline i.v.) until sacrifice (1 or 4 days post-
transplantation).  
After allogenic transplantation, interstitial macrophage accumulation was strongly reduced 
by Y27632-lysozyme at day 4 after transplantation. Interstitial lymphangiogenesis, which 
was induced in allografts as compared to control kidney, was also reduced by renal Rho 
kinase inhibition at day 4 after transplantation. The increase of vimentin and procollagen-
1alpha1 gene expression in renal allografts from day 1 to day 4 after transplantation was 
significantly reduced by Y27632-lysozyme. Y27632-lysozyme did not affect systolic blood 
pressure in isogenic or allogenic transplantation groups. In cultured tubular epithelial cells 
(NRK-52E), Rho kinase inhibition dose-dependently reduced IL-1-induced MCP-1 gene 
expression. 
Renal inhibition of Rho kinase causes a marked reduction in renal inflammation and renal 
lymphangiogenesis during acute transplant rejection, suggesting that this treatment 
regimen is a valuable future treatment in renal transplantation. 




During the last decades, kidney transplantation has been recognized as the best therapeutic 
strategy for patients with end-stage renal disease (1). In spite of the progress in surgical 
techniques, the development of improved immunosuppressive agents, and a better 
understanding of immunologic phenomena, acute rejection remains a serious complication 
of kidney transplantation (2). Both cellular and humoral immune responses and many 
different types of immune cells and cytokines are involved in acute rejection, although the 
underlying pathophysiologic mechanisms have not been fully elucidated. 
Activation of Rho-GTPases plays an important role in the regulation of actin cytoskeleton 
reorganization and inflammation (3, 4). Rho-associated coiled-coil protein kinase (ROCK) is 
one of the downstream effectors of Rho and has been shown to play a role in inflammation 
and profibrotic processes in several models of renal damage (5, 6).We therefore postulated 
that inhibition of the Rho/ROCK pathway might also be beneficial in acute allograft 
rejection, by reducing renal inflammation. Furthermore, recent studies have identified 
inflammation-associated de novo renal lymphangiogenesis in human renal transplants (7), 
and suggested that this process may be associated with renal allograft rejection (8).  
As acute allograft rejection is characterized by tubular damage (9), it may be advantageous 
to specifically deliver the kinase inhibitor to renal tubular cells. Besides, cellular targeted 
delivery of Y27632 to the tubular cells can enhance the efficacy of the drug in the target 
cells and prevent side effects due to distribution to non-targeted organs (5). 
In the present study we investigated whether cell-specific inhibition of the Rho/ROCK 
pathway in proximal tubular epithelial cells reduces renal inflammation and 
lymphangiogenesis in a rat model of acute renal allograft rejection. 
Materials and Methods 
Drug preparation 
To achieve local accumulation of Y27632 in tubular cells of the transplanted kidney, the drug 
was conjugated to lysozyme, a low molecular weight protein that is filtered in the kidneys and 
efficiently accumulated in proximal tubular cells. Drug-lysozyme conjugates have been used 
successfully for the intracellular delivery of small molecule drugs to proximal tubular cells 
(10). Y27632-lysozyme was prepared as described previously (5). The Rho kinase inhibitor 
Y27632 [(+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl) cyclohexanecarboxamide 
dihydrochloride monohydrate] was purchased from Tocris (Bristol, UK). Lysozyme was 
obtained from Sigma-Aldrich (St. Louis, MO). Cis-[Pt(ethylenediamine)nitrate-chloride] 
(universal linkage system, ULS™) was freshly prepared from cis-
[Pt(ethylenediamine)dichloride as described previously (11). Y27632 (2.95 µmol, 10 mg/ml in 
water) was basified with 1 M NaOH to pH 8 and reacted with ULS (5.90 µmol) at 50°C 
overnight. Consumption of the starting drug and formation of the products were followed by 
high-performance liquid chromatography (HPLC) and liquid chromatography–mass 
spectrometry. Following the reaction, purification was achieved by preparative HPLC. The 
appropriate fractions were combined, lypophylised, desalted through Sep-Pak column and 
subsequently eluted with dimethylformamide. Y27632-ULS was subsequently reacted with 
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Boc-l-methionyl modified lysozyme (0.7 µmol) in 0.02 M tricine/sodium nitrate buffer (pH 
8.5). After addition of Y27632-ULS (3.5 µmol), the mixture was reacted at 37°C for 24 h. The 
product was purified by dialysis against water for 48 h, filtered, lyophilized, and stored at –
20°C. Mass spectrometry analysis confirmed the formation of Y27632-lysozyme conjugate. 
The amount of conjugated drug was quantified after competitive displacement of the drug 
from the conjugate by overnight incubation with 0.5 M potassium thiocyanate in PBS at 80°C, 
by HPLC analysis as described previously (5). The absence of free drug in the preparation was 
investigated by HPLC analysis of freshly prepared dilutions of the conjugate in PBS. Previous 
studies demonstrated the pharmacokinetics of Y27632-lysozyme and confirmed its selective 
uptake in proximal tubular cells. Cellular internalization of Y27632-lysozyme occurs via 
megalin receptor-mediated endocytosis (5). 
 
Animal experimental techniques 
Inbred male rats, weighing 215±9 g were used (Harlan, Horst, The Netherlands). Lewis rats 
(Lew.Ssn) served as recipients and Fisher 344 (F344.NHsd) as donors. F344 kidneys placed in 
F344 recipients served as controls. Rats were anaesthetized with isoflurane, left donor 
kidneys were flushed with saline, preserved in saline on ice for 20 minutes and transplanted 
orthotopically. The left vessels and ureter of the recipient were anastomosed end-to-end 
using 10-0 Prolene sutures (Johnson & Johnson Intl., Brussels, Belgium). Vascular clamps were 
released after the vascular anastomosis was completed, with a warm ischemia time of 15 to 
18 minutes. The right native kidney was left in situ. Ten percent of the transplantations 
performed were considered a technical failure due to hydronephrosis and these rats were 
excluded from the study. To achieve acute rejection of the transplanted kidneys, rats were 
not treated with cyclosporine or other immunosuppressive drugs. Kidneys from healthy 
Fisher F344 rats (n=4) were used as controls. All experimental protocols for animal studies 
followed the national guide for the care and use of laboratory animals, and were approved by 
the local Animal Ethic Committee of the University of Groningen. 
From one day before transplantation until sacrifice, rats received daily intravenous 
injections with either Y27632-lysozyme (10 mg/kg equivalent to 278 µg/kg of free Y27632) 
or vehicle (saline i.v.). Animals were sacrificed at day 1 (n=12 allogenic, n=9 isogenic) or at 
day 4 (n=12 allogenic, n=9 isogenic) after transplantation. Blood pressure was measured at 
day 0, 1 and 4 after transplantation. A multi-channel computerized system was used with 
tail cuffs and photoelectric sensors to detect the tail pulse (CODATM; Kent Scientific 
Corporation, Torrington, CT, USA). Rats were placed in restrainers while the temperature of 
the tail was maintained at 35 to 37°C. For each rat, the systolic blood pressure value was 
calculated from the mean of three to five consecutive measurements. Animals were trained 
for 2 weeks to get adapted to the equipment and procedure. 
 
Determination of mRNA expression 
Total RNA was extracted using the TRIZOL method (Invitrogen, Carlsbad, CA). DNase treatment 
was performed using a Turbo DNA-free kit (Applied Biosystems, Foster City, CA). cDNA was 
synthesized using Superscript II RT and random hexamer primers (Invitrogen). Relative 
quantification was performed on an ABI7900HT Taqman (Applied Biosystems). The primers we 
used were Gene Expression Assays (Applied Biosystems) and hypoxanthine 
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phosphoribosyltransferase (HPRT) was used as housekeeping gene. The primer reference 
numbers were as follows: chemokine (C-C motif) receptor 2 (CCR2): Rn 01637698_sl, 
procollagen1α1: Rn01463848_ml, vimentin: Rn00579738_ml, transforming growth factor-β 
(TGF-β): Rn00572010_ml, monocyte chemotactic protein-1 (MCP-1): Rn00580555_ml. The 
following primer sequences were used for HPRT: forward, 5'-
GCC.CTT.GAC.TAT.AAT.GAG.CAC.TTC.AA-3', reverse, 5'-TCT.TTT.AGG.CTT.TGT.ACT.TGG.CTT.TT-
3'. SDS2.1 software (Applied Biosystems) was used for data report and calculation. Mean Ct 
values of the target genes were normalized to the HPRT value (ΔCt) and relative results were 
expressed as 2-ΔCt. 
 
Double-immunofluorescence 
For confirming the identification of lymphatic vessels, double immunofluorescence on 
acetone-fixed cryostat sections was performed with primary antibodies specific for 
podoplanin and vascular endothelial growth factor receptor-3 or with lymphatic vessel 
endothelial hyaluronan receptor-1. Briefly, 4 µm frozen sections fixed in acetone were 
blocked for endogenous peroxidase activity with 0.03% H2O2 if appropriate. Sections were 
incubated with primary antibodies against podoplanin (AngioBio, Del Mar, CA), rabbit anti-
lymphatic vessel endothelial hyaluronan receptor-1 (Millipore, Billerica, MA) or goat anti-
vascular endothelial growth factor receptor-3 (R&D systems, Minneapolis, MN), 
respectively. Binding of primary antibodies was detected by incubation with secondary 
antibodies labelled with horseradish peroxidase (DAKO, Glostrup, Denmark) or goat anti-
mouse FITC (SouthernBiotech, USA), where appropriate. Horseradish peroxidase activity 
was visualized using the TSATM Tetramethylrhodamine system (PerkinElmer, Waltham, 
MA). Nuclei were stained with DAPI. Individual channels were auto- contrasted and overlaid 
using Photoshop CS5 (Adobe, San Jose, CA). 
 
Immunohistochemistry 
For the immunohistochemical detection of macrophages (ED1+), lymph vessels 
(podoplanin+) and vimentin in tissues, 4-µm-thick paraffin-embedded sections were used. 
Sections were deparaffinized in xylene and rehydrated in alcohol and distilled water. 
Antigen retrieval was achieved by overnight incubation at 60ºC in 0.1 M Tris/HCl buffer (pH 
9.0) for ED-1 staining. For vimentin staining, sections were incubated in a microwave for 15 
min at 300W with 1mM EDTA (pH 8.0). Endogenous peroxidase activity was blocked with 
0.03% H2O2 for 30 min. Slides were then incubated with primary antibodies against ED-1 
(Serotec, Oxford, UK), podoplanin (AngioBio) or vimentin (Clone V9, monoclonal mouse 
anti-vimentin, DAKO). Binding was detected by sequential incubation with peroxidase-
labelled secondary and tertiary antibodies in the presence of 1% normal rat serum for 30 
min. The peroxidase activity was visualized using 3,3’-diaminobenzidine tetrahydrochloride 
(DAKO) for 10 min. Sections stained for podoplanin were counterstained with period acid-
Schiff and subsequently analyzed for quantification, whereas sections stained for ED1 were 
quantified first and then counterstained with period acid-Schiff. 
 
Quantification 
The extent of tubulointerstitial vimentin expression was measured using computerized 
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morphometry in 30 fields per section at 200x magnification. Glomeruli and vascular areas 
were manually excluded. Interstitial macrophages were counted in 30 fields per section 
with a grid at 200x magnification and glomerular macrophages were counted in 50 
glomeruli per sections at 400x magnification.  
The lymphatic vessel density was quantified as number of podoplanin positive vascular 
profiles per medium-power field (20X objective). The sections were scanned using a 
NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). A total of 30 fields per 
kidney cortex were evaluated and the number of lymph vessel were counted using ImageJ 
1.41 (Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA) 
which was downloaded from http://rsb.info.nih.gov/ij/download.html. 
 
Cell culture studies 
In vitro experiments were performed in a rat tubular epithelial cell line (NRK-52E, American 
Type Culture Collection (ATCC), Manassas, VA, USA). Cells were grown in DMEM (Gibco, Life 
technologies, UK) containing 4.5 g/l glucose, supplemented with penicillin (50U/ml) / 
streptomycin (50 µg/ml), and 5% fetal calf serum, in humidified air at 37 °C with 5% CO2. 
Cells were seeded in 12-well plates until ±80% confluence; prior to each experiment cells 
were washed twice with HBSS and starved in serum-free medium for 24h. 
Subsequently, cells were stimulated with recombinant rat IL-1β (10 ng/ml, R&D Systems, 
Abingdon, United Kingdom) under serum-free conditions. One hour before stimulation, 
cells were either pre-incubated with the ROCK inhibitor Y27632 or vehicle. After 6 hrs cells 
were lysed, mRNA was isolated and realtime qPCR for MCP-1 was performed as described 
above. Experiments were performed three times. 
 
Statistical analysis 
Statistical analyses were performed using SPSS 16.0 (SPSS Inc., Chicago, IL) and GraphPad 
Prism 5.0 (GraphPad Software Inc, La Jolla, CA). Differences between groups were 
calculated using Kruskal Wallis, with P<0.05 as the minimal level of significance. The data 
are expressed as mean ± standard error of the mean. 
Results 
Clinical parameters  
At time of transplantation, systolic blood pressure was not significantly different between 
animals treated with the Rho kinase inhibitor Y27632-lysozyme or with vehicle (not shown). 
Treatment with Y27632-lysozyme did not affect systolic blood pressure in any of the 
groups, neither at day 1 nor at day 4 after transplantation. The clinical parameters 
measured in isograft and allograft recipients are summarized in Table 1. Body weight at 
sacrifice was not different between any of the groups. Serum creatinine levels were not 
increased in any of the allogenic transplanted groups as compared to isografts, nor did 
Y27632-lysozyme change serum creatinine as compared to vehicle. Oppositely, in vehicle-
treated isografts at 1 day post-transplantation, serum creatinine was slightly higher than 
other groups (P<0.05 vs vehicle-treated allografts day 1 post-transplantation). At 4 days 
after transplantation, serum creatinine values were similar among all groups. 












Figure 1. Effect of Y27632-lysozyme on interstitial and glomerular macrophage accumulation in renal 
allografts. 
(A) Interstitial ED1+ macrophage accumulation was increased in isografts and allografts at day 4 post-transplantation, as 
compared to healthy control kidneys. Y27632-lysozyme treatment significantly reduced tubulointerstitial macrophage 
accumulation in allografts 4 days post-Tx. (B) Y27632-lysozyme treatment significantly attenuated glomerular macrophage 
accumulation in allograft rats at day 4 post-Tx. Y27632-lysozyme did not affect glomerular macrophage accumulation in isografts. 
 
Renal accumulation of macrophages 
Allogenic kidney transplantation resulted in an increased accumulation of macrophages in 
both the tubulo-interstitial (Fig. 1A) and glomerular (Fig. 1B) compartment. At 1 day post-
transplantation, tubulo-interstitial macrophage influx was equally low in both isografts and 
allografts. However, at 4 days post-transplantation tubulo-interstitial macrophage influx 
was significantly increased in allografts (vs. healthy control kidneys, P<0.05). Treatment 


















Figure 2. Y27632-lysozyme significantly reduced tubulointerstitial ED-1+ macrophage influx 4 days 
after transplantation.  
Representative photomicrographs of renal sections from allografts from vehicle (A: day 1, B: day 4) and Y27632-lysozyme (C: 
day 1, D: day 4) treated recipients. These images indicate strongly reduced numbers of ED1+ macrophages (dark brown cells) 
in Y27632-lysozyme -treated recipients 4 days after transplantation (panel D) as compared to vehicle-treated allograft 
recipients (panel B). Inset: high power magnification of the framed areas shown in panels B & D. Isografts are not shown. 
Sections were counterstained with PAS. Magnification 200x. 
CHAPTER 7 
122 
allografts 4 days post-transplantation. Representative photomicrographs of the 
tubulointerstitium of allografts with or without Y27632-lysozyme treatment are shown in 
Fig. 2. Glomerular macrophage influx was already increased in allografts 1 day post-
transplantation (vs. healthy control kidneys, P<0.05). Treatment with Y27632-lysozyme 
significantly reduced glomerular macrophage influx in allografts to the level of isografts 
both 1 and 4 days post-transplantation.  
 
Renal lymphangiogenesis 
Specificity of podoplanin as a lymph vessel marker was first confirmed by double-
immunolabeling, as demonstrated in Fig. 3. Double-labeling with podoplanin and vascular 
endothelial growth factor receptor-3 (Fig. 3A) as well as double-labeling with podoplanin 
and lymphatic vessel endothelial hyaluronan receptor-1 (Fig. 3B) confirmed that podoplanin 























Figure 3. Co-localization of podoplanin with lymph vessel markers. 
Double-immunofluorescence of kidney sections, double-stained for (A) podoplanin (green) and vascular endothelial growth 
factor receptor-3 (VEGFR-3, red) or (B) podoplanin (green) and lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1, 
red), respectively, confirms the expression of podoplanin by lymph vessels (yellow in merged image). 
 
all groups (Fig. 4) revealed that the number of lymph vessel was increased in allografts at 
day 1 and day 4 post-transplantation as compared to kidneys from healthy animals. 
Treatment with Y27632-lysozyme reduced the number of lymph vessels at both time 
points. Representative photomicrographs of lymph vessel staining are presented in Fig. 5. 
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Renal expression of markers for EMT, inflammation and fibrosis 
As demonstrated in Fig. 6A, renal gene expression of vimentin, a marker of epithelial to 
mesenchymal transformation (EMT), increased in vehicle-treated rats from day 1 to day 4 in 
both allografts and isografts (P<0.05). In rats treated with Y27632-lysozyme on the other 
hand, the increase from day 1 to 4 was far less pronounced (P=NS, day 1 vs day 4) both in 
allografts and isografts. Similarly, renal vimentin protein expression was reduced in rats 
treated with Y27632-lysozyme as compared to vehicle at day 4 after transplantation (Fig. 
6B), although the difference did not reach statistical significance.  
Expression of the pro-inflammatory gene MCP-1 increased from day 1 to day 4 in allografts; 














Figure 4. Renal lymph vessel numbers are increased in acute rejection at both day 1 and day 4 after 
allogenic kidney transplantation. Both at day 1 and day 4, treatment with Y27632-lysozyme reduced renal 
lymphangiogenesis as compared to vehicle-treated allografts at the same time point. 
 
Renal expression of the proinflammatory gene CCR2 was significantly increased in allografts 
at day 4 after transplantation (relative gene expression 2.10±0.33) as compared to day 1 
(0.20±0.03, P<0.05). Treatment with Y27632-lysozyme reduced CCR2 at 4 days after 
transplantation in allografts (1.74±0.37), but this difference did not reach statistical 
significance. The fibrotic marker procollagen-1α1 was increased at 4 days after 
transplantation as compared to day 1 in both allografts and isografts from animals treated 
with vehicle (Fig. 6D). In Y27632-treated animals, this increase was less pronounced (P=NS vs 
day 1). Renal TGF-β gene expression also increased in allografts from day 1 (2.05±0.17) to day 
4 (4.01±0.26), but Y27632-lysozyme did not affect renal TGF-β gene expression at day 4 after 
transplantation (3.91±0.14). 
 
Rho kinase inhibition reduces MCP-1 gene expression in cultured tubular epithelial cells 
The role of Rho kinase in renal inflammation was further evaluated in cultured rat renal 
tubular epithelial cells (NRK-52E). After stimulation with IL-1β (10 ng/ml) for 6h, MCP-1 
gene expression was strongly (>600 times compared to medium control) increased, while 
pre-incubation with the ROCK inhibitor, Y27632, dose-dependently reduced IL-1β-induced 



















Figure 5. Representative photographs of podoplanin immunohistochemistry, identifying lymph 
vessels (arrows). (A) Perivascular lymph vessel in a healthy control kidney. (B) Peritubular localization of lymph vessels in 
healthy control kidneys was very rarely observed. In vehicle-treated allografts, numbers of lymph vessels were increased at 1 
day post-transplantation (C), but much more pronounced at day 4 post-transplantation (E). Inhibition of renal Rho kinase by 















Figure 6. Y27632-lysozyme reduced tubular vimentin expression and renal procollagen-1α1 
expression 4 days after transplantation. 
(A) In both allografts and isografts, renal vimentin gene expression increased from day 1 to day 4 in vehicle-treated rats. In 
rats treated with Y27632-lysozyme, there was no significant increase in renal vimentin gene expression from day 1 to day 4, 
neither in allografts nor in isografts. At day 4 after transplantation, vimentin gene expression was reduced in Y27632-
lysozyme-treated animals as compared to vehicle-treated animals (both in allografts and in isografts), but this difference did 
not reach statistical significance. (B) Similarly, renal vimentin protein expression showed a trend to reduction by Y27632-
lysozyme. (C) Renal MCP-1 gene expression was not affected by Y27632-lysozyme. (D) In both allografts and isografts, renal 
procollagen-1α1 gene expression increased from day 1 to day 4 in vehicle-treated rats. In rats treated with Y27632-lysozyme, 
there was no significant increase in renal procollagen-1α1 gene expression from day 1 to day 4, neither in allografts nor in 
isografts. At day 4 after transplantation, procollagen-1α1 gene expression was reduced in Y27632-lysozyme-treated animals as 
compared to vehicle-treated animals (both in allografts and in isografts), but this difference did not reach statistical 
significance. * P<0.05 vs day 1 (same treatment) 














Figure 7.  Dose-response curve for the effect of Y27632 on MCP-1 gene expression in cultured 
tubular epithelial cells (NRK-52E). 
Cells were pre-incubated with different doses of Y27632 (black bars) or vehicle (DMSO, white bar) for 1 h and then stimulated 
with IL-1β (10ng/ml) for 6 hrs. Expression of MCP-1 gene expression was determined by qPCR. The Rho kinase inhibitor 










1 day 4 days 1 day 4 days 1 day 4 days 1 day 4 days 
SBP (mmHg) 140±8 125±3 142±10 134±7 141±4 154±11 144±5 142±4 
SBP, sacrifice 
(mmHg) 
120±7 122±4 137±4 135±14 168±14 159±10 144±6 161±11 
Body weight, 
sacrifice (g) 
244±21 242±24 243±22 239±243 228±14 215±10 228±13 220±17 
Kidney weight, Tx 
kidney (g) 








32.8±5.0a 29.7±3.0 33.0±5.7 29.0±2.7 42.6±8.1 32.0±5.7b 34.3±6.3 30.4±2.4 
 
Table 1. Clinical parameters 
aP<0.05 vs isografts at similar time point (day 1 or day 4) and treatment (Y27632-lysozyme or vehicle), bP<0.05 vs day 1. SBP = 
systolic blood pressure, Tx kidney= transplanted kidney, Y27632-lysozyme = Rho kinase inhibitor Y27632 coupled to lysozym 
Discussion 
Rho kinase activation plays a role in several processes crucial to the pathophysiology of 
acute renal allograft rejection (i.e. inflammation, ischemia/reperfusion injury). The aim of 
the current study was therefore to investigate whether renal inhibition of Rho kinase would 
reduce renal damage in a rat model of acute rejection. Indeed, we found a significantly 
reduced renal macrophage influx, both in the glomerular and tubulointerstitial 
compartment. Furthermore, renal Rho kinase inhibition reduced the development of EMT 
in tubular cells of allogenic transplanted kidneys, and reduced the induction of the fibrotic 
marker procollagen-1α1 in allografts.  
To generate Y27632-lysozyme, the widely used Rho kinase inhibitor Y27632 was chemically 
coupled to lysozyme, resulting in a conjugate that releases the drug specifically within the 
proximal tubular epithelial cells of the kidney (5, 12, 13). In follow-up to an earlier study in 
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which Y27632-lysozyme was evaluated in a renal ischemia-reperfusion injury model, we 
now investigated its efficacy in kidney allograft transplantation. This study is the first to 
demonstrate that intrarenal delivery of a Rho kinase inhibitor is an effective strategy to 
reduce graft-associated inflammation. Together with prior studies in which the systemic 
efficacy of Y27632 in renal allograft transplantation was shown (14), our study furthermore 
demonstrates that local activation of tubular Rho kinase plays an important role in 
macrophage chemoattraction into the renal tubulointerstitium. We also observed an effect 
of Y27632-lysozyme on glomerular macrophage accumulation, which was slightly but 
significantly increased compared to healthy control kidneys. This could be explained by 
tubuloglomerular cross-talk (15, 16); i.e. the reduced tubulointerstitial inflammation by 
Y27632-lysozyme may subsequently reduce the glomerular influx of macrophages. Similarly 
to our previous study (5), the absence of effects on blood pressure supports our hypothesis 
that Y27632-lysozyme acts locally in the kidney without systemic side-effects. 
The pathophysiologic role of macrophage accumulation in acute allograft rejection is 
increasingly recognized (17). Two decades ago, it was demonstrated that in acute allograft 
rejection, macrophages accumulate in the renal interstitium (18); its abundant presence 
has been associated with a more severe type of rejection (19). Furthermore, acute vascular 
rejection is characterized histologically by subendothelial infiltration of mononuclear cells 
in the arterial intima (20). Besides their immunologic role, macrophages play a fundamental 
role in tissue remodeling during embryonic development, acquired kidney disease, and 
renal allograft responses (21). Thereby, the reduction of the procollagen-1α1 gene in 
response to renal Rho kinase inhibition may be the consequence of reduced renal 
macrophage accumulation, although the Rho kinase pathway may also directly modulate 
collagen-1α gene expression (22, 23). Of interest, a recent study demonstrated that 
leucocytes induce EMT in a model of renal fibrosis (24). Thus, specific Rho kinase inhibition 
in renal tubular epithelial cells reduced renal macrophage accumulation in acute rejection, 
which may in turn have reduced EMT and pro-fibrotic (procollagen-1α1) gene expression.  
Pro-inflammatory factors are considered to play a central role in macrophage recruitment 
towards the damaged renal tubulointerstitium (25-27). Although we could not demonstrate 
a reduction of total kidney MCP-1 mRNA expression by Y27632-lysozyme in our in vivo 
experiment, we did find a dose-dependent reduction of IL-β-induced MCP-1 expression by 
the Rho kinase inhibitor (Y27632) in cultured rat tubular epithelial cells. This supports the 
hypothesis that reduced accumulation of macrophages in our in vivo model was indeed 
through reduced tubular expression of the chemo-attractant MCP-1.  
Beside the effect on macrophage accumulation, Y27632-lysozyme also reduced the number 
of renal lymph vessels. Our finding that in acute renal allograft rejection the number of 
lymph vessels is higher than in healthy kidneys is in line with previous studies (8, 28). Of 
interest, we also found that renal Rho kinase inhibition reduced the numbers of lymph 
vessels in the kidney. Although the current study does not provide a mechanistic 
explanation, it could be explained through lower macrophage infiltration in the Y27632-
lysozyme-treated group as compared to vehicle. Macrophages may play a major role in 
lymphangiogenesis, not only by producing high level of chemokines and lymphangiogenic 
factors (29), but also by incorporating into the lymphatic vessel wall (30). Therefore, 
reduction of lymph vessel numbers in treated animals compare to controls, could be 
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secondary to decrease macrophage influx. 
Conclusions 
In conclusion, using a lysozyme-ULS-based drug targeting strategy to deliver the Rho kinase 
inhibitor Y27632 to renal proximal tubular epithelial cells, we demonstrated reduced 
macrophage accumulation and lymph vessel density in allografts after induction of acute 
rejection. Furthermore, the induction of renal vimentin and procollagen-1α1 was reduced 
by renal Rho kinase inhibition. Rho kinase activation in tubular epithelial cells may play an 
important role in the tubulointerstitial accumulation of macrophages, and consequently 
EMT and renal fibrosis, following acute rejection. Renal delivery of Rho kinase inhibitors 
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Proteinuria is an important cause of tubulointerstitial damage. Anti-proteinuric 
interventions are not always successful, and residual proteinuria often leads to renal 
failure. This indicates the need for additional treatment modalities by targeting the harmful 
downstream consequences of proteinuria. We previously showed that proteinuria triggers 
renal lymphangiogenesis before the onset of interstitial inflammation and fibrosis. 
However, the interrelationship of these interstitial events in proteinuria is not yet clear. To 
this end, we specifically blocked lymphangiogenesis (anti-VEGFR3 antibody), 
monocyte/macrophage influx (clodronate liposomes) or lymphocyte and myofibroblast 
influx (S1P agonist FTY720) separately in a rat model to investigate the role and the possible 
interaction of each of these phenomena in tubulointerstitial remodeling in proteinuric 
nephropathy. Proteinuria was induced in 3-month old male Wistar rats by 
adriamycininjection. After 6 weeks, when proteinuria has developed, rats were treated for 
another 6 weeks by anti-VEGFR3 antibody, clodronate liposomes or FTY720 up to week 12. 
In proteinuric rats, lymphangiogenesis, influx of macrophages, T cells and myofibroblasts, 
and collagen III deposition and interstitial fibrosis significantly increased at week 12 vs week 
6. Anti-VEGFR3 antibody prevented lymphangiogenesis in proteinuric rats, however, 
without significant effects on inflammatory and fibrotic markers or proteinuria. Clodronate 
liposomes inhibitedmacrophage influx and partly reduced myofibroblast expression; 
however, neither significantly prevented the development of lymphangiogenesis, nor 
fibrotic markers and proteinuria. FTY720 prevented myofibroblast accumulation, T-cell 
influx and interstitial fibrosis, and partially reduced macrophage number and proteinuria; 
however, it did not significantly influence lymphangiogenesis and collagen III deposition. 
This study showed that proteinuria-induced interstitial fibrosis cannot be halted by blocking 
lymphangiogenesis or the influx of macrophages. On the other hand, FTY720 treatment did 
prevent T-cell influx, myofibroblast accumulation and interstitial fibrosis, but not renal 
lymphangiogenesis and proteinuria. We conclude that tubulointerstitial fibrosis and 
inflammation are separate from lymphangiogenesis, at least under proteinuric conditions. 




Proteinuria is a major challenge in clinical nephrology because sustained proteinuria can 
lead to a progressive decline in kidney function, worsening to chronic kidney disease (CKD) 
and end-stage renal disease (ESRD), and eventually the need for dialysis or renal 
transplantation (Cravedi and Remuzzi, 2013; Ruggenenti et al., 2012; Lea et al., 2005; Gorriz 
and Martinez-Castelao, 2012). Many renal diseases are accompanied by proteinuria. 
Because proteinuria is independently associated with a decline in renal function, anti-
proteinuric treatment [mainly renin-angiotensin-aldosterone system (RAAS) intervention, 
eventually in combination with reduced salt intake] makes up a major cornerstone in renal 
medicine. Nevertheless, complete annihilation of proteinuria is practically not possible, and 
most patients slowly progress towards renal failure. Forced titration of proteinuria by dual 
RAAS intervention (ONTARGET trial) or angiotensin-converting enzyme (ACE) inhibition 
under very-low salt conditions worsened renal outcomes (Mann et al., 2008) or interstitial 
fibrosis (Hamming et al., 2006). Even under rather low proteinuria values kidneys 
deteriorate over time. This indicates the need for additional treatment modalities, not only 
trying to reduce proteinuria even further, but also reduce the harmful effects downstream 
of proteinuria (de Zeeuw, 2008). It is well recognized that proteinuria (ultrafiltrated plasma 
proteins) activates tubular cells to secrete many chemokines and mediators that can elicit 
proinflammatory and profibrotic cascades (Eddy, 2004; Zoja et al., 2004; Bakris, 2008; 
Moreno et al., 2014), and leads to renal inflammation and fibrosis (Abbate et al., 2006). An 
additional treatment option is thus to reduce tubulointerstitial changes secondary to 
proteinuria. 
We previously showed that proteinuria can promote renal lymphangiogenesis that 
concomitantly occurs with an increase of the profibrotic response and tubular activation 
(Yazdani et al., 2012). Several studies have proposed both a direct and an indirect link 
between lymphangiogenesis, inflammation and fibrotic reactions. Nevertheless, their causal 
interplay in tubulointerstitial remodeling in kidney diseases has not been investigated yet 
(Yazdani et al., 2014). A wealth of evidence has shown a reciprocal interaction between 
inflammation and lymphangiogenesis (Johnson and Jackson, 2010; Dieterich et al., 2014). 
On one hand, leukocytes are able to produce mediators and growth factors that can 
promote lymphangiogenesis, and, on the other hand, activated lymph endothelial cells 
(LECs) can secrete several mediators that recruit inflammatory cells and can further 
exacerbate this inflammatory microenvironment (Loffredo et al., 2014). Among 
inflammatory cells, macrophages have been shown to play a prominent role ininducing 
lymphangiogenesis, at least in two distinct ways: by producing lymphangiogenic growth 
factors and stimuli, and/or by directly trans-differentiating into LECs (Ran and Montgomery, 
2012). 
The direct link between inflammation and fibrosis has been well established as well (Wick 
et al., 2013). Despite many clinical and experimental investigations, effective treatment for 
fibrosis is still lacking in the clinic (Friedman et al., 2013). FTY720, an S1P analog, effectively 
inhibits the egress of T and B cells from lymph nodes (Kabashima et al., 2006; Matloubian et 
al., 2004), thereby reducing the number of antigen-primed/restimulated cells that 
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recirculate to peripheral inflammatory tissues (Brinkmann and Lynch, 2002), and 
consequently halts inflammation. FTY720 can also directly block lymphangiogenesis (Yoon 
et al., 2008), and has been reported to prohibit renal fibrogenesis (Shiohira et al., 2013; Ni 
et al., 2013a,b). Taking these all into account, FTY720 seems to be a promising agent in 
targeting tubulointerstitial remolding. However, the exact interaction among these 
interstitial phenomena (inflammation, fibrosis and lymphatic remodeling) in proteinuric 
nephropathy has not been clearly explored. Understanding of the detailed mechanisms of 
the complex interaction between these proteinuria-induced downstream tubulointerstitial 
events might reveal their significance to the progression towards ESRD, and hence might 
have potential therapeutic values in affected individuals. 
To mimic a clinically relevant situation, a mild proteinuric model was chosen: thus, a low 
amount of adriamycin was used to induce moderate proteinuria, without the development 
of nephrotic syndrome but with chronic tubular epithelial cell activation and progressive 
interstitial remodeling. In this model, we chose a therapy aimed at reducing interstitial 
remodeling, thus not aiming to reduce proteinuria even further, but to target its 
downstream consequences. Therefore, in this interventional studywe specifically blocked 
lymph vessel (LV) formation (antibody treatment with anti-VEGFR3), 
monocyte/macrophage influx (clodronate liposomes, which selectively deplete 
monocytes/macrophages), and lymphocyte and α-SMA-positive-cell influx (by oral FTY720, 
as an S1P receptor agonist) separately to investigate the role of each of these phenomena 
in tubulointerstitial remodeling in proteinuric nephropathy. As read-out parameters we 
evaluated proteinuria and histological changes. 
Materials and methods 
Animal experimental protocol and treatments 
Proteinuria was induced in 78 3-month-old male Wistar rats (weighing 180- 200 g) by single 
injection of adriamycin in the tail vein [1.8 mg/kg body weight (BW)], and healthy rats 
served as controls. After 6 weeks, when proteinuria had developed (∼150 mg/24 h), a 
kidney biopsy was taken via dorsolateral incision. After recovery, 60 rats were assigned 
randomly to one of the interventional or control groups. 18 rats did not develop sufficient 
proteinuria and were excluded from the study. Proteinuric rats wererandomly divided into 
five groups: a proteinuric untreated group (n=8), and four interventional groups, which 
were treated with FTY720 (n=8), anti- VEGFR3 antibody (n=8), CLs (n=8) or empty (PBS) 
liposomes (n=6), which served as a control for the CLs. The healthy rats were randomly 
divided into a healthy untreated control group (n=6) and three different healthy control 
groups, which were treated with FTY720 (n=6), anti- VEGFR3 antibody (n=4) or CLs (n=6). 
The treatment by the abovementioned agents then started from week 6 and was continued 
untilweek 12: anti-VEGFR3 antibody (IMC-3C5, ImClone/Eli Lilly, USA) intraperitoneally (i.p.) 
40 mg/kg BW, three times per week; CLs (ClodronateLiposomes.org, The Netherlands) i.p. 
twice weekly 1 ml/rat; and FTY720 (Novartis, Basel, Switzerland) 1 mg/kg BW/day in 
drinking water. At week 12, blood pressure was measured under general anesthesia with 
the Cardiocap/5 (Datex-Ohmeda, Newark, USA). Then, after saline perfusion, organs were 
harvested and some parts were preserved in liquid nitrogen for cryosections, and other 
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parts in formaldehyde 10% for paraffin embedment. At the beginning of the study, at the 
time of the biopsy (6 weeks) and at the end of the experiment (12 weeks), body weight was 
measured, blood samples were collected and rats were placed in metabolic cages for 24 h 
for urine collection and the measurement of food and water intake. Proteinuria was 
determined in urine samples by a turbidimetric assay (Roche Modular P, Mannheim, 
Germany). Experimental procedures were carried out according to the national guidelines 
for the care and use of laboratory animals, and approved by the local Animal Ethics 
Committee of the University of Groningen. 
 
Immunohistochemistry 
Staining was performed on 3-μm-thick formalin-fixed paraffin sections after 
deparaffinization in xylene and rehydration in alcohol series. Antigenretrieval was done for 
15 min in a microwave oven for Tris/EDTA buffer pH:9 and citrate buffer pH:6, or overnight 
at 80°C in Tris/HCl buffer pH:8. Endogenous peroxidase activity was blocked with 0.3% 
hydrogen peroxide. Sections were incubated for 1 h or overnight at 4°C with the following 
primary antibodies: mouse anti-human α-SMA (clone 1A4, Sigma-Aldrich, St Louis, USA), 
goat anti-collagen III (cat. no. 1330-01, SouthernBiotech, Birmingham, USA), rabbit anti-rat 
CD3 (clone A0452, Dako, Glostrup, Denmark), mouse anti-rat CD68 (clone ED1, AbD 
Serotec, Oxford, UK) and mouse anti-rat podoplanin (cat. no. 11-035, Angio Bio, Del Mar, 
USA). After this step, the sections were incubated with secondary and tertiary antibodies 
diluted in PBS/BSA 1% and 1% normal rat serum. We used rabbit anti-mouse Ig horseradish 
peroxidase (HRP), goat anti-rabbit Ig HRP, goat anti-mouse Ig HRP, rabbit anti-goat Ig HRP, 
swine anti-rabbit HRP and anti-rabbit poly HRP (all from Dako, Glostrup, Denmark). As 
negative controls, the primary antibodies were replaced by PBS/BSA 1%. Bound antibodies 
were visualized by aminoethylcarbazole (AEC) or by the peroxidase substrate 3,3′-
diaminobenzidine (DAB) (Sigma-Aldrich, St Louis, USA) and then counterstained with 
diluted hematoxylin. PAS was also performed on series of sections in order to quantify the 
extent of structural changes (interstitial fibrosis). The sections were then scanned by a 
NanoZoomer HT (Hamamatsu Photonics K.K., Shizuoka Pref., Japan). The quantification was 
done using Aperio ImageScope software (version 9.1.772.1570, Aperio Technologies Inc., 
Vista, CA, USA) and ImageJ 1.46r (Rasband, W.S., U.S. National Institutes of Health). 
 
Quantification of lymph vessels and renal histomorphology 
For identification of LVs, we counted podoplanin-positive vessels in 30 cortical interstitial 
fields per kidney. The amount of collagen III, myofibroblasts (α-SMA), ED1-positive 
macrophages and CD3-positive T cells were measured as described previously (Yazdani et 
al., 2012). In short, collagen III expression, myofibroblasts, ED1-positive macrophages and 
CD3-positive T cells were evaluated in 30 (high or medium power field) cortical interstitial 
areas of each kidney in a blinded fashion. The quantification was done using ImageJ 1.41 
(Rasband, W.S., U.S. National Institutes of Health). PAS staining was semi-quantitatively 
scored on a scale ranging from 1 to 5. The scoring indicates which part of renal cortical 
tissue was affected by tubulointerstitial fibrosis (broadening interstitial area in between the 




Urine and plasma analysis 
The sodium, potassium and chloride concentrations in both plasma and urine were 
analyzed by an electrolyte analyzer ISE (Roche Modular P, Mannheim, Germany). The urea 
and creatinine in plasma and urine were measured by an enzymatic UV assay (Roche 
Modular P). For the measurement of total protein in plasma/serum, we used a colorimetric 
assay (Roche Modular P). 
 
RNA isolation and cDNA synthesis  
For RNA isolation from kidney tissue, we used the Favorprep RNA minikit (Favorgen Biotech 
Corp., Denmark). For each sample, we used 5-μm sections, in total weighing approximately 
30 mg (no DNase treatment during RNA isolation). Concentration measurement was done 
by Nanodrop and the integrity of the RNA was tested by running the samples on a 1% 
agarose gel in loading buffer. cDNA was synthesized using a QuantiTect Reverse 
Transcription Kit (Qiagen, Germany). Genomic DNA was eliminated during this procedure. 
 
RT-PCR  
mRNA expression of osteopontin, MCP-1 (CCL2), VCAM-1, collagen I (α1), collagen III (α1) 
and TGF-β1 were determined by qRT-PCR. Primers were bought from QIAGEN, The 
Netherlands. Primers were: collagen I (α1) primer (5′-AGCCTGAGCCAGCAGATTGA-3′ and 5′-
CCAGGTTGCAGCCTTGGTTA-3′), MCP-1 primer (5′-CCGACTCATTGGGATCATCTT-3′ and 5′-
TGTCTCAGCCAGATGCAGTTAAT-3′). Other primers were ordered ‘on demand’ with the 
following order names: Rn_Col3- a1_2_SG QuantiTect primer assay (QT01083537), 
Rn_Tgfb1_1_SG QuantiTect primer assay (QT00187796), Rn-Vcam1-1-SG QuantiTect primer 
assay (QT00178500) and Rat-Spp-1 RT2 qPCR Primer assay (osteopontin) (PPR44222B). qRT-
PCR was performed using the C1000 CFX384 from Bio-Rad, using SYBR Green (SensiMix 
SYBR No-ROX kit, GC biotech). GAPDH was used as a housekeeping gene to normalize 
mRNA expression. GAPDH primers: (5′-CATCAAGAAGGTGGTGAAGC-3′ and 5′-
ACCACCCTGTTGCTGTAG-3′). 6.7 ng cDNA per well were brought on a 384-well plate ( 
plateHard-Shell PCR plates, 384-well white well/CRL shell). Every sample was measured in 
triplicate. The cycle procedure was as followed: 10 min at 95°C, with 40 repeats of a 15 s 
denaturation step at 95°C and a 15 s extension and annealing step at 60°C, followed with a 
5 s extension step at72°C. A dissociation stage was added to ensure that the 
desiredamplification was detected. Results are expressed as 2-deltaCT, and finally 
presented as relative expression to GAPDH. 
 
White blood cell counting 
The number of white blood cells, neutrophils, lymphocytes, monocytes, eosinophils and 
basophils was measured by the Sysmex XN9000 (Kobe Japan). 
 
Statistical analysis 
Statistical analyses were performed using SPSS 20.0 (SPSS Inc., Chicago, IL, USA), and 
GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla, CA, USA) was used for making graphs 
and figures. Statistical differences were tested using Mann–Whitney U-test. Because the 
PAS staining was scored semi-quantitatively into five categories, by Chi-square analyses we 
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compared the number of kidneys without interstitial fibrosis (score 1) with those showing 
interstitial fibrosis (score >1). P<0.05 was considered statistically significant. 
Results 
Proteinuria developed over time in adriamycin-injected rats 
Urinary protein excretion was significantly increased at week 6 in the adriamycin-injected 
rats compared with their saline-injected controls [146 (ranging from 77 to 230) in 
adriamycin-injected rats vs 18 (13-27) mg/24 h in control rats; P<0.001]. Except for 
proteinuria, at week 6 other clinical parameters, such as body weight, blood pressure and 
kidney function, evidenced by creatinine clearance, were not significantly different 
between healthy and proteinuric rats, but heart rate was reduced in proteinuric rats (Table 
1). Also, there was no difference in water intake between both groups of rats at that time. 
However, food intake was significantly higher in the proteinuria rats (Table 1). In this way, 
we developed a model of so-called pure proteinuria without signs of nephrotic syndrome. 
Histological inspection of the kidneys revealed that, at 6 weeks, a non-significant influx of 
α-SMA-positive cells was observed in adriamycin-injected rats compared with healthy 
controls. 
Otherwise, no changes were seen in week-6 proteinuric kidneys, neither for number of LVs, 
ED-1-positive macrophages and CD3-positive T cells, nor for interstitial fibrosis evidenced 
by collagen III quantification (Fig. 1) and periodic acid-Schiff (PAS) staining (not shown at 
week 6). In contrast, at week 12, tubulointerstitial tissue remodeling occurred. This was 
characterized by lymphangiogenesis measured by an increase in LV density (Fig. 1C), 
increased numbersof ED-1-positive macrophages (Fig. 1F) and CD3-positive T cells (Fig. 1I), 
increased α-SMA-positive myofibroblasts (Fig. 1L), and interstitial fibrosis measured by 
collagen III deposition (Fig. 1O) and PAS staining (Fig. 2K). 
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Table 1. General parameters at 12 weeks 
Groups are divided into healthy untreated rats, proteinuric untreated rats, and proteinuric rats treated with anti-VEGFR3 
antibody (3C5), FTY720 or clodronate liposomes (CL). The table shows that, in the proteinuric rats, urinary protein excretion 
increased compared to the healthy controls. The proteinuric rats treated with 3C5, FTY720 and CL did not show any significant 
differences compared to untreated proteinuric rats. 
The table shows medians and interquartile ranges. All P-values below <0.05 are shown (bold) (only significant for proteinuric 
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Anti-VEGFR3 antibody totally prevented LV formation in proteinuric rats 
Treatment for 6 consecutive weeks with anti-VEGFR3 antibody (IMC-3C5) in proteinuric rats 
(weeks 6-12) did not significantly alter proteinuria, compared with non-treated proteinuric 
controls. No noticeable changes were observed in body weight, blood pressure, heart rate, 
food and fluid intake, and creatinine clearance compared with untreated proteinuric rats 
(Table 1). On histology, proteinuric kidneys at week 12 presented significantly more 
podoplanin-positive LVs by immunohistochemistry in the cortical interstitium, compared to 
week 6, implying renal lymphangiogenesis between weeks 6 to 12 (Fig. 1A-C; P<0.05).IMC-
3C5 treatment showed a robust and significant decrease in the amount of LVs, not only in 
the proteinuric rat kidneys, compared with non-treated proteinuric rats (P<0.001), but also 
in the kidneys of healthy rats upon treatment, compared with the non-treated healthy 
controls (Fig. 2A,B; P<0.001). Looking at macrophages and T cells, although the proteinuric 
rats treated with IMC-3C5 showed a trend in reducing the ED1-positive macrophages, this 
was not statistically significant (Fig. 2C,D). Rats treated with IMC-3C5 antibody did not show 
any marked changes in T-cell number (Fig. 2E,F). α-SMA and collagen III expression and 
interstitial fibrosis (scored by PAS staining) did not show any marked changesafter IMC-3C5 
treatment (Fig. 2G-L). Regarding mRNA level [quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR)], IMC-3C5 treatment decreased the collagen III (α1) mRNA level 
almost significantly, but not collagen I (α1) and TGF-β1. This intervention did not show 
significant effects on inflammatory marker vascular cell adhesion molecule 1 (VCAM-1), 
Targeting tubulointerstitial remodeling in proteinuric nephropathy  
 
139 
monocyte chemoattractant protein-1 (MCP-1/CCL2) and osteopontin (Fig. 3), although a 
tendency towards a reduction of these inflammatory markers was suggestive. There were 
no significant differences for total white blood count, lymphocytes, neutrophils, basophils 
and eosinophils in IMC-3C5-treated groups. Thus, treatment of proteinuric rats with anti-
VEGFR3 completely prevented tubulointerstitial LV formation, however without prominent 

































Figure 1. Development of renal lymphangiogenesis, inflammation and fibrosis in an adriamycin-
induced proteinuria model. Representativephotomicrographs show the differences in several markers in the kidneys of 
healthy rats, and in proteinuric rats at week 6 and week 12. (A-C) Podoplanin+ LVs(arrows); (D-F) ED1+ macrophages (arrows); 
(G-I) CD3+ T cells (arrows); (J-L) α-SMA+ myofibroblasts; (M-O) collagen III deposition. All markers were significantly increased 
at week 12 in proteinuric rats compared with the healthy controls at week 12 and the proteinuric rats at week 6. For 
quantification of these data at 12 weeks between proteinuric rats with and without treatment, see Figs 2, 4 and 6. 
Magnification: (A-C;J-O) 200×; (D-I) 400×. 
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FTY720 prevented the increase in myofibroblasts accumulation, T-cells infiltration and 
interstitial fibrosis, but not collagen III deposition, macrophage influx or LVs number  
Treatment of proteinuric rats with FTY720 did not affect body weight, food and water 
intake, blood pressure, heart rate, creatinine clearance or proteinuria (Table 1). FTY720 
treatment had no effect on renal lymphangiogenesis (Fig. 4A,B). The influx of ED1-positive 
macrophages showed a tendency to be reduced upon FTY720 treatment, although not 
significantly (Fig. 4C,D). Because the number of white blood cells and leukocytes were 
strongly reduced by FTY720 treatment (Fig. 8A,B; P<0.001), renal influx of CD3- positive T 
cells was significantly reduced at 12 weeks (Fig. 4E,F;P<0.05). FTY720 completely prevented 
α-SMA-positive myofibroblast accumulation at week 12 compared with non-treated 
proteinuric rats (Fig. 4G,H; P<0.05), but did not show any marked effect on collagen III 
deposition by immunohistochemistry (Fig. 4I,J). Nevertheless, this intervention significantly 
reduced interstitial fibrosis scored by PAS staining (Fig. 4K,L; P<0.05). At the mRNAlevel, 
FTY720 also could not prevent the increase in collagen I (α1), collagen III (α1), TGF-β1, MCP-
1/CCL2 and osteopontin, although significantly prevented the increase of VCAM-1 mRNA 
expression (Fig. 5). In summary, in the kidneys of FTY720-treated proteinuric rats, 
accumulation of α-SMA-positive myofibroblasts, CD3-positive T cells and interstitial fibrosis 
were prevented; however, there was no effect on collagen III deposition, macrophage influx 
and lymphangiogenesis. 
 
Clodronate liposome prevented macrophage influx in the kidney without any major effect on 
other histological and clinical parameters 
Targeting monocyte/macrophages by clodronate liposomes (CLs) in proteinuric rats did not 
result in changes in body weight, blood pressure, heart rate, food and water intake, 
creatinine clearance and proteinuria (Table 1). This treatment also did not prevent the 
formation of new LVs in proteinuric rats compared with non-treated proteinuric control 
rats (Fig. 6A,B). However, kidneys of proteinuric rats showed a significant decrease in 
macrophage number upon CL treatment (Fig. 6C,D; P<0.05), whereas proteinuric rats 
treated by ‘placebo’ liposomes (PBS instead of clodronate) showed a small non-significant 
reduction (Fig. 6D). Even in non-proteinuric healthy controls treated with CLs, the number 
of kidney macrophages significantly decreased compared with non-treated healthy controls 
(Fig. 6D; P<0.01). CL treatment did not influence the number of circulating white blood cells 
and lymphocytes in the blood (Fig. 8). Treatment of proteinuric rats with CLs, despite 
effective prevention of macrophage influx, did not significantly influence influx of T cells, 
myofibroblast accumulation, interstitial fibrosis or collagen III deposition (Fig. 6E-L). At the 
mRNA level, this treatment also did not show any marked effect on collagen I (α1), collagen 
III (α1), TGF-β1 and osteopontin, whereas it inhibited the increase in mRNA expression of 
MCP-1/CCL2 and VCAM-1 (Fig. 7). Thus, despite effective reduction of renal inflammation 
by CL treatment, interstitial fibrosis and lymphangiogenesis was not influenced by this 
intervention. 
Discussion 
In the adriamycin-induced proteinuria model, in a curative approach we thus targeted 
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tubulointerstitial lymphangiogenesis (VEGFR3 blockade), monocyte/macrophage influx 
(depletion by clodronate liposomes), and pre-fibrotic myofibroblast accumulation and 
interstitial fibrosis (by S1P agonist FTY720). Anti-VEGFR3 antibody completely blocked renal 



































Figure 2. Effects of anti-VEGFR3 antibody treatment on renal lymphangiogenesis, inflammation and 
fibrosis. Quantification of renal cortical podoplanin-positivevessel-like structures of the rats who received treatment with 
anti-VEGFR3 antibody (IMC-3C5) showed a significant reduction of LVnumber at 12 weeks (A,B; 400×),whereas it showed a 
non-significant trend in reducing the number ofmacrophages in the cortical interstitium of proteinuric rats (C,D; 400×), and 
did not influence T-cell influx (E,F; 400×) at week 12. Anti-VEGFR3 antibody also did not have a significant effect on α-SMA 
(G,H; 200×), collagen III deposition (I,J; 200×) and interstitial fibrosis (K,L; 200×). White dotted bars represent week 6 before 
treatment; black bars represent week 12 after treatment. The PAS staining quantification (interstitial fibrosis) is showed at 12 
weeks. HL, healthy; PR, proteinuric untreated; 3C5, anti-VEGFR3 antibody. *P<0.05, **P<0.01, ***P<0.001. 
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the anti-VEGFR3 antibody did not show any major effects on inflammatory (macrophages 
and T cells) or fibrotic (-SMA, collagen III and interstitial fibrosis) markers despite some 
apparent reductions in fibrotic and inflammatory markers at mRNA level. FTY720 
considerably prevented α-SMA positive myofibroblasts accumulation and interstitial 
fibrosis, but not specifically collagen III deposition and lymphangiogenesis. The treatment of 
proteinuric rats with CL prevented the increase in tissue macrophage number in proteinuric 
kidneys, but did not show major changes on the clinical parameters, neither on 
tubulointerstitial lymphangiogenesis and fibrotic markers. This study thereby shows the 
dissociation of inflammatory (macrophages, T cells) or fibrotic (myofibroblasts, collagen III 
and interstitial fibrosis) responses from renal lymphangiogenesis, at least in this 
proteinuric-nephropathy model. Importantly, proteinuria-induced interstitial fibrosis can 
not be halted by blocking lymphangiogenesis or the influx of macrophages. 
Tubulointerstitial remodeling is one of the key events in proteinuric nephropathy, which in 
the end, will cause massive renal fibrosis culminating into loss of renal function and ESRD 
(Nangaku, 2004; Theilig, 2010). Although targeting proteinuria directly is the most 
commonly used and effective treatment in the clinic, nevertheless, complete annihilation of 
proteinuria is very difficult and attempts to do so resulted in increased mortality (Nangaku, 
2004; Khan et al., 2013; Hou et al., 2007; Chen et al., 2014). Therefore, preventing and/or 
curing damage downstream of proteinuria in the kidney would be of high importance in 
order to preserve kidney function, and halt progression towards CKD and eventually ESRD. 
Vascular remodeling plays a major role in tubulointerstitial homeostasis in the 
microenvironment of all organs, and specifically in the kidney (Rienstra et al., 2010; Schrijvers et 
al., 2004). Lymphangiogenesis, the growth and formation of new LVs, has caught increasing 
attention over the last years due to its immense importance in many pathological conditions in 
the body (Alitalo, 2011). Lymphangiogenesis has been shown to be in close relation to 
fibrogenesis in different organs including the kidney (Sakamoto et al., 2009; Zampell et al., 2012; 
El-Chemaly et al., 2009). Yet, the causal interplay between fibrosis and lymphangiogenesis is not 
clearly explored. Meinecke AK. et al.showed in an elegant study that LVs play central role in 
fibrogenesis, at least in pulmonary fibrosis (Meinecke et al., 2012). They meticulously showed 
that in the early stage of the disease, activated LECs stimulate PDGFR-ß receptor-expressing 
mural cells, by secretion of platelet derived growth factor-B (PDGF-B), recruiting them around 
LVs and then by attaching to LVs, impeding their drainage capacity. These defects then hamper 
the most important function of LVs, which is fluid drainage, and thereby leading to fibrotic 
processes in the lung. Although, it is not yet known whether this phenomenon holds true in 
renal fibrosis, however, this study proposed an important role of LVs in fibrogenesis. CCL21, by 
signalling CCR7 receptor-expressing cells, initiates a vital pathway in renal fibrogenesis (Sakai et 
al., 2006). LECs of renal LVs also showed to be able to secrete CCL21 (Kerjaschki et al., 2004). As 
blocking of lymphangiogenesis by anti-VEGFR3 decreased CCL21 secretion (Nykänen et al., 
2010), this strategy might be useful in targeting fibrosis. We previously showed that in the 
experimental unilateral proteinuric model, prolonged and sustained proteinuria triggers new 
LVs formation in the kidney and that renal lymphangiogenesis occurs before the influx of 
macrophages and collagen deposition (Yazdani et al., 2012). To explore the importance of LVs in 
tubulointerstitial damage and its potential roles in modulating the microenvironmental milieu, 
we targeted lymphangiogenesis distinctly. Anti-VEGFR3 antibodies have been extensively 
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studied in experimental models, and are currently in the phase 1 clinical trial for the treatment 













Figure 3. Effects of anti-VEGFR3 antibody treatment on mRNA expression of fibrotic and 
inflammatory markers. 
Anti-VEGFR3 injections tended to reduce the proteinuria-induced expression of Collagen III (α1) and TGF-β1 mRNA, however, 
not with Collagen I (α1) (A-C). Likewise, anti VEGFR3 intervention tended to reduce the proteinuria-induced mRNA expression 
of MCP-1, osteopontin and VCAM-1 (D-F). HL=Healthy; PR= Proteinuric untreated; 3C5=anti-VEGFR3 antibody. (*p<0,05 ** 
p<0,01 ***p<0,001)  
 
this current study, by specific blocking of lymphangiogenesis in renal injury model, we 
aimed to explore more about its implication. In this study, IMC-3C5 perfectly blocked 
lymphangiogenesis in our proteinuric model in rats and also in the healthy controls, which 
indicates LVs regression (Mäkinen et al., 2001). This intervention however failed in 
preventing renal inflammation (at least not macrophage and T-cell number) and fibrosis (at 
least not α-SMA and collagen III expression, and interstitial fibrosis scored by PAS staining), 
although some apparent effects on mediators of inflammation and fibrosis on mRNA level is 
suggested by qRT-PCR data. The reason might be that in this model tubular epithelial cells 
which continuously encounter the ultrafiltered plasma proteins and are being activated, are 
the main source of many chemokines and mediators which induce tubulointerstitial 
remolding such as lymphangiogenesis, inflammation and fibrosis (Moreno et al. 2014).  
LVs are an integral part of the inflammatory process, and they have been proposed as a 
therapeutical target in inflammation (Johnson and Jackson, 2010; Dieterich et al., 2014; Kim et 
al., 2012). Different leukocytes are capable of prompting lymphangiogenesis (Loffredo et al., 
2014), however, among them the role of macrophages is far more highlighted (Ran and 
Montgomery, 2012; Kerjaschki, 2005), and macrophage depletion or reduction has been shown 
to abolished lymphangiogenesis in several disease models (Poosti et al., 2012; Maruyama et al., 
2012). Still, the role of macrophages, specifically in renal lymphangiogenesis, is not 
distinguished clearly. Several groups, including ours, have shown that macrophages are actively 
involved in inducing lymphangiogenesis in kidney diseases (Yazdani et al., 2014), however, there 
are some conflicting findings in these studies. Lee AS. et al. (Lee et al., 2013) depleted 
macrophages by clodronate liposomes in UUO kidney damage in mice and found the striking 
blockage of lymphangiogenesis. In a rat UUO model, Suzuki Y. et al. (Suzuki et al., 2012) showed 








































Figure 4. Effects of FTY720 treatment on renal lymphangiogenesis, inflammation, and fibrosis. 
Quantification of the staining of kidneys from proteinuric rats treated with FTY720 did not show any effect on the increased 
number of LVs in proteinuric rats at week 12 (A, B). Although FTY720 did not show a significant effect on the influx of 
macrophages (C, D), it did show a complete blocking of T cells influx at week 12 compared to the untreated proteinuric rats (E, 
F) and also of α-SMA positive cells at 12 weeks (G, H), while it did not show to have a significant effect on collagen III 
deposition (I, J). Nevertheless, interstitial fibrosis (PAS scoring) revealed that FTY720 could markedly prevent the development 
of interstitial fibrosis in proteinuric rats compare to healthy controls at week 12 (K, L). Grey bars represent week 6 before 
treatment, black bars represent week 12 after treatment. PAS staining and quantification has been done at week 
12.HL=Healthy; PR= Proteinuric untreated; FTY=FTY720.(*p<0,05 ** p<0,01 ***p<0,001). 
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It seems that, at least in this experimental model, macrophages are not the main 
lymphangiogenic inducer. We now showed, that complete prevention of tubulointerstitial 
macrophage influx, also reduced some markers of inflammation at mRNA level. However, 
neither interstitial fibrosis, nor lymphangiogenesis could be reduced by this intervention. 
Hence, the role of macrophages in inducing lymphangiogenesis seems to be very much 
context-dependent. 
FTY720, a FDA-approved drug to treat multiple sclerosis, inserts different kind of effects in 
the body (Halmer et al., 2014; Pitman et al., 2012). One of the most well-known influences 
is the immunosuppression by blocking the egress of lymphocytes from the lymph nodes, 
thereby reducing inflammation (Kabashima et al., 2006; Matloubian et al., 2004). Several 
reports have shown the beneficial effect of FTY720 not only in a renal inflammatory 
reactions, but also in hampering renal profibrotic and fibrotic development such as 
myofibroblast activation and collagen deposition (Shiohira et al., 2013; Ni et al., 2013a; Ni 















Figure 5. Effects of FTY720 treatment on mRNA expression of fibrotic and inflammatory markers. 
Quantitative RT-PCR data showed that the mRNA expression of fibrotic and inflammatory markers which have been increased 
significantly upon proteinuria (A-F), was not reduced by FTY720 treatment (A-E), except for significant prevention of VCAM-1 
mRNA increase (F). HL=Healthy; PR= Proteinuric untreated; FTY=FTY720.(*p<0,05 ** p<0,01,***p<0,001). 
 
By binding to the S1P1 receptor on LECs, FTY720 showed to be an effective drug in blocking 
lymphangiogenesis (Yin et al., 2011). In this current study, FTY720 treatment effectively 
reduced the number of lymphocytes in the blood circulation, and T cells in proteinuric 
kidneys, but did not show to have any impact on renal lymphangiogenesis. Interestingly, 
while FTY720 significantly prevented the increase of α-SMA positive myofibroblasts, it was 
not effective in decreasing collagen III deposition, however significantly reduced 
tubulointerstitial fibrosis (PAS scoring). Apparently, collagen III is not fully representative 
for interstitial fibrosis, which is a reflection of interstitial matrix accumulation of many 
different extracellular matrix molecules. Results also showed that α-SMA is not an ideal 
marker for collagen-secreting cells in interstitial injuries, as many (myo)fibroblasts which do 
not express α-SMA, have the ability of collagen deposition (Boor et al., 2010; Farris and 









































Figure 6. Effects of macrophages depletion by clodronate liposomes on renal lymphangiogenesis, 
inflammation and fibrosis. Quantification of immunohistochemical stainings of the kidneys of the clodronate-liposome 
(CL) treated proteinuric rats did not prevent the increase in LV number in proteinuric rats (A, B) despite a complete blocking of 
macrophage influx at week 12 (C, D). However, this treatment had no obvious effect of T-cells influx (E, F), and did not show to 
have a significant effect on α-SMA (G, H) or collagen III deposition (I, J). In the same line, the development of interstitial 
fibrosis was also not inhibited by CL intervention (K, L). Grey bars represent week 6 before treatment, black bars represent 
week 12 after treatment. The PAS staining quantification (interstitial fibrosis) is shown at 12 weeks.  
HL=Healthy; PR= Proteinuric untreated; CL=Clodronate Liposome; EL=Empty liposomes; (*p<0,05 ** p<0,01 ***p<0,001). 



















Figure 7. Effects of clodronate liposomes treatment on mRNA expression of fibrotic and 
inflammatory markers. 
Targeting macrophages by clodronate liposome (CL) did not markedly alter the mRNA expression of fibrotic markers Collagen I 
(α1), Collagen III (α1) and TGF-β1 compared to non-treated proteinuric rats (A-C). The CL intervention strongly prevented the 
increase of VCAM-1 mRNA expression in proteinuric rats (D, F). MCP-1 expression was non-significantly (p<0.06) reduced by 
CL treatment (E), whereas osteopontin expression was not influenced by the treatment (D). HL=Healthy; PR= Proteinuric 











Figure 8. Number of total white blood cells (WBCs) and lymphocytes in the blood in both healthy and 
proteinuric rats at week 12. 
Total WBCs did not show any difference in healthy non-proteinuric compared to proteinuric rats (A). However, upon 
treatment with FTY720, the total WBCs dramatically decreased at week 12, in both healthy (grey bars) and proteinuric (black 
bars) groups. CL and IMC-3C5 did not show any effect. In order to see the effect of treatments on specific subset of WBCs in 
the blood, we also measured the number of lymphocytes. FTY720 markedly reduced the lymphocyte in the circulation, even in 
healthy rats who received the drug. However, again the other two interventions did not have any effect on lymphocyte 
number in the blood circulation (B). 
HL=Healthy; PR= Proteinuric untreated; CL=Clodronate Liposome; EL=Empty liposomes; 3C5=anti-VEGFR3 antibody; 
FTY=FTY720 
*compared to healthy control, # compared to the proteinuric non-treated rats  
(*/#p<0,05 **/## p<0,01 ***/###p<0,001). 
 
 
In summary, our study showed that tubulointerstitial fibrosis, inflammation or 
lymphangiogenesis are rather independent tissue remodeling responses, at least under 
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proteinuric conditions. Our work also shows that blocking renal interstitial lymphangiogenesis 
or inflammation did not effectively reduce the development of renal fibrosis. It proposed 
that, for the treatment of the downstream consequences of proteinuria there is no specific 
target in just one of the tubulointerstitial changes that we investigated in this study. Data 
rather suggest combination of intervention strategies to reduce proteinuria-driven 
tubulointerstitial tissue remodeling, eg by combining FTY720 or clodronate-liposomes with 
lymphangiostatic treatments to evaluate the effects on fibrosis and functional renal outcome 
parameters. Earlier data indicated that activated tubular epithelial cells trigger 
lymphangiogenesis, inflammation and fibrosis. Our group previously showed that specific 
targeting of Rho-kinase pathway in proximal tubular epithelial cells markedly reduced renal 
inflammation and renal lymphangiogenesis in an acute renal allograft rejection model (Poosti 
et al., 2012). Although it warrants future studies, these findings suggest that strategies to 
preserve tubular epithelial cells or directly target their secreted chemokines and mediators 
could be a promising approach in preventing or treating tubulointerstitial damages secondary 
to proteinuria. 
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In the present thesis, we have provided more insight into the mechanistical role of 
lymphatic vessels (LVs) and lymphangiogenesis in the pathophysiology of renal diseases. To 
this end, we evaluated whether lymphangiogenesis occurs in renal disease conditions, and 
if so, whether lymphangiogenesis associates with the degree of renal damage. Even more 
important, we studied whether targeting lymphangiogenesis can pose a beneficial 
therapeutic effect in experimental models of kidney injury. 
A breakthrough finding from Titze’s laboratory demonstrated the water-free storage of 
sodiumin subcutaneous interstitium which subsequently induces lymphangiogenesis in the 
skin via the macrophage/VEGF-C signaling pathway, thereby creating buffering phenomena 
to halt hypertension in the sodium-overloaded state (1). In line with that, in patients with 
refractory hypertension circulating VEGF-C levels were elevated compared to normotensive 
subjects (1). This suggests that this extrarenal regulatory mechanism might play a role in 
sodium homeostasis and regulation of blood pressure in humans as well. These captivating 
findings stimulated us to hypothesize in chapter 3 that circulating levels of VEGF-C may 
respond to changes in sodium intake, with higher VEGF-C levels during high dietary sodium 
intake. We found that VEGF-C levels are indeed modulated by sodium intake in two 
different independent studies, i.e. in proteinuric CKD patients after two 6-week periods of 
dietary intervention and in healthy subjects after two 1-week periods of dietary 
intervention. Our data were the first to document an effect of sodium intake on VEGF-C in 
humans, both in a sodium-sensitive as well as a sodium-resistant condition. However, we 
could not provide data on total body composition and sodium content. In addition, it was 
not possible to directly monitor local interstitial changes, for example in skin, in humans 
during dietary sodium intervention. Although the VEGF-C levels are increased by a high-
sodium diet in proteinuric CKD patients and in healthy subjects, considering the rise in 
blood pressure during a high-sodium diet, this buffering mechanism for sodium-sensitive 
hypertension appears to be insufficient in proteinuric CKD patients. Future studies should 
investigate the clinical relevance; the reasons for failure in CKD and potential targets for 
intervention, of VEGF-C mediated interstitial electrolyte and volume homeostasis in 
humans. 
Renal lymphangiogenesis seems to play an important role in kidney pathophysiology, 
especially in renal transplantation (2). Several original papers showed new lymph vessel 
formation upon renal transplantation (3-5). Nevertheless, the precise role of 
lymphangiogenesis in organ transplantation is still under debate. Conflicting data emerged 
from published work regarding the functional consequences of renal lymphangiogenesis in 
renal transplantation outcome and survival. For example, in biopsies collected from 
transplanted kidneys with interstitial fibrosis and tubular atrophy no significant differences 
were observed in the number of LVs independently of rejection (3), while in another study 
more LVs around cellular infiltrates were correlated with superior graft function at one year 
after renal transplantation (5). However, the exact role of LVs within preexisting renal 
damage at time of kidney donation and transplantation had not been established. In 
addition, the majority of organs for transplantation are derived from deceased brain dead 
(DBD) donors who generally have worse transplantation outcome than kidneys retrieved 
from living donors (LD). Whether the lymphatic vessel density (LVD) is affected in kidneys of 
DBD had not been studied. It was also not clear if LVD is associated with other histological 
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changes in biopsies from (pre)transplant DBD compared to living donors. Hence, in chapter 
4, we quantified LVD and other pre-existent damage parameters in kidney biopsies of DBD 
and living donors, and investigated the association between these structural changes. This 
study showed that the number of LVs is significantly higher in pretransplant kidney biopsies 
of DBD compared to LD. In line with the number of LVs, pro-fibrotic, vascular and 
inflammatory damage in the pretransplant DBD kidney biopsies were also higher. In our 
study, the number of interstitial (mostly peri-arterial region) LVs in (pre)transplant biopsies 
was associated with arteriopathy and tubulointerstitial injury and not with fibrotic 
parameters. The living donors were somehow selected; since they had higher diastolic 
pressure, lower kidney function and higher BMI than the DBD donors. In the kidneys, this 
was histologically reflected by the glomerulosclerosis, interstitial fibrosis and arterial intima 
thickness. Despite this, all inflammatory parameters and LVD were low in these kidneys. 
This already suggests that pre-existent fibrotic responses are rather independent of 
inflammation and lymphangiogenesis. LVD correlated with vascular hyalinosis, which is a 
sign of vascular leakage and fluid drainage. Therefore, it seems plausible that interstitial 
fluid accumulation and tissue swelling as one of the most potent lymphangiogenic stimuli 
induced lymphangiogenesis in order to increase the key functional task of LVs in draining 
interstitial fluid (6). The data presented in this study suggest that lymphangiogenesis, as 
part of a complex tubulointerstitial tissue remodeling program, is already present in donor 
biopsies prior to implantation. Whether interventional therapy aiming at the modulation of 
lymphatic numbers and/or functions can improve functional outcome after transplantation 
warrants future investigation. 
In recent years there has been increased focus on the mechanisms of lymphangiogenesis 
and LV’s growth. However, the information regarding what will happen after formation of 
these new LVs when the initial injury is removed or treated is still lacking. Few studies 
looked at the regression of LV after lymphangiogenesis (7-9), while there is no report on 
this topic in the kidney. To address this issue, in chapter 5 we measured the number of LVs 
over time after inducing renal lymphangiogenesis in an Angiotensin II infusion model in 
rats, and during the recovery period after withdrawal of the infusion. Following transient 
renal damage induced by Angiotensin II infusion, all functional parameters such as blood 
pressure, kidney function and proteinuria spontaneously recovered within one week and 
remained normal throughout the follow-up period of eight weeks. In contrast with the 
persistence of LVs after lymphangiogenesis in a model of chronic airway inflammation (9), 
we found that eight weeks after cessation of Angiotensin II both Podoplanin mRNA and 
protein expression returned to control levels. This is the first evidence showing that newly 
formed renal LVs can undergo regression. It might be that during the process of renal 
remission growth factors involved in stimulating lymphangiogenesis such as VEGF-C and D 
are absent which eventually lead to lymphatic endothelial cell apoptosis and LVs regression. 
Despite dynamic changes in LVs formation, the number of peritubular capillaries was 
unaltered in our model. Nevertheless, the functional importance of this LV regression in the 
kidney pathophysiology is not known. This warrants further studies to identify the most 
important players in this process and to investigate to what extent this regression has 
consequences for long-term renal outcome, both histologically and functionally. 
Proteinuria is an important cause of progressive tubulointerstitial damage (10). Many renal 
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diseases are accompanied by proteinuria which is independently associated with a decline 
in renal function (10, 11). Whether proteinuria could induce a renal lymphangiogenic 
response has not been established. In addition, the temporal relationship in the 
development of three most important tubulointerstitial remodeling events, namely fibrosis, 
inflammation and lymphangiogenesis in progressive kidney disease has not been 
investigated. For that reason, in chapter 6 we evaluated the time course of lymph vessel 
formation in relation to proteinuria and interstitial damage in a rat model of chronic 
unilateral adriamycin nephrosis. We evaluated the degree of proteinuria and kidney 
histology up to 30 weeks after induction of nephrosis. The results show that early, albeit 
established, proteinuria is not sufficient to evoke a renal lymphangiogenic response, at 
least in our experimental model. However, chronic proteinuria via tubular activation 
triggers renal lymphangiogenesis, concomitantly with a pro-fibrotic response and 
osteopontin expression, and prior to the development of interstitial fibrosis identified by 
collagen deposition. Expression of VEGF-C by activated tubular cells seemed to be an 
important lymphangiogenic factor. Anti-proteinuric intervention significantly prevented the 
renal lymphangiogenic response, confirming the hypothesis that proteinuria triggers renal 
lymphangiogenesis. Based on these data, we concluded that renal lymphangiogenesis is 
induced by proteinuria-driven tubular activation, osteopontin expression and/or VEGF-C 
synthesis. The degree and duration of proteinuria seems crucial to activate tubular 
epithelial cell for production of osteopontin and VEGF-C. Whereas this study showed for 
the first time that proteinuric conditions could promote renal lymphangiogenesis, 
nevertheless, the design of the study did not allow demonstrating possible renoprotective 
effects of targeting lymphangiogenesis in proteinuric conditions. To answer this question, 
we performed an interventional study which presented in chapter 9. 
Inflammation-associated de novo renal lymphangiogenesis has been shown in human renal 
transplants and suggested that this process might be associated with renal allograft 
rejection (3). Activation of Rho-GTPases plays an important role in the regulation of 
inflammation. As acute allograft rejection is characterized by tubular damage and activation 
(12), we hypothesized that cell-specific inhibition of the Rho/ROCK pathway in proximal 
tubular epithelial may reduce renal inflammation and lymphangiogenesis. To address this 
question, in chapter 7 we treated rats in a model of acute rejection up to 4 days (sacrificed 
1or 4days post-transplantation) with the Rho kinase inhibitor Y27632 coupled to lysozyme 
(Y27632-lysozyme), in order to provide kidney-specific conjugate that can release its drug in 
proximal tubular cells. This treatment reduced both the number of macrophages and LVs in 
acute renal allograft rejection. These data are consistent with the assumption that 
inhibition of lymphangiogenesis could be due to lower macrophage infiltration, but do not 
demonstrate an underlying mechanism. Macrophages may play a major role in 
lymphangiogenesis, not only by producing high levels of chemokines and lymphangiogenic 
factors, but also by transdifferentiating into the lymphatic vessel cells (13). In many kidney 
diseases, activated tubular cells form a major source of many chemokines and growth 
factors that induce profibrotic/fibrotic, inflammatory and lymphangiogenic responses. The 
same approach as has been used in this study may hold promise in other conditions where 
tubular epithelial cells are the main triggers for renal lymphangiogenesis, fibrosis and 
inflammation. 
General discussion, Conclusions and Future perspectives 
 
159 
In chapter 6 we showed that proteinuria can promote renal lymphangiogenesis, but we did 
not address the possible renoprotective effects of targeting lymphangiogenesis in 
proteinuric conditions and the possible causal relation between lymphangiogenesis and 
development of inflammation and fibrosis. To answer these questions, in chapter 8, we 
performed another animal experiment using the same proteinuric rat model. In the 
previous experiment (chapter 6) we observed that renal lymphangiogenesis occurred 
between 6 to 12 weeks after induction of adrimaycin nephrosis. Because of that, in this 
interventional experiment we aimed to specifically block lymphangiogenesis (anti-VEGFR3 
antibody), monocyte/macrophage influx (clodronate liposomes) and lymphocyte and 
myofibroblast influx (S1P agonist FTY720) separately in the time frame from 6 to 12 weeks. 
This study showed that tubulointerstitial fibrosis, inflammation and lymphangiogenesis are 
rather independent tissue remodeling responses, and indicated the dissociation of 
inflammatory (macrophages) and fibrotic (myofibroblasts and collagen III) responses from 
renal lymphangiogenesis, at least under proteinuric condition. Our work also showed that 
blocking renal interstitial lymphangiogenesis, influx of macrophages, T-cells or 
myofibroblasts did not effectively reduce the development of renal fibrosis. Although it 
warrants future studies, these findings suggest that strategies to preserve tubular epithelial 
cells or directly target their secreted chemokines and mediators (such as the approach used 
in chapter 7) could be a promising approach in preventing or treating tubulointerstitial 
tissue remodeling secondary to proteinuria. 
Future perspective 
LVs and lymphangiogenesis play a central role in a vast array of functions in many 
pathological conditions. Understanding the molecular mechanisms regulating 
lymphangiogenesis and LV’s remodeling could result in the design of new therapies for 
many human diseases (14-17). The beneficial or detrimental effects of lymphangiogenesis 
would appear to be very context-dependent and organ-specific. As such, both promoting 
lymphangiogenesis and inhibiting it could be used as therapeutic modalities. The available 
knowledge brings the renal lymphatic network forward as an intriguing and promising 
structure in modulating interstitial homoeostasis, inflammation and fibrosis in kidney 
diseases. Specific targeting of lymphangiogenesis in renal disease models would appear to 
be crucial to unravel the causal relationships between lymphangiogenesis and fibrosis, and 
could be a novel therapeutic strategy to prevent renal fibrosis, progression to End Stage 
Renal Disease and renal function loss. Nevertheless, these potential therapeutic options are 
still in a very early phase, and far from clinical application. Improved understanding of the 
detailed mechanisms involved in renal lymphatic remodeling are needed, as well as insights 
in the contextual factors that determine the role of lymphangiogenesis in the disease 
process, would be rational next steps in the characterization of lymphangiogenesis as a 
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In dit proefschrift bieden we meer inzicht in de mechanistische rol van lymfevaten (LV’s) en 
lymfangiogenese (nieuwvorming van lymfvaten) binnen de pathofysiologie van nierziekten. 
Hiertoe hebben wij onderzocht of lymfangiogenese optreedt bij nierziekten, en zo ja, of 
lymfangiogenese geassocieerd is met de mate van nierschade. Daarnaast hebben wij 
onderzocht of het gericht remmen van lymfangiongenese een gunstig therapeutisch effect 
heeft in experimentele modellen van nierschade.  
In baanbrekend onderzoek van Titze et al. werd water-vrije opslag van natrium in het 
subcutane interstitium aangetoond, wat vervolgens lymfangiogenese in de huid induceert 
via de macrofaag/VEGF-C signalerings route. Hierdoor wordt een buffersysteem gecreeërd 
waarmee hypertensie kan worden gereduceerd in een status van natrium overbelasting. 
Hiermee in overeenstemming is dat patiënten met refractoire hypertensie verhoogde 
circulerende VEGF-C levels hebben in vergelijking met normotensieve patiënten. Dit 
suggereert dat dit extrarenale regulatoire mechanisme wellicht een rol speelt bij de 
natrium homeostase en ook bij de regulatie van de bloeddruk in mensen. Deze boeiende 
bevindingen stimuleerden ons om in hoofdstuk 3 te veronderstellen, dat circulerende 
niveaus van VEGF-C kunnen reageren op veranderingen van de inname van natrium, met 
hogere VEGF-C niveaus bij een dieet met een hoge inname van natrium. We hebben 
gevonden dat VEGF-C levels inderdaad gemoduleerd worden door natrium inname in twee 
verschillende onafhankelijke studies, te weten in proteinurische CKD patiënten na twee 
perioden van zes weken dieet interventie, en in gezonde mensen na twee perioden van 1 
week dieet interventie. Onze resultaten zijn de eerste resultaten die een effect van natrium 
inname laten zien op VEGF-C levels in mensen, zowel onder natrium-gevoelige als onder 
natrium-resistente omstandigheden. Echter, we konden geen data verschaffen over de 
totale lichaamssamenstelling en het natriumgehalte. Bovendien was het niet mogelijk om 
de lokale interstitiële veranderingen bij mensen gedurende de natrium interventie in het 
dieet te monitoren, bijvoorbeeld die in de huid. Ook al zijn de VEGF-C levels verhoogd bij 
een hoog-natrium dieet bij proteinurische CKD patiënten en in gezonde mensen; rekening 
houdend met de stijging van de bloeddruk gedurende het hoog-natrium dieet, lijkt dit 
buffersysteem voor natrium-gevoelige  hypertensie onvoldoende bij proteinurische CKD 
patiënten. Toekomstige studies zullen de klinische relevantie, de redenen voor falen in CKD 
en mogelijke doeleinden voor interventie moeten onderzoeken van VEGF-C gemedieerde 
interstitiële elektrolyt- en volume homeostase in mensen.  
Renale lymfangiogenese lijkt een belangrijke rol te spelen binnen de pathofysiologie van 
nieren, in het bijzonder bij niertransplantaties. Verschillende onderzoeken hebben 
nieuwvorming van lymfevaten aangetoond na niertransplantatie. Desalniettemin staat de 
precieze rol van lymfangiogense bij orgaan transplantatie nog ter discussie. Er zijn 
tegenstrijdige data verschenen in gepubliceerd werk betreffende de functionele 
consequenties van renale lymfangiogenese voor uitkomst en overleving bij 
niertransplantatie. Bijvoorbeeld, in verkregen biopsieën uit getransplanteerde nieren met 
interstitële fibrose en tubulaire atrofie werden geen significante verschillen gevonden in 
het aantal LV’s, onafhankelijk van rejectie, terwijl in een andere studie meer LV’s rond 
cellulaire infiltraten gecorreleerd waren met een verbeterde functie van het transplantaat, 
een jaar na niertransplantatie. Echter, de exacte rol van LV’s bij preexistente nierschade ten 
tijde van de nier donatie en transplantatie is nog niet duidelijk. De meerderheid van de 
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organen voor transplantatie is afkomstig van overleden hersendode donoren (eng: 
deceased brain dead, DBD), die over het algemeen een slechtere transplantatie uitkomst 
hebben dan nieren afkomstig van levende donoren (LD). Of de lymfatische vaatdichtheid 
(LVD) veranderd is in nieren van DBD donoren is nog niet onderzocht. Het was ook niet 
duidelijk of LVD geassocieerd is met andere histologische veranderingen in biopsieën van 
(pre)transplantatie DBD donoren in vergelijking met LD. Daarom hebben we in hoofdstuk 4 
LVD en enkele pre-existente schade parameters in nierbiopsieën van DBD en LD gemeten, 
en de associatie onderzocht tussen deze structurele veranderingen. Deze studie toonde aan 
dat het aantal LV’s significant hoger is in pretransplantatie nieren van DBD in vergelijking 
met LD. In overeenstemming met het aantal LV’s, was ook de pro-fibrotische, vasculaire en 
inflammatoire schade in pretransplantatie DBD nier-biopsieën hoger. In onze studie, was 
het aantal interstitiële LV’s (met name in de peri-arteriële regio) in (pre)transplantatie 
biopsieën geassocieerd met arteriopathie en tubulointerstitiële schade, en niet met 
fibrotische parameters. Voor de levende donoren had op een of andere manier een vorm 
van selectie plaatsgevonden, aangezien zij een hogere diastolische bloeddruk, lagere 
nierfunctie en een hoger BMI hadden dan de DBD donoren. In de nieren werd dit 
histologisch gereflecteerd door de glomerulosclerose, interstitiële fibrose en arteriële 
intima dikte. Desondanks, waren alle inflammatoire parameters en LVD laag in deze nieren. 
Dit suggereert al dat pre-existente fibrotische reacties onafhankelijk blijken van inflammatie 
en lymfangiogenese. LVD was gecorreleerd aan vasculaire hyalinose, wat een teken is van 
vasculaire lekkage en vochtdrainage. Om deze reden lijkt het plausibel dat interstitiële 
vochtophoping en zwelling van weefsel, als een van de meest potente lymfangiogenetische 
stimuli, lymfangiogenese induceren om zo de hoofdtaak van LV’s te versterken voor 
drainage van vocht. De gepresenteerde data in deze studie suggereren dat 
lymfangiogenese, als onderdeel van een complex tubulointerstieel weefsel remodelerings 
programma, al aanwezig is in donor biopsieën voorafgaande aan de implantatie. Of 
interventie-therapieën gericht op de modulering van het aantal lymfevaten en/of de functie 
de functionele uitkomst na transplantatie kan verbeteren behoeft verder onderzoek.  
In de afgelopen jaren is er een toenemende focus op mechanismen van lymfangiogenese 
en groei van LV’s. Echter, de informatie ten aanzien van de gevolgen van deze nieuwe LV’s 
wanneer de initiële schade verwijderd of behandeld is, ontbreekt nog altijd. Een aantal 
studies hebben gekeken naar de regressive van LV’s na lymfangiogenese, terwijl er geen 
artikelen zijn over dit onderwerp in de nier. Om dit te onderzoeken, hebben wij in 
hoofdstuk 5 het aantal LV’s gedurende de tijd gemeten na het induceren van renale 
lymfangiogenese in een Angiotensine II infusie model in ratten, en gedurende de 
herstelperiode na het stoppen van de infusie. Na de voorbijgaande nierschade, welke 
geïnduceerd was door Angiotensine II infusie, herstelden alle functionele parameters zoals 
bloeddruk, nierfunctie en proteinurie zich spontaan binnen een week en bleven zij normaal 
gedurende de follow-up periode van 8 weken. In tegenstelling tot de persistentie van LV’s 
na lymfangiogenese in een model van chronische luchtwegontsteking, vonden wij dat 8 
weken na het stoppen van de Angiotensine II, zowel Podoplanine mRNA en eiwitexpressie 
normaliseerde tot het niveau van de controles. Dit is het eerste bewijs wat aantoond dat 
nieuw gevormde renale LV’s regressie kunnen ondergaan. Het kan zo zijn dat tijdens het 
proces van renale remissie, groeifactoren welke betrokken zijn bij de stimulatie van 
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lymfangiogenese (zoals VEGF-C en D), afwezig zijn, wat uiteindelijk leidt tot apoptose van 
lymfatische endotheelcellen en regressie van LV’s. Ondanks dynamische veranderingen in 
de LV formatie, is het aantal peritubulaire capillairen onveranderd in ons model. 
Desondanks, is het functionele belang van LV regressie in de pathofysiologie van de nier 
onbekend. Dit vraagt om verdere studies, om de meest belangrijke spelers te identificeren 
welke bij dit proces betrokken zijn en om te onderzoeken in hoeverre deze regressie 
gevolgen heeft voor lange-termijn renale uitkomst, zowel histologisch als functioneel.  
Proteinurie is een belangrijke oorzaak van progressieve tubulointerstiële schade. Veel 
nierziekten worden vergezeld door proteinurie, wat onafhankelijk geassocieerd is met een 
afname van de nierfunctie. Of proteinurie een renale lymfangiogenetische respons kan 
induceren is nog niet bewezen. Daarnaast is de temporale relatie tijdens de ontwikkeling 
van de 3 meest belangrijke tubulointerstiële remodelerings fenomenen, namelijk fibrose, 
ontsteking en lymfangiogenese, nog niet onderzocht in progressieve nierziekten. Om deze 
reden hebben wij in hoofdstuk 6 het tijdsverloop van lymfevat formatie geëvalueerd in 
relatie tot proteinurie en interstitiële schade in een ratmodel voor chronische unilaterale 
adriamycine nefrose. We onderzochten de mate van proteinurie en de veranderingen in 
nierhistologie tot 30 weken na de inductie van de nefrose. De resultaten laten zien dat 
vroege, maar bewezen, proteinurie onvoldoende is om een renale lymfangiogenetische 
respons uit te lokken, ten minste in ons experimentele model. Echter, chronische 
proteinurie triggert renale lymfangiogenese via tubulaire activatie, parallel aan een pro-
fibrotische respons en osteopontine expressie, en voorafgaand aan de ontwikkeling van 
interstitiële fibrose (gekenmerkt door collageen depositie). De expressie van VEGF-C door 
geactiveerde tubulaire cellen leek een belangrijke lymfangiogenetische factor. Anti-
proteinurische interventie voorkwam de renale lymfangiogenetische respons significant, 
wat de hypothese bevestigt dat proteinurie renale lymfangiogenese induceert. Op basis van 
deze gegevens, concludeerden we dat renale lymfangiogenese geïnduceerd wordt door 
proteinurie-gedreven tubulaire activatie, osteopontine expressie en/of VEGF-C synthese. 
De mate en duur van de proteinurie lijkt cruciaal voor het activeren van de tubulaire 
epitheliale cel voor de productie van osteopontine en VEGF-C. Terwijl deze studie voor het 
eerst laat zien dat proteinurische omstandigheden renale lymfangiogenese kan induceren, 
laat het design van de studie het echter niet toe om de mogelijke renoprotectieve effecten 
te laten zien van het gericht beïnvloeden van lymfangiogenese tijdens proteinurische 
omstandigheden. Om deze vraag te kunnen beantwoorden, hebben we een interventie 
studie uitgevoerd welke beschreven staat in hoofdstuk 9. 
Ontsteking-geassocieerde de novo renale lymfangiogenese is reeds aangetoond in humane 
renale transplantaten en suggereert dat dit proces wellicht geassocieerd is met 
nierafstoting. Activatie van Rho-GTPases speelt een belangrijke rol bij de regulatie van 
ontsteking. Aangezien acute nierafstoting gekarakteriseerd wordt door tubulaire schade en 
activatie, veronderstellen we dat de cel-specifieke inhibitie van de Rho/ROCK route in het 
proximale tubulaire epitheel interstitiele ontsteking en lymfangiogenese kan verminderen. 
Om deze vraag te kunnen beantwoorden, hebben we in hoofdstuk 7, tot 4 dagen lang 
(opgeofferd 1 tot 4 dagen na transplantatie) ratten behandeld met de Rho kinase inhibitor 
Y27632 gekoppeld aan lysozym (Y27632-lysozym), om zo een nier-specifiek conjugaat aan 
te kunnen bieden welke het medicijn kan vrijmaken in de proximale tubulaire cel, in een 
Samenvatting, conclusies en perspectieven voor de toekomst 
 
165 
model van acute afstoting. Deze behandeling verminderde het aantal macrofagen en LV’s 
tijdens acute nierafstoting. Deze gegevens zijn in lijn met de veronderstelling dat het 
remmen van lymfangiogenese veroorzaakt kan worden door verlaagde macrofaag 
infiltratie, maar het laat het onderliggende mechanisme niet zien. Macrofagen spelen 
mogelijk een enorme rol bij de lymfangiogenese, omdat zij niet alleen hoge levels 
chemokinen en lymfangiogenetische factoren produceren, maar ook door te 
transdifferentiëren in lymfatisch endotheel. In veel nierziekten vormen geactiveerde 
tubulaire cellen een enorme bron voor vele chemokinen en groeifactoren welke 
profibrotische/fibrotische, inflammatoire en lymfangiogenetische responsen induceren. De 
onderzoeksopzet van deze studie is veelbelovend voor het onderzoeken van andere 
aandoeningen waarbij tubulaire epitheelcellen the voornaamste triggers zijn voor renale 
lymfangiogenese, fibrose en inflammatie. 
In hoofdstuk 6 lieten we zien dat proteinurie renale lymfangiogenese kan induceren, maar 
we hebben niet de mogelijke beschermende effecten onderzocht van het gericht 
behandelen van de lymfangiogenese onder proteinurische omstandigheden en de 
mogelijke causale relatie tussen lymfangiogenese en de ontwikkeling van ontsteking en 
fibrose.  Om deze vragen te kunnen beantwoorden, hebben we in hoofdstuk 8 een ander 
dierexperiment uitgevoerd waarbij we gebruik maakten van hetzelfde proteinurische 
rattenmodel. Tijdens het vorige experiment (hoofdstuk 6) hebben we gezien dat renale 
lymfangiogenese optreedt tussen 6 en 12 weken na inductie van de adriamycine nefrose. 
Om deze reden, hadden we in dit interventie experiment als doel om lymfangiogenese 
(anti-VEGFR3 antilichaam), monocyt/macrofaag influx (clodronaat liposomen) en lymfocyt- 
en myofibroblasten influx (S1P agonist FTY720) apart van elkaar te blokkeren, in de 
tijdsperiode van 6 tot 12 weken. Deze studie toonde aan dat tubulointerstitële fibrose, 
ontsteking en lymfangiogenese onafhankelijke weefsel remodelerings reacties zijn, en wijst 
dit op een dissociatie van inflammatoire (macrofagen) en fibrotische (myofibroblasten en 
collageen III) reacties van renale lymfangiogenese, in ieder geval onder proteinurische 
condities. Ons werk liet ook zien dat het blokkeren van renale interstiële lymfangiogenese, 
het blokkeren van de influx van macrofagen, T-cellen of myofibroblasen, de ontwikkeling 
van fibrose niet effectief verminderde. Ondanks het feit dat het verder onderzoek behoeft, 
suggereren deze bevindingen dat strategieën om de tubulaire epitheel cellen of de door 
hun uitgescheiden chemokinen en mediatoren op een directe manier te behandelen, een 
veelbelovende aanpak zouden kunnen zijn bij de preventie of behandeling van tubulaire 
weefsel remodelering, secundair aan proteinurie.  
Toekomstperspectieven  
LV’s en lymfangiogenese spelen een centrale rol in een groot aantal functies binnen vele 
pathologische aandoeningen. Het begrijpen van de moleculaire mechanismen welke 
lymfangiogenese en de remodelering van LV’s reguleren, kan resulteren in het ontwerpen 
van nieuwe therapieën voor veel humane ziekten. De gunstige of nadelige effecten van 
lymfangiogenese lijken zeer context-afhankelijk en orgaan-specifiek te zijn. Daarom kan 
zowel het promoten van lymfangiogense als het remmen ervan gebruikt worden als 
therapeutische mogelijkheid. De beschikbare kennis presenteert het renale lymfatische 
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netwerk als een intrigerend en veelbelovende structuur bij de modulering van interstitële 
homeostase, ontsteking  en fibrose bij nierziekten. Het specifiek benaderen van 
lymfangiogenese in modellen voor nierziekten lijkt crucuiaal om de causale relatie tussen 
lymfangiogenese en fibrose te kunnen ontrafelen, en het kan een nieuwe therapeutische 
strategie zijn om renale fibrose te voorkomen, evenals de progressie tot Eind Stadium 
Renale Ziekte en verlies van nierfunctie. Desalniettemin zijn deze mogelijke therapeutische 
opties nog in een zeer vroeg stadium, en nog ver verwijderd van klinische toepassingen. Er 
is meer kennis nodig van de gedetailleerde mechanismen welke betrokken zijn bij renale 
lymfatische remodelering, even als inzicht in de contextuele factoren welke de rol van 
lymfangiogenese binnen het ziekteproces bepalen. Dit zijn rationele vervolgstappen voor 
de karakterisering van lymfangiogenese als een doelwit voor interventie, voor zowel 
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